
Cell

A Genome-wide ER-phagy Screen Highlights Key Roles of Mitochondrial Metabolism and ER-Resident UFMylation

Graphical Abstract



Authors

Jin Rui Liang, Emily Lingeman, Thao Luong, ..., Truc Nguyen, James A. Olzmann, Jacob E. Corn

Correspondence

jacob.corn@biol.ethz.ch

In Brief

An unbiased, genome-wide screen implicates mitochondrial oxidative phosphorylation and ER surface UFMylation as regulators of starvationinduced ER-phagy.

Highlights

- Genome-wide CRISPRi screen identifies 200 highconfidence ER-phagy regulators
- Disruption of mitochondrial OXPHOS system inhibits ER-phagy
- ER-resident UFMylation mediates autophagy of the ER sheets



A Genome-wide ER-phagy Screen Highlights Key Roles of Mitochondrial Metabolism and ER-Resident UFMylation

Jin Rui Liang,^{1,2,4,6} Emily Lingeman,^{1,2,6} Thao Luong,^{1,2} Saba Ahmed,^{1,2} Matthias Muhar,⁴ Truc Nguyen,³ James A. Olzmann,^{3,5} and Jacob E. Corn^{1,2,4,7,*}

¹Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA 94720, USA

²Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA

³Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA 94720, USA

⁴Department of Biology, ETH Zürich, 8093 Zürich, Switzerland

⁵Chan Zuckerberg Biohub, San Francisco, CA 94158, USA

⁶These authors contributed equally

7Lead Contact

*Correspondence: jacob.corn@biol.ethz.ch

https://doi.org/10.1016/j.cell.2020.02.017

SUMMARY

Selective autophagy of organelles is critical for cellular differentiation, homeostasis, and organismal health. Autophagy of the ER (ER-phagy) is implicated in human neuropathy but is poorly understood beyond a few autophagosomal receptors and remodelers. By using an ER-phagy reporter and genome-wide CRISPRi screening, we identified 200 high-confidence human ER-phagy factors. Two pathways were unexpectedly required for ER-phagy. First, reduced mitochondrial metabolism represses ERphagy, which is opposite of general autophagy and is independent of AMPK. Second, ER-localized UFMylation is required for ER-phagy to repress the unfolded protein response via IRE1 α . The UFL1 ligase is brought to the ER surface by DDRGK1 to UFMylate RPN1 and RPL26 and preferentially targets ER sheets for degradation, analogous to PINK1-Parkin regulation during mitophagy. Our data provide insight into the cellular logic of ER-phagy, reveal parallels between organelle autophagies, and provide an entry point to the relatively unexplored process of degrading the ER network.

INTRODUCTION


Macroautophagy (herein referred to as autophagy) mediates the delivery of cellular cargo to the lysosome for degradation. Once thought to be a non-specific process, it has become clear that autophagy is complexly regulated and induced by various stresses to remove damaged or excessive cellular components. Targeted removal of entire organelles by autophagy is necessary for cellular homeostasis, and, during selective autophagy of mitochondria (mitophagy), the surface proteins of damaged mitochondria are marked by phosphorylation and ubiquitylation to recruit autophagic machinery (Nguyen et al., 2016; Youle and

Narendra, 2011). Dysregulation of selective organelle autophagy negatively impacts cellular fitness and is linked to degenerative diseases, particularly in non-regenerative cell types such as neurons. For example, mutations of key mitophagy genes, such as PINK1 and Parkin, are strongly associated with disorders such as Parkinson's disease (Deas et al., 2011; Dodson and Guo, 2007; Geisler et al., 2010; Pickrell and Youle, 2015; Pilsl and Winklhofer, 2012).

The endoplasmic reticulum (ER) plays a critical role in numerous cellular functions, such as the the storage of calcium, the biosynthesis of lipids, and the maturation and transport of secretory and membrane proteins (Schwarz and Blower, 2016). The ER is tightly regulated by multiple quality-control mechanisms, such as ER-associated degradation (ERAD) and ER to Lysosome Associated Degradation (ERLAD) (Fregno et al., 2018; Ruggiano et al., 2014). The ER-autophagy (ER-phagy) pathway intersects with the selective autophagy machinery to send portions of the ER for wholesale lysosomal degradation. While ER-phagy has long been observed in yeast (Hamasaki et al., 2005), it has only recently been described in mammalian cells (Khaminets et al., 2015).

During ER-phagy, several ER surface proteins, including FAM134B, RTN3L, TEX264, and ATL3, act as specific receptors through LC3/GABARAP-interacting regions (LIRs/GIMs) to recruit autophagy machinery (An et al., 2019; Chino et al., 2019; Grumati et al., 2017; Khaminets et al., 2015; Chen et al., 2019). ER expansion can also be reversed via ER-phagy that is mediated by the SEC62 and CCPG1 LIR-containing ER-phagy receptors (Fumagalli et al., 2016; Smith et al., 2018). The reticular ER network is remodeled for delivery to the lysosome by Atlastin GTPases that are also involved in basal ER morphology maintenance (Liang et al., 2016; Rismanchi et al., 2008; Wang et al., 2016; Zhao et al., 2016). But beyond the few receptors and remodelers most proximal to autophagosomal function, relatively little is known about the signals that regulate ER-phagy.

We performed a genome-wide CRISPR interference (CRISPRi) reporter-based screen to discover new players in ER-phagy, identifying both activators and inhibitors in a variety of cellular compartments. We deeply interrogated two pathways that



positively regulate ER-phagy: (1) mitochondrial oxidative phosphorylation (OXPHOS) and (2) ER-resident UFMylation. While inhibition of OXPHOS reduces cellular energy levels and stimulates general autophagy, genetic or chemical inhibition of OXPHOS instead represses ER-phagy. Surprisingly, OXPHOSdependent ER-phagy bypasses the canonical energy-sensing AMP-dependent protein kinase (AMPK). We furthermore found that UFMylation, a ubiquitin-like post-translational modification, is required for ER-phagy. The protein DDRGK1 recruits UFMylation machinery to the ER surface in a striking parallel to the mitophagic recruitment of Parkin by PINK1. DDRGK1 is specifically required for the ER-phagy of ER sheets, including ER-phagy mediated by LIR/GIM receptors located on these subdomains. Unbiased proteomics identified Ribophorin 1 (RPN1), an ER-localized quality control factor, as an ER sheet-localized target of DDRGK1-dependent UFMylation. Interfering with UFMylation-dependent ER-phagy leads to the accumulation of misfolded proteins and induces the unfolded protein response (UPR) via IRE1α signaling. Overall, our data provide a detailed map of ER-phagy regulators and highlight how organelle crosstalk and ER-resident factors mediate this emerging process of quality control.

RESULTS

A Genome-wide Flow Cytometry CRISPRi Screen for ER-phagy

To develop a genome-wide screen for ER-phagy, we employed the previously-developed ER-autophagy tandem reporter (EATR) system (Figure 1A) (Liang et al., 2018). We first exposed HCT116 colon cancer cells stably expressing either the EATR construct or a general autophagy reporter (mCherry-eGFP-LC3B) to several stresses that could induce general autophagy and/or ER stress. Only prolonged amino acid starvation (16 h) using Earl's buffered saline solution (EBSS) robustly induced both ER-phagy and general autophagy (Figures S1A-S1C). Torin1, which induces general autophagy via inactivation of mTORC1 and mTORC2 complexes, triggered general autophagy but did not induce ER-phagy (Figures S1A-S1C) (Thoreen et al., 2009). Rapamycin, which partially inhibits mTORC1 but spares mTORC2, induced neither general autophagy nor ER-autophagy in HCT116 cells (Figures S1A-S1C) (Jacinto et al., 2004; Thoreen and Sabatini, 2009). Direct activation of the unfolded protein response (UPR) using tunicamycin or thapsigargin also failed to stimulate general autophagy or ER-phagy (Figures S1A– S1C). By quantifying the ratio of eGFP/mCherry reporter fluorescence, we found that EBSS starvation induces ER-phagy in up to 80% of cells, with an average of 8% of the ER present in an acidified compartment at any given time (Figures S1B and S1D).

Having established amino acid starvation (using EBSS) as a robust ER-phagy stimulus, we coupled EATR-based fluorescence-activated cell sorting (FACS) screening with genomewide CRISPR transcriptional inhibition (CRISPRi) to identify novel pathways involved in ER-phagy (Figures 1A and 1B) (Gilbert et al., 2014; Horlbeck et al., 2016; Liang et al., 2018). Since autophagy is influenced by the availability of cellular energy, we reasoned that complete knockout of ER-phagy regulators via CRISPR cutting could be detrimental to cells and mask interesting players. Indeed, mTOR is an essential gene and so cannot be queried using CRISPR screens beyond cell survival. The variability in single-guide RNA (sgRNA) efficiencies of CRISPRi leads to different knockdown efficiencies, allowing for allelic series and residual function of essential genes involved in cellular energy regulation (Horlbeck et al., 2016).

As a proof of concept, we first assessed the suitability of EATR for CRISPRi screening by conducting a pilot screen with a custom CRISPRi library targeting known autophagy genes (Table S1). We used EATR-based FACS to isolate the top 25% of cells with the most ER-phagy ("enhanced" sort gate), and the bottom 25% of cells with the least ER-phagy ("inhibited" sort gate) (Figure S1E). This pilot screen successfully identified sgRNAs targeting core autophagy genes as required for ER-phagy and correctly assigned their role in promoting ER-phagy such that knockdown of autophagy components was enriched in the inhibited gate (Figure S1F) and depleted in the enhanced sort gate (Figure S1G).

We scaled up to perform an unbiased, genome-wide CRISPRi-v2 screen for ER-phagy regulators using EATR-FACS (Gilbert et al., 2014; Horlbeck et al., 2016). We developed a very stringent list of ER-phagy genes by first performing a cutoff at p < 0.01 and then requiring that true hits have opposite phenotypes in the enhanced and inhibited sort gate. For example, sgRNAs that knockdown a bona fide ER-phagy gene should be depleted in a population undergoing more ER-phagy but enriched in one undergoing less ER-phagy. We quantified involvement in ER-phagy by ratiometrically comparing sgRNA

Figure 1. Unbiased Identification of ER-Phagy Regulators by Genome-wide CRISPRi Screening

(A) Schematic of the ER Autophagy Tandem Reporter (EATR) and CRISPR inhibition (CRISPRi) system used for screening. HCT116 cells stably express a doxycycline-inducible EATR construct that consists of mCherry and eGFP fused to ER localized RAMP4. Cells also stably express dCas9-KRAB for sgRNA-targeted transcriptional repression.

(B) FACS screening strategy to identify genes whose knockdown enhances or inhibits ER-phagy. HCT116 cells described in (A) are transduced with a genomewide lentiviral CRISPRi sgRNA library. After selection for sgRNA expression and removal of essential genes, doxycycline was added to express EATR. Cells were then starved in EBSS for 16 h to induce ER-phagy. The top and bottom quartiles correspond to enhanced and inhibited ER-phagy, respectively. Cells were sorted and processed for next-generation sequencing to identify sgRNA representation in each sort bin.

(C) Gene ontology analysis identifies autophagy and mitochondrial metabolism as major signatures of ER-phagy. High-confidence ER-phagy genes were defined as having opposite phenotypes in the enhanced and inhibited sort gates and gene level p < 0.01. Ontologies with Benjamini-Hochberg false discovery rate (FDR) <0.05 are shown.

(D) Genes involved in ER-phagy form a physical interaction network. For clarity, only interactions between two or more high-confidence hits are shown. Red and blue circles represent genes whose knockdown represses and enhances ER-phagy, respectively.

(E) Subcellular classification of high-confidence ER-phagy genes highlights roles in the ER, auto-lysosomes, and mitochondria. See also Figure S1.

distributions in the enhanced gate to those in the inhibited gate (Figure 1B), so that a positive log_2 fold change indicates a gene whose knockdown increases ER-phagy and a negative log_2 fold change indicates a gene whose knockdown inhibits ER-phagy. The resulting high-confidence hit list includes 200 genes, with gene-level log_2 fold change phenotypes ranging from 3.62 to -5.37 (Table S2).

As expected, genes involved in multiple stages of general autophagy and membrane trafficking were high-confidence hits in our screen (Figure 1C; Figure S1H). Individual stable knockdown of these factors and testing using EATR, and mCherry-Cleaved ER-phagy Reporter (CCER) western blot assay, and other measures of autophagy verified their requirement for ER-phagy (Figures S1I-S1K). Our stringent criteria for calling a high-confidence hit narrowly exclude some known players in core autophagic pathways (e.g., multiple components of the V-ATPase complex), which have large log₂ fold changes but moderate p values. Since our goal was to identify new and bona fide regulators in the relatively unexplored process of ERphagy, we opted to maintain very strict statistical cutoffs and thus bias toward false negatives rather than introduce false positives. Overall, the presence of many known autophagic components in the screen indicate that the EATR assay and hence the genome-wide screen reports on ER-phagy pathways rather than ERAD or ERLAD, since the latter do not depend on autophagic components (Fregno et al., 2018; Ruggiano et al., 2014).

Consistent with recent reports of functional redundancy between ER-phagy receptors, we found that knockdown of SEC62, TEX264, and FAM134A (paralog of FAM134B) showed consistent but only moderate ER-phagy inhibition upon knockdown (Figure S1H) (Chino et al., 2019). We also examined the performance of individual FAM134B sgRNAs by qRT-PCR and found that none of the CRISPRi sgRNAs in the genome-wide library successfully knocks down FAM134B (Figure S1L). This highlights a tradeoff in current CRISPRi screening technology, where allelic series enable interrogation of otherwise essential genes but may introduce false negatives. Genetic redundancy and potential underperformance of CRISPRi guide RNAs means that failure to observe a gene in the ER-phagy screen dataset does not exclude potential role in ER-phagy. However, positive membership in the high-confidence set of 200 genes strongly indicates a role in ER-phagy.

As expected, unbiased gene ontology (GO) analysis, shows enrichment of GO related to autophagy (Figure 1C) (Huang et al., 2009). However, multiple aspects of mitochondrial metabolism were unexpectedly prominent. We integrated the highconfidence genetic hits against physical interaction databases to create a putative physical network of ER-phagy (Chatr-Aryamontri et al., 2017; Szklarczyk et al., 2015) (Figure 1D). This network falls into several major classes: autophagic execution, such as ATG10 and WIPI1 (Phillips et al., 2008; Wartosch et al., 2015; Yuan et al., 2013); ubiquitylation, such as the ERlocalized UBE2J1 ubiquitin-conjugating enzyme involved in recovery from ER stress (Elangovan et al., 2017); mitochondrial metabolism and OXPHOS genes; and post-translational modification by the ubiquitin-like protein UFM1, including CDK5RAP3 and DDRGK1 (Cai et al., 2015; Wei and Xu, 2016; Wu et al., 2010). Finally, we manually annotated and subdivided all 200 high-confidence hits into those associated with the lysosome/ endosome, ER-associated factors, and nuclear-encoded mitochondrial proteins (Table S2; Figure 1E) (Binder et al., 2014).

Mitochondrial Oxidative Phosphorylation Promotes ER-phagy

We were surprised to find that the largest set of genes required for ER-phagy are involved in OXPHOS (Figure 2A), since crosstalk between ER-phagy and mitochondrial processes has not yet been described. While interference with mitochondrial energy metabolism induces general cytoplasmic autophagy, loss of mitochondrial factors instead repressed ER-phagy. Mitochondrial factors required for ER-phagy are directly involved in multiple aspects of the electron transport chain (ETC) and OXPHOS: complex I (NDUFA8, NDUFB2, NDUFB4, NDUFS2, NDUFS5), complex III (UQCRC2), and the ATP synthase/complex V (ATP5O and ATP5J) (Figure 1E). We also found a large number of factors indirectly required for OXPHOS through either ETC maturation or the synthesis of mitochondrially encoded ETC components (Taanman, 1999): mitochondrial chaperones (BCS1L, COA3, COA4, and OXA1L), mitochondrial ribosome subunits (MRPL17, MRPL16, MRPL22, MRPL24, MRPL30, MRPL33, MRPL34, MRPL41, and MRPL55), mitochondrial tRNAs (AARS2, VARS2, and TARS2), mitochondrial tRNA maturation (PTCD1), and mitochondrial RNase P (KIAA0391, TRMT10C, and HSD17B10). To further interrogate the link between mitochondrial metabolism and ER-phagy, we focused on further investigation of three factors that are involved in different parts of OXPHOS: NDUFB2, NDUFB4, and ATP5O (Figure S2A).

Stable knockdown of OXPHOS components quantitatively inhibited starvation-induced ER-phagy in multiple assays in a manner that paralleled knockdown efficiency (Figures 2B and S2B-S2D). However, knockdown of NDUFB2, NDUFB4, or ATP5O did not grossly affect starvation-induced general autophagy (Figure S2E). Knockdown of NDUFB2 destabilized NDUFB4 and vice versa, presumably because both are integral subunits of complex I (Figure S2B). Consistently, re-expressing the cognate OXPHOS cDNA rescued both the cognate protein and the destabilized partner (Figure S2F). Re-expressing the destabilized partner only rescued the abundance of that partner without affecting the knocked-down gene (e.g., NDUFB2 knockdown depletes both NDUFB2 and NDUFB4, and re-expressing NDUFB4 in this background only rescues NDUFB4 levels). Reexpressing the appropriate OXPHOS cDNA rescued ER-phagy, while cross-expressing a non-cognate OXPHOS cDNA had no effect, indicating that each knockdown was specific and on target (Figure 2C; Figures S2F-S2H).

We further explored the necessity of functional OXPHOS for normal ER-phagy using chemical genetics (Figure S2I). Rotenone is a known inhibitor of both general autophagy and complex I (Mader et al., 2012) and reduced both general autophagy and ER-phagy by multiple assays (Figures 2D and 2E; Figures S2J–S2L). By contrast, inhibiting complex III with antimycin A or ATP synthase with oligomycin A reduced ER-phagy but increased general autophagy at both early (4 h) and late time points (16 h) (Figures 2D and 2E; Figures S2J–S2M). Using Cell-Titer Glo to measure ATP levels (Figure S2N) and Seahorse




Figure 2. Intact OXPHOS Promotes ERphagy

(A) Genes that are components of the OXPHOS pathway were top hits in screen (highlighted in blue). Additional mitochondria-related genes are indicated in black and all other targeting sgRNAs are indicated in gray.

(B) Knockdown of NDUFB4 and NDUFB2 significantly inhibit ER-phagy. HCT116 CRISPRi EATR cells were transduced with sgRNAs targeting ULK1, NDUFB4, NDUFB2, or ATP50 and starved for 16 h before FACS measurement for ER-phagy. Data are presented as mean \pm SD of eight biological replicates.

(C) Re-expression of cognate cDNA of each OXPHOS gene rescues ER-phagy. HCT116 CRISPRI EATR cells were transduced with NDUFB4 or NDUFB2 cDNA constructs and then transduced with the indicated sgRNAs. Cells were starved for 16 h before FACS measurement for ER-phagy. Data are presented as mean \pm SD of three biological replicates.

(D) Small-molecule inhibitors of the different OXPHOS compartments phenocopy the effect of genetic inhibitions. HCT116 EATR cells were treated with rotenone, antimycin A, or oligomycin A and starved for 16 h before FACS measurement of ER-phagy. Data are presented as mean \pm SD of three biological replicates.

(E) General autophagy proceeds in cells where NDUFB2, NDUFB4, or ATP50 are knocked down. HCT116 CRISPRi cells expressing mCherry-eGFP-LC3B were transduced with the indicated sgRNAs. Cells were starved for 4 h before FACS measurement for general autophagy. Data represent mean \pm SD of four biological replicates. See also Figures S2 and S3.

to measure oxygen consumption (Figure S2O), we confirmed that knockdown of the OXPHOS genes reduced cellular energy levels.

We explored several hypotheses to determine how interfering with OXPHOS reduces ER-phagy. First, we found that increased mitophagic flux is not responsible for reduced ER-phagy by titrating away autophagic machinery. OXPHOS conditions that repressed ER-phagy did not grossly alter mitochondrial abundance or membrane potential and starvation actually increased the amount of Mitotracker accumulation (Figure S3A) (Johnson et al., 2014; Xiao et al., 2016). We also found no evidence of increased mitophagy during knockdown of OXPHOS components, either with or without stable overexpression of Parkin (Figures S3B–S3G).

Second, we found that interfering with OXPHOS reduced levels of the autophagic kinase ULK1 during starvation, but this is not causative of reduced ER-phagy. Knockdown of NDUFB2, NDUFB4, and ATP50 did not affect ULK1 under basal conditions, but during starvation reduced levels of ULK1 almost as much as knockdown of ULK1 itself (Figure S3H). Cognate cDNA re-expression in the appropriate stable knockdown background rescued levels of ULK1, and these same conditions also rescued ER-phagy (Figure S3H; Figure 2C). But overexpression of ULK1 itself in the context of OXPHOS knockdown did not rescue ER-phagy, indicating that reduced ULK1 is not limiting (Figure S3I).

Third, we found that reduced ER-phagy upon knockdown of OXPHOS components is independent of 5' AMP-activated Protein Kinase (AMPK) signaling. This is surprising, since AMPK is a master regulator of general autophagy in response to cellular energy availability (Egan et al., 2011; Kim et al., 2011; Toyama et al., 2016). We generated AMPKa CRISPR-Cas9 knockout cells (Figure S3J) and found that they still mount a robust ER-phagy response (Figures S3K and S3L). The ability to perform ERphagy in AMPKa-knockout cells was unaffected by stable re-expression of constitutively active or kinase dead AMPKa (Figures S3K and S3L). Overall, while genetically or chemically interfering with mitochondrial OXPHOS potently reduces ERphagy, the mechanism of this cross-talk is independent of canonical pathways and remains unclear.

DDRGK1-Mediated UFMylation Regulates ER-Specific Autophagy of ER Sheets

The genome-wide screen for ER-phagy regulators yielded several hits that are localized to the ER and/or involved in ER-related processes (Figures 1E and 3A). We focused on one of these factors, DDRGK1/C20orf116/UFBP1, which has emerging roles in ER homeostasis (Leto et al., 2019; Liu et al., 2017; Walc-zak et al., 2019; Zhu et al., 2019).

Individual, stable knockdown of DDRGK1 resulted in ERphagy as measured using both EATR and CCER assays (Figures 3B and 3C; Figure S4A) but had no apparent effect on general autophagy as determined using mCherry-eGFP-LC3B assay and the degradation of endogenous p62 and LC3B (Figures 3C and 3D). Immunofluorescence confirmed that an mCherrytagged DDRGK1 construct co-localized with the ER (Figure 3E).

DDRGK1 is reported to be post-translationally modified by UFMylation, which is in turn required for further UFMylation of other factors (Cai et al., 2015; Liu et al., 2017; Wei and Xu, 2016; Wu et al., 2010). UFMylation involves the sequential activation, conjugation and ligation of UFM1 to a target substrate via an E1 (UBA5), E2 (UFC1), and E3 (UFL1) cascade that mirrors ubiquitin conjugation (Figure 4A) (Daniel and Liebau, 2014; Komatsu et al., 2004). We found that stable knockdown of UFL1 decreases DDRGK1 protein levels in a proteasome-dependent manner and also inhibited ER-phagy (Figures 4B and 4C; Figure S4B), as did knockdown of UFM1 and UBA5 (Figures 4D and S4C). Double knockdown of both UFL1 and DDRGK1 did not further inhibition of ER-phagy as compared to individual depletion of either factor, suggesting that they act in the same pathway to regulate ER-phagy (Figures S4D and S4E). Stable re-expression of UFL1 in UFL1-depleted cells rescued levels of DDRGK1 and restored ER-phagy (Figures 4E and 4F), but overexpression of DDRGK1 in UFL1-depleted cells led to high levels of DDRGK1 without ER-phagy (Figures 4E and 4F). Knockdown of DDRGK1 and UFL1 impeded lysosomal cleavage of both mCherry-RAMP4 and mCherry-KDEL, consistent with UFMylation mediating the autophagic turnover of both ER surface and lumenal proteins (Figures 4C, S4F, and S4G) (Munro and Pelham, 1987).

We made tandem fluorescent reporters for ER sheets (CLIMP63-mCherry-eGFP) and ER tubules (REEP5-mCherryeGFP) and found that knockdown of either DDRGK1 or UFL1 specifically impaired the autophagy of ER sheets (Figures 4G, S4H, and S4I). Different ER-phagy receptors are expressed on ER sheets or ER tubules. We found that overexpression of the sheet-localized ER-phagy receptors FAM134B, TEX264, and SEC62 induced ER-phagy, and this was perturbed by the depletion of DDRGK1 in the presence and absence of starvation (Figures 4H and S4J-S4L) (An et al., 2019; Chino et al., 2019; Fumagalli et al., 2016; Khaminets et al., 2015). Far less ERphagy was induced by overexpression of the tubule-located ER-phagy receptors CCPG1, RTN3L, and ATL3, and loss of DDRGK1 did not have a statistically significant effect in this context (Figure 4H) (Chen et al., 2019; Grumati et al., 2017; Smith et al., 2018). DDRGK1 co-localizes with FAM134B both on the ER and in the lysosome, suggesting that subdomains of the ER containing DDRGK1 are cargos of FAM134B-mediated ERphagy (Figure 4I).

DDRGK1 Acts as an ER Surface Adaptor for UFL1 Rather Than a UFMylation Substrate

DDRGK1 is reported to be UFMylated by UFL1 on one or more lysines and thereby stabilized (Figure 5A) (Wu et al., 2010). Using immunoprecipitation of DDRGK1 point mutants, we indeed found higher molecular weight species consistent with lysine posttranslational modification of DDRGK1 (Figures 5B and S5A). However, this modification was unaffected by CRISPR-Cas9 knockout of UFL1 or CRISPRi knockdown of UFM1 (Figure 5B and S5A). Furthermore, knockdown of UFM1 had no effect on the abundance of DDRGK1 (Figure S5B), and DDRGK1 still stably interacted with UFL1 even when all 12 conserved lysines were mutated (K-less) (Figure 5B). Taken together, these data indicate that the stability of endogenous DDRGK1 is maintained not by UFMylation but by its interaction with UFL1. Along these lines, we found that DDRGK1's ability to promote ER-phagy was




Figure 3. DDRGK1 Specifically Regulates ER-phagy

(A) ER-phagy CRISPRi screen identifies genes that are associated with the ER. Previously reported ER-phagy regulators are highlighted in red. DDRGK1 is highlighted in blue.

(B) DDRGK1 depletion results in inhibition of ER-phagy. HCT116 CRISPRi EATR cells were transduced with sgRNAs targeting ULK1 or DDRGK1 and starved for 16 h before FACS measurement for ER-phagy. Data are presented as mean ± SD of three biological replicates.

(C) DDRGK1 specifically inhibits ER-phagy but not general autophagy. HCT116 CRISPRi CCER cells were transduced with sgRNAs targeting DDRGK1 and starved for 16 h. Cells were lysed for western blotting of the indicated proteins.

(D) HCT116 CRISPRi cells stably expressing mCherry-eGFP-LC3B constructs were transduced with sgRNAs targeting either ULK1, ATG10, or DDRGK1. Cells were starved for 16 h before FACS measurement for general autophagy. Data are presented as mean ± SD of three biological replicates.


(E) DDRGK1 localizes to the ER. HeLa cells were stably transduced with DDRGK1-mCherry construct and immunostained for calnexin (CANX) as an ER marker. Insets represent a 3-fold enlargement of boxed areas. Scale bar represents 10 µm.

See also Figure S4.

independent of its major reported site of UFMylation on Lys267 (Figures 5C and S5C). Eleven other lysine mutants also substantially supported ER-phagy, as could a DDRGK1 mutant with all 12 conserved lysines mutated (Figures S5D and S5E). Overall, these data strongly suggest that DDRGK1 is not a target of UFMylation during ER-phagy, as has been reported for DDRGK1's involved in the UPR and other signaling pathways (Lemaire et al., 2011; Yoo et al., 2014).

Using immunofluorescence and immunoprecipitation, we found that UFL1's localization to the ER is dependent on DDRGK1. CRISPR-Cas9 knockout of DDRGK1 abrogated ER

localization of UFL1, resulting in diffuse, cytosolic UFL1 (Figure 5D). We re-expressed various cDNA constructs of DDRGK1 in the DDRGK1 knockout background to map functional regions of the protein. Deleting DDRGK1's N-terminal ER-targeting transmembrane domain (TM) still supported a DDRGK1-UFL1 interaction but led to cytoplasmic localization of both DDRGK1 and UFL1 without ER-phagy (Figures 5E–5H, S6A, and S6B). Removing DDRGK1's C-terminal PCI domain did not affect normal ER localization of DDRGK1 but abolished its interaction with UFL1 (Figures 5E–5G and S6A). This led to cytoplasmic localization of UFL1 and abolished the cell's ability to



(legend on next page)

perform ER-phagy (Figures 5E–5G, S5A, and S5B). Re-targeting DDRGK1 to the mitochondria (TOM20- Δ TMDD-HA) or peroxisomes (PMP34- Δ TMDD-HA) was sufficient to re-target GFP-tagged UFL1 to each organelle (Figure 5I). Hence, DDRGK1's interaction with UFL1 via its PCI domain dictates the subcellular localization of UFL1.

During mitophagy, numerous proteins are ubiquitylated on the mitochondrial surface. But current models of mitophagy suggest that overall ubiquitin load is more important than any one substrate (Chan et al., 2011; Heo et al., 2015; Ordureau et al., 2014). Hence, we asked whether directly recruiting UFL1 to the ER surface could bypass the need for DDRGK1 (Figure S6C). However, expression of UFL1-RAMP4 in DDRGK1-depleted cells was not sufficient to rescue ER-phagy despite robust localization to the ER surface (Figures S6C–S6F). Together, these data indicate that DDRGK1 both recruits UFL1 to the ER and plays a role in activation of its ligase activity or recruitment of substrates during ER-phagy. We find that DDRGK1 is not a UFMylation substrate during ER-phagy and is instead analogous to an ubiquitin substrate adaptor (e.g., an F-box protein) that works with Cullin-RING family proteins.

To identify candidate substrates of DDRGK1/UFL1 dependent UFMylation on the ER, we first knocked down previously reported substrates of UFL1 including CDK5RAP3, SOX9, and ASC1 (Cai et al., 2015; Egunsola et al., 2017; Liu et al., 2017; Wu et al., 2010; Yoo et al., 2014), but none of them affected ER-phagy (Figures S6G and S6H).

We therefore performed immunoprecipitation-tandem mass spectrometry (IP-MS/MS) label-free proteomics to identify new interactors of DDRGK1 and DDRGK1-dependent UFMylation substrates during EBSS starvation. To identify DDRGK1 interactors, non-denaturing IP-MS/MS was performed in DDRGK1 knockout HEK293T clones that either did or did not stably reexpress HA-tagged DDRGK1 (Figure 6A). To identify DDRGK1dependent UFMylated proteins, we counteracted the constitutive deconjugation of UFM1 from substrates by UFSP2 (Walczak et al., 2019) by generating CRISPR-Cas9 UFSP2 knockout clones in both wild-type and DDRGK1 knockout HEK2393T cells (Figure 6B). In the UFSP2 knockout and DDRGK1/UFSP2 double-knockout cells, we transiently expressed UFM1 lacking the C-terminal Cys-Ser residues (HA-UFM1- Δ CS) to override the need for UFSP2 cleavage prior to conjugation (Figure 6B). UFMylated proteins were isolated using a denaturing HA-tag IP during EBSS starvation and folimycin treatment (to prevent lyso-somal degradation).

The top differentially enriched proteins from DDRGK1 immunoprecipitation in cells lacking or expressing DDRGK1 were DDRGK1 itself and UFL1 (Figure 6C; Table S3). We also identified several large ribosomal subunits and ribosome-associated factors, including RPL7A, RPLP0, RPL10A, RPL30, and RPL19. This is consistent with recent reports that the ribosome interacts with and is modified by the UFMylation machinery (Simsek et al., 2017; Walczak et al., 2019).

The top UFMylated proteins in both UFSP2 knockout and DDRGK1/UFSP2 double-knockout cells were UFM1 itself, UBA5, and UFC1; UFL1 and DDRGK1 were not identified (Figure 6D; Table S4). These data confirm that this experiment monitors UFMylation, since UFM1 forms a covalent bond with UBA5 and UFC1 but non-covalent interactions with UFL1 and DDRGK1 (Table S4) (Komatsu et al., 2004; Tatsumi et al., 2010). Comparing UFMylation in UFSP2 knockout cells to DDRGK1/UFSP2 double-knockout cells, we identified RPL26, which is a recently reported substrate of DDRGK1-mediated UFMylation (Figure 6D) (Walczak et al., 2019; Wang et al., 2020). Several factors involved in membrane trafficking between organelles and endosomes were also UFMylated in a DDRGK1dependent manner, such as RAB1A/B, RAB5C, ARF4, and Clathrin. We further identified Ribophorin1 (RPN1), which was notable for several reasons. First, RPN1 is an ER-resident quality-control factor present on ER sheets that is part of the

Figure 4. DDRGK1-Dependent UFMylation Regulates Autophagy of ER Sheets

(A) Schematic of the three-step enzymatic reaction of the UFMylation cascade. UBA5 (E1) activate UFM1 and UFC1 acts as an E2 enzyme that interacts with the E3 ligase, UFL1. UFL1 recognizes and transfer UFM1 from UFC1 to its target substrate. Asterisk indicates that DDRGK1 is reported as a substrate of UFMylation in the literature.

(B) UFL1 knockdown reduces DDRGK1 protein levels. HCT116 CRISPRi cells were transduced with the indicated sgRNAs and then harvested to immunoblot for UFL1 protein levels.

(C) UFL1 knockdown phenocopies DDRGK1 knockdown during ER-phagy. The cells generated in (B) were starved for 16 h before FACS measurement for ER-phagy. Data are presented as mean ± SD of three biological replicates.

(D) UFMylation components are required for ER-phagy. HCT116 CRISPRi EATR cells expressing the indicated sgRNAs were starved for 16 h before FACS measurement for ER-phagy. Data are presented as mean ± SD of three biological replicates.

(E) UFL1 controls DDRGK1 protein levels. HCT116 CRISPRi cells were transduced with the indicated sgRNAs and further transduced with either DDRGK1-HA or HA-UFL1. Cell lysates were immunoblotted for DDRGK1 and UFL1.


(F) Re-expression of DDRGK1 in UFL1 knockdown cells does not rescue ER-phagy. The cells generated in (E) were starved for 16 h and then subjected to FACS measurement for ER-phagy. Data represent mean ± SD of three biological replicates.


(G) DDRGK1 selectively mediates ER sheets degradation. The RAMP4 in EATR system was replaced with either REEP5 (ER tubule marker) or CLIMP63 (ER sheets). The cells were transduced with the indicated sgRNAs and were starved for 16 h before FACS analysis for ER-phagy progression. Data represent mean ± SD of three biological replicates.


(H) DDRGK1 depletion selectively affect FAM134B, TEX264, and SEC62-mediated ER-phagy. HCT116 CRISPRi EATR cells were stably transduced with the cDNA for the indicated ER-phagy receptors. ER-phagy induced by overexpression of the ER-phagy receptors at basal state was measured by FACS analysis. Data represent mean ± SD of three biological replicates.

(I) DDRGK1 colocalizes with FAM134B and is co-degraded with FAM134B. U2OS cells stably expressing GFP-FAM134B were transiently transfected with mLAMP1-BFP and DDRGK1-mCherry. Cells were then starved for 4 h in the presence of 50 nM folimycin. Scale bar represents 10 μ m. Insets represent a 4-fold enlargement of the boxed area.

See also Figure S4.







(legend on next page)

oligosaccharyltransferase (OST) complex (Figure S6I) (Kelleher et al., 1992). Second, RPN1 contains a significant cytoplasmic domain that could potentially be accessible for UFMylation during ER-phagy (Figure 6E) (Tsao et al., 1992). Third, RPN1 and the rest of the OST are associated with the SEC61/62/63 translocon complex (Yan and Lennarz, 2005). SEC62 has been identified as an ER-phagy receptor, and we found that that SEC62 is epistatic with DDRGK1 during ER-phagy (Figure 5I) (Fumagalli et al., 2016). And fourth, the SEC61/62/63 translocon complex and OST associate with the ribosome during co-translational folding, where they are structurally located immediately adjacent to RPL26 and large ribosomal subunit proteins that we found to interact with DDRGK1 such as RPL30 (Figure 6E) (Braunger et al., 2018). RPN1 and RPL26 are both "common essential" genes, required for the survival of every cell line tested by Dep-Map. The raw guide RNA counts for RPN1 and RPL26 are very low in all populations of the CRISPRi ER-phagy screen, explaining why neither appeared in the high-confidence hit list. Using immunoprecipitation and western blotting, we validated that both RPL26 and RPN1 are UFMylated and this UFMylation is abrogated by knockout of DDRGK1 (Figures 6F and 6G).

DDRGK1-Dependent UFMylation Facilitates ER-phagy and Represses UPR

IRE1 α is an ER stress sensor and was previously reported as a substrate of UFMylation to promote the UPR, but we found no evidence for DDRGK1-mediated UFMylation nor stabilization of IRE1 α during ER-phagy by either IP-MS/MS or IP-western blot (Figure 6B; Table S4; Figure S7A) (Liu et al., 2017). Instead, we conversely found that depletion of DDRGK1, UFL1, or UFM1 (HepG2, MCF7 and HeLa cells) resulted in elevated protein levels of IRE1 α in multiple cell types (Figures 7A and S7B–S7D). These results suggested that an inability to perform UFMylation-dependent ER-phagy could lead to upregulation of an ER stress response through IRE1 α , which senses misfolded proteins in the ER lumen. Indeed, knockdown of UFMylation ER-phagy fac-

tors led to elevated levels of several other UPR proteins including PERK, BiP, and CANX (Figures 7A and S7B). We also observed an increase in levels of CLIMP63 (ER sheet marker) and REEP5 (ER tubule marker), suggesting possible ER expansion (Figures 7A and S7B) (Schuck et al., 2009). Consistent with this idea, immunofluorescence of DDRGK1 CRISPR-Cas9 knockout HeLa cells showed increased CANX staining (Figures S7D and S7E). Knockdown of DDRGK1 or UFL1 led to modest but consistent transcriptional upregulation of the UPR transcripts PERK and BiP, increased differential splicing of XBP1, and upregulation of CLIMP63 and REEP5 (Figure 7B). As opposed to the other ER stress markers, IRE1a showed higher protein levels upon DDRGK1 knockdown but no change in transcript abundance (Figures 7A and 7B), indicating that IRE1a protein levels could be post-translationally regulated in response to UFM1 signaling. The transcriptional upregulation of multiple UPR transcripts, differential splicing of XBP1, post-translational upregulation of IRE1a, and ER expansion are all consistent with increased ER stress and consequent UPR under conditions where UFMylation-dependent ER-phagy cannot be executed. The upregulation of ER stress markers upon DDRGK1 or UFL1 knockdown are weaker than during acutely toxic tunicamycin treatment, suggesting that the disruption of the UFMylation-mediated ERphagy represents a chronic, survivable ER stress (Figure 7B).

IRE1 α senses unfolded proteins in the ER lumen and so is a good candidate to mediate stress signals caused by defective ER-phagy. While we did not observe direct UFMylation of IRE1 α under either fed or starved conditions (Figure S7A), knockdown of IRE1 α in DDRGK1-depleted cells reversed the high levels of UPR markers downstream of IRE1 α caused by an inability to execute ER-phagy (Figure S7F). BiP, which is an upstream factor of IRE1 α signaling, was upregulated in DDRGK1-depleted cells but was not affected by IRE1 α depletion (Figure S7F) (Amin-Wetzel et al., 2017; Oikawa et al., 2009). Knockdown of IRE1 α had only a modest reciprocal effect upon ER-phagy, and only somewhat reversed the ER-phagy defect

Figure 5. DDRGK1 Recruits UFL1 to the ER Surface via the PCI Domain

(A) Schematic of DDRGK1 domains and its conserved lysine residues. The reported major lysine residue for UFMylation (K267) is labeled in red. The two truncated forms of DDRGK1 that either lacks the N-terminal transmembrane domain (Δ TM) or the C-terminal proteasome component domain (Δ PCI) are also shown. (B) Post-translational modification of DDRGK1 occurs on lysine residues. Parental or UFL1 knockout HCT116 cells were transfected with either wild-type (WT) or

lysine-less (K-less) DDRGK1-HA constructs. Cells were harvested for HA immunoprecipitation.

(C) DDRGK1's role during ER-phagy does not require post-translational modification on any lysine residue. HCT116 CRISPRi EATR cells were transduced with DDRGK1 sgRNA and then rescued using the indicated DDRGK1-HA mutant constructs. Cells were starved for 16 h before FACS ER-phagy measurement. Data represent mean \pm SD of three biological replicates.

(D) Loss of DDRGK1 relocalizes UFL1 to the cytoplasm. Wild-type or DDRGK1KO HeLa cells were transiently transfected with GFP-UFL1 and mCherry-KDEL for 48 h. Cells were then fixed and immunostained for endogenous DDRGK1. Insets represent a 3-fold enlargement of boxed areas. Scale bar represents 20 μ m. (E) DDRGK1 interacts with UFL1 via its PCI domain. Parental HCT116 cells were stably transfected with the indicated DDRGK1-HA mutant constructs. Cells were then harvested for HA immunoprecipitation.

(F) DDRGK1 recruits UFL1 to the ER. DDRGK1KO HeLa cells were stably transduced with mCherry-RAMP4 (ER marker) and the indicated DDRGK1-HA mutant constructs. Cells were then transiently transfected with GFP-UFL1 for 24 h. Cells were then fixed and immunostained for HA epitope. Representative images are shown. Insets represent a 3-fold enlargement of boxed areas. Scale bar represents 10 μm.

(G) Pearson's correlation coefficient for (F) was measured between DDRGK1 versus UFL1, DDRGK1 versus RAMP4, and UFL1 versus RAMP4. Data were generated from one biological experiment, and 20–26 cells were analyzed from each condition. Error bar represents standard deviation of each condition.

(H) DDRGK1's role during ER-phagy requires both the SP and PCI domains. HCT116 CRISPRI EATR cells with DDRGK1 knockdown were rescued using the indicated DDRGK1-HA mutant constructs. Cells were then starved for 16 h and ER-phagy was measured by FACS analysis. Data represent mean ± SD of three biological replicates.

(I) DDRGK1's determines the subcellular localization of UFL1. DDRGK1 knockout HeLa cells were stably transduced with either TOM20MTS-DDRGK1-dSP-HA (MTS, mitochondrial targeting signal) or PMP34-DDRGK1-dSP-HA and transiently transfected with GFP-UFL1 and the respective mCherry-organelle constructs. Insets represent a 3-fold enlargement of boxed areas. Scale bar represents 10 μ m. See also Figure S5.




Figure 6. DDRGK1 Mediates UFMylation of ER Surface Proteins

(A) Workflow of mass spectrometry identification of DDRGK1 interactome. DDRGK1KO HEK293T cells ± DDRGK1-HA stable expression were starved for 4 h in the presence of 50 nM folimycin. Cell lysates were harvested for HA immunoprecipitation and mass spectrometry identification of co-immunoprecipitated proteins.

(legend continued on next page)

induced by loss of DDRGK1 (Figure 7C). Hence, UFMylationinduced ER-phagy is upstream of IREα signaling.

Overall, our data indicate that DDRGK1-mediated, ER-resident UFMylation is critical for ER-phagy. DDRGK1 recruits UFL1 to promote ER surface UFMylation. We propose that the inability to UFMylate downstream ER substrates such as RPN1 and RPL26 leads to an inability to execute ER-phagy, resulting in the consequent build-up of ER stress, and eventual activation of the unfolded protein response via IRE1 α (Figure 7D).

DISCUSSION

Our genome-wide ER-phagy screen provides a rich set of genes and pathways that greatly expands our understanding of ERphagy and provides many starting points for further investigation. Among these, we identified several aspects of the core autophagy machinery, consistent with studies showing that ER-phagy shares effectors with general autophagy (Grumati et al., 2017; Khaminets et al., 2015; Smith et al., 2018).

So far, nutrient starvation is the only stress known to directly induce ER-phagy. We found that ER stress-inducing compounds do not lead to ER-phagy, but repression of ER-phagy by knockdown of DDRGK1 UFMylation induces ER stress and the UPR. UFMylation has previously been linked to ER stress through unclear mechanisms (DeJesus et al., 2016; Leto et al., 2019; Walczak et al., 2019), and our data suggest that this is connected to the regulation of ER-phagy. How is it that ER stress does not induce ER-phagy but an inability to perform ER-phagy induces ER stress? Under nutrient depletion, protein misfolding may increase in the ER, but these signals are repressed as cells catabolize the protein- and lipid-rich organelle. Blocking ERphagy could then result in the toxic accumulation of excessive ER and misfolded ER-resident proteins that cannot be sufficiently kept in check by ERAD, thus activating the UPR. Under this model, blocking ER-phagy leads to UPR as a byproduct of ER stress that is no longer relieved by eating portions of the ER. This hypothesis and ordered prioritization of ER stress-relief pathways will require a great deal of investigation but could lead to a molecular rationale for why cells go to the extreme of ER-phagy.

We found extensive interplay between the mitochondria and ER-phagy. The ER and mitochondria are known to crosstalk at membrane contact sites, including transfer and expansion of the lipid bilayer, Ca2+ homeostasis, and mitochondria division (Friedman et al., 2011; Lombardi and Elrod, 2017). Previous studies indicate a unidirectional regulatory role of ER processes toward mitochondrial homeostasis. We found that impairment of mitochondrial OXPHOS represses ER-phagy, demonstrating that mitochondrial metabolism can also inform decisions in the ER. It still remains to be seen whether this communication is directly orchestrated via mitochondria-ER contacts or indirectly as a result of metabolic products. Alternatively, inhibition of OXPHOS could initiate UPR that takes over to repress lastresort ER-phagy. Consistently, mitochondrial dysfunction was reported to trigger the integrated stress response (ISR) which converges with the UPR pathway, further highlighting the complex cross-talk between the two organelles (Guo et al., 2019). Cellular energy levels are regulated by multiple energy sensing mechanisms that have complex roles during general autophagy (Egan et al., 2011; Herzig and Shaw, 2018; Kim et al., 2011), and the interplay between mitochondrial metabolism and ER homeostasis will no doubt involve a rich set of pathways for future investigation.

UFMylation have been implicated in DNA repair, transcriptional regulation, and ribosomal modification, all of which occur in different subcellular compartments (Egunsola et al., 2017; Qin et al., 2019; Walczak et al., 2019; Wang et al., 2019). It has been unclear how the mostly cytoplasmic UFL1 ligase accesses each compartment. We found that DDRGK1 recruits UFL1 to the ER surface for UFMylation-dependent ER-phagy. Post-translational modifications of organelle surfaces are widely involved in organelle autophagy. For example, ubiquitylation of PEX5 serves as a signal for peroxisomal autophagy (Nordgren et al., 2015; Zhang et al., 2015a), and ubiquitylation of multiple mitochondrial substrates promotes mitophagy (Chan et al., 2011; Karbowski and Youle, 2011). Since DDRGK1 recruits UFL1 to the ER surface and their combined ER-resident activity with UFM1 are required for ER-phagy, we speculate that UFMylation of ER surface protein(s) serves as an effector of ER-phagy, similar to PINK1's recruitment of Parkin to ubiquitylate mitochondrial surface

⁽B) Workflow of mass spectrometry identification of DDRGK1-dependent UFMylation substrates. UFSP2KO or DDRGK1 and UFSP2 double-knockout (KO) HEK293T cells were transfected with HA-UFM1- Δ CS for 48 h. Cells were starved for 4 h in the presence of 50 nM folimycin. The cells were then lysed and denatured prior to HA immunoprecipitation and mass spectrometry identification of UFMylated proteins.


⁽C) DDRGK1 interacts with several ribosomal subunit proteins. The volcano plot depicts the log2 fold change of the total peptide count of each identified protein between Ctrl (DDRGK1KO) cells and DDRGK1-HA-expressing cells.


⁽D) Selective enrichment of UFMylated proteins in UFSP2KO cells relative to DDRGK1 and UFSP2 double-KO cells. The volcano plot depicts the log2 fold change of the total peptide count of each identified protein between DDRGK1 and UFSP2 KO versus UFSP2KO cells.

⁽E) RPN1 is structurally in close proximity with RPL26. Structural model of the ribosome, oligosaccharyl transferase (OST), and SEC61 complex generated from Protein Data Bank deposition (PDB: 6FTG) using PyMol (Braunger et al., 2018). RPN1 (orange) is part of the ER-localized OST complex (blue), whereas RPL26 (red) is a component of the large 60S ribosomal subunit (gray). The OST complex and the ribosome are also closely associated with the SEC61 translocon complex (green).

⁽F) RPL26 and RPN1 are both UFMylated in a DDRGK1-dependent manner. The same experimental setup as in (B) was performed to probe for the indicated proteins. Note that the size shift corresponding to UFMylated RPN1 is not obvious due to the use of 2-(*N*-morpholino)ethanesulfonic acid (MES) buffer that better resolves smaller molecular weight proteins, in this case, RPL26.

⁽G) Reverse immunoprecipitation of RPN1-HA showed DDRGK1-dependent UFMylation of RPN1. The same cell lines as in (B) were transfected with the indicated combinations of RPN1-HA and/or UFM1-ΔCS for 24 h. Cells were then lysed for immunoprecipitation of HA epitope. Samples were resolved using 3-(*N*-morpholino)propanesulfonic acid (MOPS) buffer for better molecular weight separation between unmodified and UFMylated RPN1 proteins. See also Figure S6.





sgNT

Figure 7. UFMylation-Mediated ER-phagy Represses IRE1a UPR

Α 4

(A) Dysregulation of UFMylation results in upregulation of UPR. HCT116 cells were transduced with the indicated sgRNAs and harvested for western blotting analysis. The graph represents densitometry measurement of the indicated proteins upon sgRNA knockdown. A representative blot is shown in Figure S7B. Data represent mean \pm SD of three biological replicates.

(B) Dysregulation of UFMylation transcriptionally upregulates UPR markers except IRE1 a. HCT116 CRISPRi cells were transduced with the indicated sgRNAs. Tunicamyin (0.5 µg/mL; 4 h) was used as a positive control for ER stress. Cells were harvested for qRT-PCR measurement of the indicated ER or UPR genes. Data represent mean \pm SD of three biological replicates.

(legend continued on next page)

Cell

proteins during mitophagy (Chan et al., 2011; Glauser et al., 2011; Karbowski and Youle, 2011; Wang et al., 2011).

We identified RPN1, a subunit of the ER-localized OST complex, as a novel DDRGK1-dependent UFMylation substrate. For several reasons, we propose that RPN1 is part of a UFMylation "hub" that participates in ER-resident quality control. The OST complex associates with ribosomes and the SEC61/62/63 complex for nascent protein translocation and maturation (Braunger et al., 2018; Kelleher et al., 1992; Shibata et al., 2010; Wilson et al., 2005; Yan and Lennarz, 2005). RPL26 is a known UFMylation substrate within the 60S large ribosomal subunit and sits in in close proximity with RPN1 (Figures 6E and 7D) (Walczak et al., 2019). DDRGK1 also physically interacts with multiple components of the large 60S ribosomal subunits that are nearby RPN1.

The downstream parts played by UFMylated RPN1 during ER marking, autophagic engulfment, and degradation remain to be determined. Dysregulation of glycosylation by interfering with the OST complex and inhibition of UFMylation both cause ER stress (Cherepanova et al., 2016; Walczak et al., 2019). The SEC62 ER-stress activated ER-phagy receptor is part of the translocon complex directly adjacent to the OST complex, and we found DDRGK1 to be epistatic to SEC62 during ER-phagy (Fumagalli et al., 2016; Kelleher et al., 1992; Tsao et al., 1992; Walczak et al., 2019; Wilson et al., 2005). Since RPN1 contains an N-terminal cytoplasmic domain and a C-terminal ER lumenal domain, it is possible that RPN1 might relay ER stress signals via ER-surface UFMylation during peptide translocation. Failure to relay and appropriately deal with these signals on the ribosome-rich ER sheets could induce the IRE1a-mediated UPR induced by blockage of DDRGK1dependent UFMylation. Nascent proteins trapped in the ribosome induces RPL26 UFMylation and lysosomal degradation of the stalled protein and ribosome en bloc (Wang et al., 2020). It is currently unknown whether these UFMylated ribosomes are physically extracted from the ER prior to lysosomal degradation. or if portions of the ER are degraded alongside the UFMylated ribosomes. Importantly, RPN1 and RPL26 might not be the exclusive targets of UFMylation and simultaneous UFMylation of other ER surface proteins could be required to drive ER-phagy in a cooperative manner. Overall, our data unify disparate reports of UFMylation impacting the UPR and provide a mechanistic rationale for how autophagy of ER sheets helps to prevent accumulation of ER stress. This opens up a great deal of further avenues to dissect the subsequent steps by which UFMylation is recognized on the ER surface to mediate ER-phagy.

While defects in ER-phagy have not been explicitly linked to human disease, human mutations in ER-phagy genes such as FAM134B and Atlastins are associated with hereditary neuropathies in OMIM and ClinVar (Abel et al., 2004; Amberger et al., 2015; Kurth et al., 2009). Several ER-phagy genes derived from our screen are also associated with human neurodegenerative phenotypes with previously unclear mechanistic bases, such as Leigh syndrome (mitochondrial OXPHOS, including ETC chaperones) (Lake et al., 2016), spastic paraplegia (ARL6IP1) (Novarino et al., 2014), encephalopathy (TRAPPC12) (Milev et al., 2017), spinocerebellar ataxia and encephalopathy (UBA5) (Daida et al., 2018; Mignon-Ravix et al., 2018), and severe early-onset encephalopathy and progressive microcephaly (UFC1, UFM1) (Nahorski et al., 2018). It is premature to broadly link deficits in ER-phagy to human disease, but the similar phenotypes stemming from mutations in various ER-phagy factors are provocative. Our work lays the foundation for future understanding of ER-phagy and its interplay with the ER stress response, as well as the consequences of ineffective ER-phagy. Further mechanistic dissection of the 200 high-confidence ERphagy regulators and executors identified here will hopefully shed light on this dramatic process.

STAR*METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- METHOD DETAILS
 - Design, Production and titering of sgRNA library lentivirus
 - CRISPRi screen: cell generation, virus transduction, puro selection, and sort
 - NGS Sample Preparation and screen analysis
 - sgRNA plasmid cloning procedures for individual plasmids
 - shRNA plasmid cloning for DDRGK1 and UFL1
 - cDNA plasmid cloning procedures
 - Cell culture
 - Cell Treatments
 - O Lentiviral packaging and transduction
 - O Knockout Cell Line Generation
 - Flow Cytometry Analysis of EATR cells
 - Quantitative real-time PCR (qRT-PCR)
 - Western blotting
 - Immunoprecipitation
 - Denaturing Immunoprecipitation and tandem-mass spectrometry analysis (IP-MS/MS)
 - Immunofluorescence
 - MitoTracker
 - ATP Assay
 - Mitochondrial Respiration Measurements
 - Statistical analysis
- DATA AND CODE AVAILABILITY

⁽C) Knockdown of IRE1a partially restores ER-phagy in DDRGK1-depleted cells. HCT116 CRISPRi EATR cells transduced with the indicated sgRNAs and starved for 16 h before FACS measurement for ER-phagy. Data represent mean ± SD of three biological replicates.

⁽D) Proposed model for the role of UFMylation during ER-phagy. DDRGK1 acts as an ER surface adaptor that recruits UFL1. At least two ER surface proteins that are in close proximity, RPN1 and RPL26, are UFMylated during ER-phagy. Dysregulation of UFMylation inhibits ER-phagy, and this potentially results in accumulation of ER stress and subsequently activates the IRE1 α-mediated unfolded protein response pathway. See also Figure S7.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j. cell.2020.02.017.

ACKNOWLEDGMENTS

J.E.C. and J.R.L. were supported by the National Institutes of Health (DP2-HL-141006), the NOMIS Foundation, the Lotte and Adolf Hotz-Sprenger Stiftung, the Li Ka Shing Foundation, and the Heritage Medical Research Institute. This research was also supported by a grant from the National Institute of Health (R01GM112948 to J.A.O.). J.A.O. is a Chan Zuckerberg Biohub investigator. E.L. was supported by the National Science Foundation. This work used the Vincent J. Coates Genomics Sequencing Laboratory at UC Berkeley, which is supported by NIH Instrumentation grant S10 OD018174. Confocal liveand fixed-cell imaging experiments were conducted at the Cancer Research Laboratory-Molecular Imaging Center Berkeley (supported by the Gordon and Betty Moore Foundation) and the Scientific Center for Optical and Electron Microscopy facility at ETH Zurich. Mass spectrometry experiments were performed by the Functional Genomics Center Zurich (ETH Zurich/University of Zurich).

AUTHOR CONTRIBUTIONS

J.R.L., E.L., and J.E.C. designed the experiments. J.R.L., E.L., T.L., S.A., M.M., T.N., and J.A.O. performed experiments. J.R.L., E.L., and J.E.C. analyzed data and wrote the manuscript. All authors contributed feedback for the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: February 14, 2019 Revised: November 4, 2019 Accepted: February 7, 2020 Published: March 10, 2020

REFERENCES

Abel, A., Fonknechten, N., Hofer, A., Dürr, A., Cruaud, C., Voit, T., Weissenbach, J., Brice, A., Klimpe, S., Auburger, G., and Hazan, J. (2004). Early onset autosomal dominant spastic paraplegia caused by novel mutations in SPG3A. Neurogenetics 5, 239–243.

Amberger, J.S., Bocchini, C.A., Schiettecatte, F., Scott, A.F., and Hamosh, A. (2015). OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res. *43*, D789–D798.

Amin-Wetzel, N., Saunders, R.A., Kamphuis, M.J., Rato, C., Preissler, S., Harding, H.P., and Ron, D. (2017). A J-Protein Co-chaperone Recruits BiP to Monomerize IRE1 and Repress the Unfolded Protein Response. Cell *171*, 1625–1637.

An, H., Ordureau, A., Paulo, J.A., Shoemaker, C.J., Denic, V., and Harper, J.W. (2019). TEX264 Is an Endoplasmic Reticulum-Resident ATG8-Interacting Protein Critical for ER Remodeling during Nutrient Stress. Mol. Cell *74*, 891–908.

Binder, J.X., Pletscher-Frankild, S., Tsafou, K., Stolte, C., O'Donoghue, S.I., Schneider, R., and Jensen, L.J. (2014). COMPARTMENTS: unification and visualization of protein subcellular localization evidence. Database (Oxford) *2014*, bau012.

Braunger, K., Pfeffer, S., Shrimal, S., Gilmore, R., Berninghausen, O., Mandon, E.C., Becker, T., Förster, F., and Beckmann, R. (2018). Structural basis for coupling protein transport and N-glycosylation at the mammalian endoplasmic reticulum. Science *360*, 215–219.

Cai, Y., Pi, W., Sivaprakasam, S., Zhu, X., Zhang, M., Chen, J., Makala, L., Lu, C., Wu, J., Teng, Y., et al. (2015). UFBP1, a Key Component of the Ufm1 Conju-

gation System, Is Essential for Ufmylation-Mediated Regulation of Erythroid Development. PLoS Genet. *11*, e1005643.

Chan, N.C., Salazar, A.M., Pham, A.H., Sweredoski, M.J., Kolawa, N.J., Graham, R.L.J., Hess, S., and Chan, D.C. (2011). Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum. Mol. Genet. *20*, 1726–1737.

Chatr-Aryamontri, A., Oughtred, R., Boucher, L., Rust, J., Chang, C., Kolas, N.K., O'Donnell, L., Oster, S., Theesfeld, C., Sellam, A., et al. (2017). The Bio-GRID interaction database: 2017 update. Nucleic Acids Res. *45* (D1), D369–D379.

Chen, Q., Xiao, Y., Chai, P., Zheng, P., Teng, J., and Chen, J. (2019). ATL3 Is a Tubular ER-Phagy Receptor for GABARAP-Mediated Selective Autophagy. Curr. Biol. *29*, 846–855.

Cherepanova, N., Shrimal, S., and Gilmore, R. (2016). N-linked glycosylation and homeostasis of the endoplasmic reticulum. Curr. Opin. Cell Biol. *41*, 57–65.

Chino, H., Hatta, T., Natsume, T., and Mizushima, N. (2019). Intrinsically Disordered Protein TEX264 Mediates ER-phagy. Mol. Cell *74*, 909–921.

Daida, A., Hamano, S.-I., Ikemoto, S., Matsuura, R., Nakashima, M., Matsumoto, N., and Kato, M. (2018). Biallelic loss-of-function UBA5 mutations in a patient with intractable West syndrome and profound failure to thrive. Epileptic Disord. *20*, 313–318.

Daniel, J., and Liebau, E. (2014). The ufm1 cascade. Cells 3, 627-638.

Deas, E., Wood, N.W., and Plun-Favreau, H. (2011). Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim. Biophys. Acta *1813*, 623–633.

DeJesus, R., Moretti, F., McAllister, G., Wang, Z., Bergman, P., Liu, S., Frias, E., Alford, J., Reece-Hoyes, J.S., Lindeman, A., et al. (2016). Functional CRISPR screening identifies the ufmylation pathway as a regulator of SQSTM1/p62. eLife 5. Published online June 28, 2016. https://doi.org/10.7554/eLife.17290.

Dodson, M.W., and Guo, M. (2007). Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr. Opin. Neurobiol. *17*, 331–337.

Egan, D.F., Shackelford, D.B., Mihaylova, M.M., Gelino, S., Kohnz, R.A., Mair, W., Vasquez, D.S., Joshi, A., Gwinn, D.M., Taylor, R., et al. (2011). Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science *331*, 456–461.

Egunsola, A.T., Bae, Y., Jiang, M.-M., Liu, D.S., Chen-Evenson, Y., Bertin, T., Chen, S., Lu, J.T., Nevarez, L., Magal, N., et al. (2017). Loss of DDRGK1 modulates SOX9 ubiquitination in spondyloepimetaphyseal dysplasia. J. Clin. Invest. *127*, 1475–1484.

Elangovan, M., Chong, H.K., Park, J.H., Yeo, E.J., and Yoo, Y.J. (2017). The role of ubiquitin-conjugating enzyme Ube2j1 phosphorylation and its degradation by proteasome during endoplasmic stress recovery. J. Cell Commun. Signal. *11*, 265–273.

Fregno, I., Fasana, E., Bergmann, T.J., Raimondi, A., Loi, M., Soldà, T., Galli, C., D'Antuono, R., Morone, D., Danieli, A., et al. (2018). ER-to-lysosome-associated degradation of proteasome-resistant ATZ polymers occurs via receptor-mediated vesicular transport. EMBO J. *37*, 37.

Friedman, J.R., Lackner, L.L., West, M., DiBenedetto, J.R., Nunnari, J., and Voeltz, G.K. (2011). ER tubules mark sites of mitochondrial division. Science *334*, 358–362.

Fumagalli, F., Noack, J., Bergmann, T.J., Cebollero, E., Pisoni, G.B., Fasana, E., Fregno, I., Galli, C., Loi, M., Soldà, T., et al. (2016). Translocon component Sec62 acts in endoplasmic reticulum turnover during stress recovery. Nat. Cell Biol. *18*, 1173–1184.

Geisler, S., Holmström, K.M., Treis, A., Skujat, D., Weber, S.S., Fiesel, F.C., Kahle, P.J., and Springer, W. (2010). The PINK1/Parkin-mediated mitophagy is compromised by PD-associated mutations. Autophagy 6, 871–878.

Gibson, D.G., Young, L., Chuang, R.-Y., Venter, J.C., Hutchison, C.A., 3rd, and Smith, H.O. (2009). Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods *6*, 343–345.

Gilbert, L.A., Horlbeck, M.A., Adamson, B., Villalta, J.E., Chen, Y., Whitehead, E.H., Guimaraes, C., Panning, B., Ploegh, H.L., Bassik, M.C., et al. (2014).

Genome-scale CRISPR-mediated control of gene repression and activation. Cell *159*, 647–661.

Glauser, L., Sonnay, S., Stafa, K., and Moore, D.J. (2011). Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1. J. Neurochem. *118*, 636–645.

Grumati, P., Morozzi, G., Hölper, S., Mari, M., Harwardt, M.I., Yan, R., Müller, S., Reggiori, F., Heilemann, M., and Dikic, I. (2017). Full length RTN3 regulates turnover of tubular endoplasmic reticulum via selective autophagy. eLife *6*. Published online June 15, 2017. https://doi.org/10.7554/eLife.25555.

Guo, X., Aviles, G., Liu, Y., Tian, R., Unger, B.A., Lin, Y.-H.T., Wiita, A.P., Xu, K., Correia, M.A., and Kampmann, M. (2019). Mitochondrial dysfunction is signaled to the integrated stress response by OMA1, DELE1 and HRI. bioRxiv. https://doi.org/10.1101/715896.

Hamasaki, M., Noda, T., Baba, M., and Ohsumi, Y. (2005). Starvation triggers the delivery of the endoplasmic reticulum to the vacuole via autophagy in yeast. Traffic *6*, 56–65.

Heo, J.-M., Ordureau, A., Paulo, J.A., Rinehart, J., and Harper, J.W. (2015). The PINK1-PARKIN Mitochondrial Ubiquitylation Pathway Drives a Program of OPTN/NDP52 Recruitment and TBK1 Activation to Promote Mitophagy. Mol. Cell *60*, 7–20.

Herzig, S., and Shaw, R.J. (2018). AMPK: guardian of metabolism and mitochondrial homeostasis. Nat. Rev. Mol. Cell Biol. *19*, 121–135.

Horlbeck, M.A., Gilbert, L.A., Villalta, J.E., Adamson, B., Pak, R.A., Chen, Y., Fields, A.P., Park, C.Y., Corn, J.E., Kampmann, M., and Weissman, J.S. (2016). Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. eLife *5*. Published online September 23, 2016. https://doi.org/10.7554/eLife.19760.

Huang, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. *4*, 44–57.

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M.A., Hall, A., and Hall, M.N. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. *6*, 1122–1128.

Johnson, M.A., Vidoni, S., Durigon, R., Pearce, S.F., Rorbach, J., He, J., Brea-Calvo, G., Minczuk, M., Reyes, A., Holt, I.J., and Spinazzola, A. (2014). Amino acid starvation has opposite effects on mitochondrial and cytosolic protein synthesis. PLoS ONE *9*, e93597.

Karbowski, M., and Youle, R.J. (2011). Regulating mitochondrial outer membrane proteins by ubiquitination and proteasomal degradation. Curr. Opin. Cell Biol. *23*, 476–482.

Kelleher, D.J., Kreibich, G., and Gilmore, R. (1992). Oligosaccharyltransferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kd protein. Cell *69*, 55–65.

Khaminets, A., Heinrich, T., Mari, M., Grumati, P., Huebner, A.K., Akutsu, M., Liebmann, L., Stolz, A., Nietzsche, S., Koch, N., et al. (2015). Regulation of endoplasmic reticulum turnover by selective autophagy. Nature *522*, 354–358.

Kim, J., Kundu, M., Viollet, B., and Guan, K.-L. (2011). AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. *13*, 132–141.

Komatsu, M., Chiba, T., Tatsumi, K., Iemura, S., Tanida, I., Okazaki, N., Ueno, T., Kominami, E., Natsume, T., and Tanaka, K. (2004). A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J. 23, 1977–1986.

Kurth, I., Pamminger, T., Hennings, J.C., Soehendra, D., Huebner, A.K., Rotthier, A., Baets, J., Senderek, J., Topaloglu, H., Farrell, S.A., et al. (2009). Mutations in FAM134B, encoding a newly identified Golgi protein, cause severe sensory and autonomic neuropathy. Nat. Genet. *41*, 1179–1181.

Lake, N.J., Compton, A.G., Rahman, S., and Thorburn, D.R. (2016). Leigh syndrome: One disorder, more than 75 monogenic causes. Ann. Neurol. *79*, 190–203.

Lemaire, K., Moura, R.F., Granvik, M., Igoillo-Esteve, M., Hohmeier, H.E., Hendrickx, N., Newgard, C.B., Waelkens, E., Cnop, M., and Schuit, F. (2011). Ubiquitin fold modifier 1 (UFM1) and its target UFBP1 protect pancreatic beta cells from ER stress-induced apoptosis. PLoS ONE 6, e18517. Leto, D.E., Morgens, D.W., Zhang, L., Walczak, C.P., Elias, J.E., Bassik, M.C., and Kopito, R.R. (2019). Genome-wide CRISPR Analysis Identifies Substrate-Specific Conjugation Modules in ER-Associated Degradation. Mol. Cell *73*, 377–389.

Li, W., Xu, H., Xiao, T., Cong, L., Love, M.I., Zhang, F., Irizarry, R.A., Liu, J.S., Brown, M., and Liu, X.S. (2014). MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. *15*, 554.

Li, W., Köster, J., Xu, H., Chen, C.-H., Xiao, T., Liu, J.S., Brown, M., and Liu, X.S. (2015). Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. *16*, 281.

Liang, J.R., Lingeman, E., Ahmed, S., and Corn, J.E. (2018). Atlastins remodel the endoplasmic reticulum for selective autophagy. J. Cell Biol. *217*, 3354–3367.

Lingeman, E., Jeans, C., and Corn, J.E. (2017). Production of purified casrnps for efficacious genome editing. Curr. Protoc. Mol. Biol. *120*, 31.10.1–31.10.19.

Liu, J., Wang, Y., Song, L., Zeng, L., Yi, W., Liu, T., Chen, H., Wang, M., Ju, Z., and Cong, Y.-S. (2017). A critical role of DDRGK1 in endoplasmic reticulum homoeostasis via regulation of IRE1 α stability. Nat. Commun. 8, 14186.

Lombardi, A.A., and Elrod, J.W. (2017). Mediating ER-mitochondrial cross-talk. Science *358*, 591–592.

Mader, B.J., Pivtoraiko, V.N., Flippo, H.M., Klocke, B.J., Roth, K.A., Mangieri, L.R., and Shacka, J.J. (2012). Rotenone inhibits autophagic flux prior to inducing cell death. ACS Chem. Neurosci. *3*, 1063–1072.

Mignon-Ravix, C., Milh, M., Kaiser, C.S., Daniel, J., Riccardi, F., Cacciagli, P., Nagara, M., Busa, T., Liebau, E., and Villard, L. (2018). Abnormal function of the UBA5 protein in a case of early developmental and epileptic encephalopathy with suppression-burst. Hum. Mutat. *39*, 934–938.

Milev, M.P., Grout, M.E., Saint-Dic, D., Cheng, Y.-H.H., Glass, I.A., Hale, C.J., Hanna, D.S., Dorschner, M.O., Prematilake, K., Shaag, A., et al. (2017). Mutations in TRAPPC12 manifest in progressive childhood encephalopathy and golgi dysfunction. Am. J. Hum. Genet. *101*, 291–299.

Munro, S., and Pelham, H.R. (1987). A C-terminal signal prevents secretion of luminal ER proteins. Cell 48, 899–907.

Nahorski, M.S., Maddirevula, S., Ishimura, R., Alsahli, S., Brady, A.F., Begemann, A., Mizushima, T., Guzmán-Vega, F.J., Obata, M., Ichimura, Y., et al. (2018). Biallelic UFM1 and UFC1 mutations expand the essential role of ufmylation in brain development. Brain *141*, 1934–1945.

Nguyen, T.N., Padman, B.S., and Lazarou, M. (2016). Deciphering the molecular signals of pink1/parkin mitophagy. Trends Cell Biol. *26*, 733–744.

Nordgren, M., Francisco, T., Lismont, C., Hennebel, L., Brees, C., Wang, B., Van Veldhoven, P.P., Azevedo, J.E., and Fransen, M. (2015). Export-deficient monoubiquitinated PEX5 triggers peroxisome removal in SV40 large T antigentransformed mouse embryonic fibroblasts. Autophagy *11*, 1326–1340.

Novarino, G., Fenstermaker, A.G., Zaki, M.S., Hofree, M., Silhavy, J.L., Heiberg, A.D., Abdellateef, M., Rosti, B., Scott, E., Mansour, L., et al. (2014). Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science *343*, 506–511.

Oikawa, D., Kimata, Y., Kohno, K., and Iwawaki, T. (2009). Activation of mammalian IRE1alpha upon ER stress depends on dissociation of BiP rather than on direct interaction with unfolded proteins. Exp. Cell Res. *315*, 2496–2504.

Olenych, S.G., Claxton, N.S., Ottenberg, G.K., and Davidson, M.W. (2007). The fluorescent protein color palette. Curr. Protoc. Cell Biol. *Chapter 21*, Unit 21.5.

Ordureau, A., Sarraf, S.A., Duda, D.M., Heo, J.-M., Jedrychowski, M.P., Sviderskiy, V.O., Olszewski, J.L., Koerber, J.T., Xie, T., Beausoleil, S.A., et al. (2014). Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. Mol. Cell *56*, 360–375.

Phillips, A.R., Suttangkakul, A., and Vierstra, R.D. (2008). The ATG12-conjugating enzyme ATG10 Is essential for autophagic vesicle formation in Arabidopsis thaliana. Genetics *178*, 1339–1353. Pickrell, A.M., and Youle, R.J. (2015). The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron *85*, 257–273.

Pilsl, A., and Winklhofer, K.F. (2012). Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol. *123*, 173–188.

Qin, B., Yu, J., Nowsheen, S., Wang, M., Tu, X., Liu, T., Li, H., Wang, L., and Lou, Z. (2019). UFL1 promotes histone H4 ufmylation and ATM activation. Nat. Commun. *10*, 1242.

Rismanchi, N., Soderblom, C., Stadler, J., Zhu, P.-P., and Blackstone, C. (2008). Atlastin GTPases are required for Golgi apparatus and ER morphogenesis. Hum. Mol. Genet. *17*, 1591–1604.

Ruggiano, A., Foresti, O., and Carvalho, P. (2014). Quality control: ER-associated degradation: protein quality control and beyond. J. Cell Biol. 204, 869–879.

Schuck, S., Prinz, W.A., Thorn, K.S., Voss, C., and Walter, P. (2009). Membrane expansion alleviates endoplasmic reticulum stress independently of the unfolded protein response. J. Cell Biol. *187*, 525–536.

Schwarz, D.S., and Blower, M.D. (2016). The endoplasmic reticulum: structure, function and response to cellular signaling. Cell. Mol. Life Sci. *73*, 79–94. Shibata, Y., Shemesh, T., Prinz, W.A., Palazzo, A.F., Kozlov, M.M., and Rapoport, T.A. (2010). Mechanisms determining the morphology of the peripheral ER. Cell *143*, 774–788.

Simsek, D., Tiu, G.C., Flynn, R.A., Byeon, G.W., Leppek, K., Xu, A.F., Chang, H.Y., and Barna, M. (2017). The Mammalian Ribo-interactome Reveals Ribosome Functional Diversity and Heterogeneity. Cell *169*, 1051–1065.

Smith, M.D., Harley, M.E., Kemp, A.J., Wills, J., Lee, M., Arends, M., von Kriegsheim, A., Behrends, C., and Wilkinson, S. (2018). CCPG1 Is a Non-canonical Autophagy Cargo Receptor Essential for ER-Phagy and Pancreatic ER Proteostasis. Dev. Cell 44, 217–232.

Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K.P., et al. (2015). STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. *43*, D447–D452.

Taanman, J.-W. (1999). The mitochondrial genome: structure, transcription, translation and replication. Biochim. Biophys. Acta *1410*, 103–123.

Tatsumi, K., Sou, Y.S., Tada, N., Nakamura, E., Iemura, S., Natsume, T., Kang, S.H., Chung, C.H., Kasahara, M., Kominami, E., et al. (2010). A novel type of E3 ligase for the Ufm1 conjugation system. J. Biol. Chem. *285*, 5417–5427.

Thoreen, C.C., and Sabatini, D.M. (2009). Rapamycin inhibits mTORC1, but not completely. Autophagy 5, 725–726.

Thoreen, C.C., Kang, S.A., Chang, J.W., Liu, Q., Zhang, J., Gao, Y., Reichling, L.J., Sim, T., Sabatini, D.M., and Gray, N.S. (2009). An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023–8032.

Toyama, E.Q., Herzig, S., Courchet, J., Lewis, T.L., Losón, O.C., Hellberg, K., Young, N.P., Chen, H., Polleux, F., Chan, D.C., et al. (2016). Metabolism. AMPactivated protein kinase mediates mitochondrial fission in response to energy stress. Science *351*, 275–281.

Tsao, Y.S., Ivessa, N.E., Adesnik, M., Sabatini, D.D., and Kreibich, G. (1992). Carboxy terminally truncated forms of ribophorin I are degraded in pre-Golgi compartments by a calcium-dependent process. J. Cell Biol. *116*, 57–67.

Walczak, C.P., Leto, D.E., Zhang, L., Riepe, C., Muller, R.Y., DaRosa, P.A., Ingolia, N.T., Elias, J.E., and Kopito, R.R. (2019). Ribosomal protein RPL26 is the principal target of UFMylation. Proc. Natl. Acad. Sci. USA *116*, 1299–1308.

Wang, X., Winter, D., Ashrafi, G., Schlehe, J., Wong, Y.L., Selkoe, D., Rice, S., Steen, J., LaVoie, M.J., and Schwarz, T.L. (2011). PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell *147*, 893–906.

Wang, S., Tukachinsky, H., Romano, F.B., and Rapoport, T.A. (2016). Cooperation of the ER-shaping proteins atlastin, lunapark, and reticulons to generate a tubular membrane network. eLife 5. Published online September 13, 2016. https://doi.org/10.7554/eLife.18605.

Wang, Z., Gong, Y., Peng, B., Shi, R., Fan, D., Zhao, H., Zhu, M., Zhang, H., Lou, Z., Zhou, J., et al. (2019). MRE11 UFMylation promotes ATM activation. Nucleic Acids Res. 47, 4124–4135.

Wang, L., Xu, Y., Rogers, H., Saidi, L., Noguchi, C.T., Li, H., Yewdell, J.W., Guydosh, N.R., and Ye, Y. (2020). UFMylation of RPL26 links translocationassociated quality control to endoplasmic reticulum protein homeostasis. Cell Res. *30*, 5–20.

Wartosch, L., Günesdogan, U., Graham, S.C., and Luzio, J.P. (2015). Recruitment of VPS33A to HOPS by VPS16 Is Required for Lysosome Fusion with Endosomes and Autophagosomes. Traffic *16*, 727–742.

Wei, Y., and Xu, X. (2016). Ufmylation: A unique & fashionable modification for life. Genomics Proteomics Bioinformatics *14*, 140–146.

Wilson, C.M., Kraft, C., Duggan, C., Ismail, N., Crawshaw, S.G., and High, S. (2005). Ribophorin I associates with a subset of membrane proteins after their integration at the sec61 translocon. J. Biol. Chem. 280, 4195–4206.

Wu, J., Lei, G., Mei, M., Tang, Y., and Li, H. (2010). A novel C53/LZAP-interacting protein regulates stability of C53/LZAP and DDRGK domain-containing Protein 1 (DDRGK1) and modulates NF-kappaB signaling. J. Biol. Chem. 285, 15126–15136.

Xiao, B., Deng, X., Zhou, W., and Tan, E.-K. (2016). Flow Cytometry-Based Assessment of Mitophagy Using MitoTracker. Front. Cell. Neurosci. 10, 76.

Yamano, K., Fogel, A.I., Wang, C., van der Bliek, A.M., and Youle, R.J. (2014). Mitochondrial Rab GAPs govern autophagosome biogenesis during mitophagy. eLife 3. Published online February 25, 2014. https://doi.org/10.7554/ eLife.01612.

Yan, A., and Lennarz, W.J. (2005). Two oligosaccharyl transferase complexes exist in yeast and associate with two different translocons. Glycobiology *15*, 1407–1415.

Yoo, H.M., Kang, S.H., Kim, J.Y., Lee, J.E., Seong, M.W., Lee, S.W., Ka, S.H., Sou, Y.-S., Komatsu, M., Tanaka, K., et al. (2014). Modification of ASC1 by UFM1 is crucial for $ER\alpha$ transactivation and breast cancer development. Mol. Cell *56*, 261–274.

Youle, R.J., and Narendra, D.P. (2011). Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. *12*, 9–14.

Yuan, H.-X., Russell, R.C., and Guan, K.-L. (2013). Regulation of PIK3C3/ VPS34 complexes by MTOR in nutrient stress-induced autophagy. Autophagy *9*, 1983–1995.

Zhang, J., Tripathi, D.N., Jing, J., Alexander, A., Kim, J., Powell, R.T., Dere, R., Tait-Mulder, J., Lee, J.-H., Paull, T.T., et al. (2015a). ATM functions at the peroxisome to induce pexophagy in response to ROS. Nat. Cell Biol. *17*, 1259–1269.

Zhang, M., Zhu, X., Zhang, Y., Cai, Y., Chen, J., Sivaprakasam, S., Gurav, A., Pi, W., Makala, L., Wu, J., et al. (2015b). RCAD/Uf11, a Ufm1 E3 ligase, is essential for hematopoietic stem cell function and murine hematopoiesis. Cell Death Differ. *22*, 1922–1934.

Zhao, G., Zhu, P.-P., Renvoisé, B., Maldonado-Báez, L., Park, S.H., and Blackstone, C. (2016). Mammalian knock out cells reveal prominent roles for atlastin GTPases in ER network morphology. Exp. Cell Res. *349*, 32–44.

Zhu, H., Bhatt, B., Sivaprakasam, S., Cai, Y., Liu, S., Kodeboyina, S.K., Patel, N., Savage, N.M., Sharma, A., Kaufman, R.J., et al. (2019). Ufbp1 promotes plasma cell development and ER expansion by modulating distinct branches of UPR. Nat. Commun. *10*, 1084.

STAR***METHODS**

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
ACC (Acetyl-CoA Carboxylase)	Cell Signaling	Cat#: 3676; RRID: AB_2219397
Actin	Cell Signaling	Cat#: 3700; RRID: AB_2242334
MPKa	Cell Signaling	Cat#: 5831; RRID: AB_10622186
NTG10	MBL International	Cat#: M151-3; RRID: AB_1278755
NTP5O	Abcam	Cat#: ab110276; RRID: AB_10887942
3iP	Cell Signaling	Cat#: 3177; RRID: AB_2119845
Calnexin (CANX)	Cell Signaling	Cat#: 2679; RRID: AB_2228381
Calnexin (CANX)	Santa Cruz	Cat#: sc-46669; RRID: AB_626784
CKAP4/ CLIMP63	Bethyl	Cat#: A302-257A; RRID: AB_1731083
DRGK1	ProteinTech	Cat#: 21445-1-AP; RRID: AB_2827383
GAPDH	Cell Signaling	Cat#: #97166; RRID: AB_2756824
)FP	Abcam	Cat#: ab6556; RRID: AB_305564
) FP	Santa Cruz	Cat#: sc-9996; RRID: AB_627695
AST	Cell Signaling	Cat#: 2625; RRID: AB_490796
ła epitope tag	Cell Signaling	Cat#: 3724; RRID: AB_1549585
RE1a	Cell Signaling	Cat#: 3294; RRID: AB_823545
.C3B	Novus Biologicals	Cat#: NB100-2220
nCherry	Abcam	Cat#: ab183628; RRID: AB_2650480
/IFN1	Cell Signaling	Cat#: 14739; RRID: AB_2744531
//FN2	Cell Signaling	Cat#: 11925; RRID: AB_2750893
IDUFB2	Abcam	Cat#: ab186748; RRID: AB_2827382
IDUFB4	Abcam	Cat#: ab110243; RRID: AB_10890994
62	Santa Cruz	Cat#: sc-28359; RRID: AB_628279
ACC S79	Cell Signaling	Cat#: 11818; RRID: AB_2687505
PERK	Cell Signaling	Cat#: 3192; RRID: AB_2095847
Raptor S792	Cell Signaling	Cat#: 2083; RRID: AB_2249475
S6K T389	Cell Signaling	Cat#: 9206; RRID: AB_2285392
ULK1 S555	Cell Signaling	Cat#: 5869; RRID: AB_10707365
laptor	Cell Signaling	Cat#: 2280; RRID: AB_561245
REP5	ProteinTech	Cat#: 14643-1-AP; RRID: AB_2178440
66K (p70 S6 Kinase)	Cell Signaling	Cat#: 9202; RRID: AB_331676
TOM20	Sigma	Cat#: HPA011562; RRID: AB_1080326
JFL1	Novus Biologicals	Cat#: NBP1-90691; RRID: AB_11040102
JFM1	Abcam	Cat#: ab109305; RRID: AB 10864675
JLK1	Cell Signaling	Cat#: #8054; RRID: AB_11178668
JFSP2 (G-11)	Santa Cruz	Cat#: sc-376084; RRID: AB_10989729
RPL26	Abcam	Cat#: ab59567; RRID: AB_945306
Ribophorin1 (RPN1)	ThermoFisher	Cat#: PA5-27562; RRID: AB_2545038
RDye 800CW Goat anti-Rabbit IgG H ⁺ L	LI-COR	925-32211; RRID: AB_2651127
RDye 680 RD Goat anti-Mouse IgG H ⁺ L	LI-COR	926-68070; RRID: AB_10956588
Chemicals, Peptides and Recombinant Proteins		
orin1	CST	Cat#: 14379S
Rapamycin	Sigma	Cat#: R8781
······	olgina	

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Thapsigargin	Sigma	Cat#: T9033
CCCP	Sigma	Cat#: C2759
Rotenone	Sigma	Cat#: R8875
Oligomycin A	Sigma	Cat#: 75351
antimycin A	Sigma	Cat#: A8674
Folimycin	Milipore	Cat#: 344085
Epoxomycin	Milipore	Cat#: 324800
EBSS	ThermoFisher	Cat#: 24010043
Critical Commercial Assays		
Seahorse XF Cell Mito Stress Test Kit	Agilent	Cat#: 103015-100
Cell Titer-Glo 2.0 Cell Viability Assay	Promega	Cat#: G9241
Pierce anti-HA magnetic beads	ThermoFisher Scientific	Cat#: 88836
Deposited Data		
CRISPRi screen data (pilot autophagy gene screen and	NCBI-SRA	PRJNA599329
genome-wide screen)		
Experimental Models: Cell Lines		
HCT116 CRISPRi	Liang et al., 2018	N/A
HCT116 CRISPRi mCherry-eGFP-RAMP4 (EATR)	Liang et al., 2018	N/A
HCT116 CRISPRi mcherry-RAMP4 (CCER)	Liang et al., 2018	N/A
HCT116 CRISPRi REEP5-mCherry-eGFP	This study	N/A
HCT116 CRISPRi CLIMP63-mCherry-eGFP	This study	N/A
HCT116 mCherry-KDEL	This study	N/A
HEK293T UFSP2 KO	This study	N/A
HEK293T UFSP2 and DDRGK1 double KO	This study	N/A
НСТ116 АМРК КО	This study	N/A
HeLa DDRGK1 KO	This study	N/A
Oligonucleotides		
shNon-targeting sequence- CCTAAGGTTAAGTCGCCCTCG	Liang et al., 2018	N/A
shDDRGK1 sequence - GGCTCTGCTAGTCGGCTTTAT	This study	N/A
shUFL1 sequence - GCTTCTTTACTCTGTGCTTGA	Zhang et al., 2015b	N/A
Protospacer sequences for all CRISPR KO or CRISPRi		See Table S5
experiments		
qPCR primer sequences		See Table S6
Recombinant DNA		
For more recombinant DNA data, see also Table S6	This study	N/A
pEF1a-dCas9-HA-BFP-KRAB-NLS	Liang et al., 2018	Addgene 102244
TetOn-mCherry-eGFP-RAMP4	Liang et al., 2018	Addgene 109014
pLenti-X1-Hygro-mCherry-RAMP4	Liang et al., 2018	Addgene 118391
mCherry-mito-7	Olenych et al., 2007	Addgene 55102
mCherry-ER-3	Olenych et al., 2007	Addgene 55041
mCherry-Peroxisomes-2	Olenych et al., 2007	Addgene 54520
pRK5-rLAMP1-BFP	This study	LAMP1 from <i>Rattus norvegicus</i> subcloned from Addgene 55073
pLenti-X1-Neo-NDUFB4	This study	Addgene 139840
pLenti-X1-Neo-NDUFB2	This study	Addgene 139841
pLenti-X1-Neo-ATP5O	This study	Addgene 139842
pLenti-XI-Neo-GST-Constitutively Active AMPK	Egan et al., 2011	Addgene 139843
pLenti-XI-Neo-GST- AMPK- Kinase Dead (K to R)	This study	Addgene 139844
		0

(Continued on next page)

Continued	201120-	
REAGENT or RESOURCE	SOURCE	IDENTIFIER
BMN-YFP-Parkin	Yamano et al., 2014	Addgene 59416
Lenti-X1-Neo-DDRGK1-WT-HA	This study	Addgene 139845
DLenti-X1-Neo-DDRGK1-dTM-HA	This study	Addgene 139846
DLenti-X1-Neo-DDRGK1-dPCI-HA	This study	Addgene 139847
DLenti-X1-Neo-DDRGK1-K267R-HA	This study	Addgene 139848
DLenti-X1-Neo-DDRGK1-K-less-HA	This study	Addgene 139849, with K116, K120, K121 K124, K128, K146, K176, K193, K224 & K227 mutated to R
DLenti-X1-Neo-DDRGK1-K116R-HA	This study	Addgene 139850
DLenti-X1-Neo-DDRGK1-K120R-HA	This study	Addgene 139851
Lenti-X1-Neo-DDRGK1-K121R-HA	This study	Addgene 139852
DLenti-X1-Neo-DDRGK1-K124R-HA	This study	Addgene 139853
Lenti-X1-Neo-DDRGK1-K128R-HA	This study	Addgene 139854
DLenti-X1-Neo-DDRGK1-K146R-HA	This study	Addgene 139855
DLenti-X1-Neo-DDRGK1-K176R-HA	This study	Addgene 139856
DLenti-X1-Neo-DDRGK1-K193R-HA	This study	Addgene 139857
DLenti-X1-Neo-DDRGK1-K224R-HA	This study	Addgene 139858
DLenti-X1-Neo-DDRGK1-K227R-HA	This study	Addgene 139859
DLenti-X1-Neo-HA-UFL1	This study	Addgene 139860
pQCXIN- myc ULK1 wt	Egan et al., 2011	Addgene 27626
Denti-X1-Neo-TOM20MTS-DDRGK1-dTM-HA	This study	Addgene 139861
Lenti-X1-Neo-PMP34-DDRGK1-dTM-HA	This study	Addgene 139862
Lenti-X1-Neo-HA-UFL1-RAMP4	This study	Addgene 139863
RK5-HA-UFM1-dCS	This study	Addgene 139869
	-	, i i i i i i i i i i i i i i i i i i i
rk5-UFM1-dCS-no tag	This study	cDNA of HCT116 cells, NM_016617.4, deleted C-terminal a.a.84-85
FetOn-REEP5-mCherry-eGFP	This study	Addgene 139870
etOn-CLIMP63-mCherry-eGFP	This study	Addgene 139871
Lenti-X1-Neo-HA-FAM134B	This study	subcloned from Addgene 109026
Lenti-X1-Neo-HA-RTN3L	This study	Addgene 139864
Lenti-X1-Neo-HA-SEC62	This study	Addgene 139865
Lenti-X1-Neo-HA-ATL3	This study	subcloned from Addgene 109024
bLenti-X1-Neo-TEX264-HA	This study	Addgene 139866
DLenti-X1-Neo-HA-CCPG1	This study	Addgene 139867
Denti-X1-Neo-mCherry-FAM134B	This study	subcloned from Addgene 109026
Denti-X1-Neo-mCherry-RTN3L	This study	cDNA of HCT116 cells, NM_001265589.1
bLenti-X1-Neo-mCherry-SEC62	This study	cDNA of HCT116 cells, NM_003262.4
•		
DLenti-X1-Neo-mCherry-ATL3	This study	subcloned from Addgene 109024
Lenti-X1-Neo-TEX264-mCherry	This study	cDNA of HCT116 cells, NM_015926.6
Denti-X1-Neo-mCherry-CCPG1	This study	cDNA of HCT116 cells, NM_001204450.
olenti-X1-Neo-RPN1-HA	This study	cDNA of HCT116 cells, NM_002950.4
DLenti-X1-Neo-RPN1-GFP	This study	cDNA of HCT116 cells, NM_002950.4
Software and Algorithms		
i-Cor's ImageStudio software V5.2	Li-Cor	https://www.licor.com/bio/image-studio/
mageJ	NIH	https://imagej.nih.gov/ij/
Adobe Photoshop CS6	Adobe Systems	https://www.adobe.com/
	Adaba Custanaa	https://www.adobe.com/
Adobe Illustrator CS6	Adobe Systems	https://www.adobe.com/

LEAD CONTACT AND MATERIALS AVAILABILITY

The plasmids generated in this study have been deposited to Addgene (catalog number indicated in Key Resources Table). In the case where the same cDNA with multiple epitope/fluorescence tags are used, only one version is deposited to Addgene. All remaining unique/stable reagents generated in this study are available from the Lead Contact, Jacob Corn (jacob.corn@biol.ethz.ch) with a complete Materials Transfer Agreement.

METHOD DETAILS

Design, Production and titering of sgRNA library lentivirus

The genome-wide CRISPRi-V2 library was a gift from the Weismann lab (Addgene catalog #100000093) and contains 5 sgRNAs per gene. For the pilot autophagy screen, we designed a comprehensive sgRNA library that targets all the reported TSS (10 gRNAs per TSS) of 31 genes that are involved in general autophagy. Overall, a total of 3301 gRNAs were designed (Table S1). The protospacer oligos were annealed and ligated to pCRISPRia vector (Addgene 84832) according to the protocol established by the Weissman lab (https://weissmanlab.ucsf.edu/CRISPR/Pooled_CRISPR_Library_Cloning.pdf) (Horlbeck et al., 2016). In addition, we added in 10% of a custom built non-targeting sgRNA library prior to virus production.

The following paragraph describes the transfection protocol for one 15 cm plate of HEK293T cells. On Day 0, 7.5 million HEK293T cells were seeded in a 15 cm plate in 20 mL of DMEM medium with 10% FBS. The following day HEK293T cells were transfected. In a 15 mL tube, 2.8 mL of Opti-MEM was mixed with 90 μ L of Mirus LT1 transfection reagent and incubated at room temperature for 5 minutes. In an eppendorf tube, 12 μ g of delta VPR, 3 μ g of VSVG, and 15 μ g of library plasmid were combined. The plasmids were then added to the Opti-MEM and Mirus mixture and incubated at room temperature for 20 minutes. The media was changed the following day. On Day 3, the virus was harvested using a 0.45 μ m syringe filter, aliquoted into 1 mL tubes, and snap frozen. If more than one 15 cm plate of virus was harvest on Day 4 as well.

Next, the virus was titered to determine the infectivity of the virus in the HCT116 cells. HCT116 were plated in a series of 6 well plates such that each well had cells and there was one 6 well plate per sub-library per time point (i.e., 48 or 72 hour virus harvest). One well on each plate was not transduced with any virus. The virus was titered such that is diluted 2-fold, 4-fold, 8-fold, 16-fold, and 32-fold. Polybrene was used at a concentration of 8 µg/mL. Fresh media were replaced 24hr post transduction. The cells were harvested 48 hours post viral transduction for flow cytometry and the percentage of BFP positive cells was recorded. The optimal virus dilution is defined as dilution-fold that results in less than 20% of BFP positive cells.

CRISPRi screen: cell generation, virus transduction, puro selection, and sort

HCT116 cells stably expressing a dcas9-KRAB and doxycycline-inducible EATR reporter was generated by lentiviral transduction of Addgene constructs 102244 and 109014 (Liang et al., 2018). The library contained seven unique sub-libraries and each sub-library was transduced separately, such that each sgRNA had an average of 500x coverage after transduction (Day 1). Puromycin selection for positively-transduced cells was performed 48 hours post transduction (Day 3). On Day 7, the sub-libraries were pooled proportionally based on the number of sgRNAs and cells were maintained at 500x coverage. On Day 10, cells were treated with doxycycline (4μ g/ml) for 16 hours to induce EATR expression and on Day 11, cells were treated with EBSS for 16 hours. Cells were then collected for sorting - cells were gated into the 25% of cells with most ER-phagy and 25% of cells with the least ER-phagy. A background population of cells was collected for downstream NGS analysis of relative enrichment. The entire CRISPRi screen was performed in two biological replicates.

NGS Sample Preparation and screen analysis

Genomic DNA was harvested using the Macherey-Nagel gDNA extraction protocol. The background samples required the XL kit whereas the midi kit was sufficient for sorted cells. After elution, the genomic DNA was treated with Sbfl-HI restriction enzyme and incubated overnight at 37°C to liberate the DNA fragment encoding the sgRNA sequences.

Samples were run an agarose gel and the gel piece around the 500 bp size (region containing the sgRNA sequence) was excised. The gel was melted in 55°C water bath and 1/100 by volume of 3 M NaAc (pH 5.2) was added to each tube and then solution was passed through an MN column. Each column was washed twice with NT3 buffer. The column was incubated for 5 minutes in 20 μ L of heated elution buffer (98°C) and then spun. The elution step was repeated so that the final elution volume was 40 μ L.

A standard PCR protocol was used with Phusion High Fidelity Enzyme and 3% DMSO final concentration. The forward primer contained a TruSeq Index that would be subsequently used during NGS analysis. Before proceeding with a full scale PCR of the samples, a test PCR for each sample was run to determine the proper number of cycles (21, 23, or 25 cycles). The cycle number was identified individually for each sample that allowed a visible band on a TBE gel after staining with ethidium bromide, but not an oversaturated PCR product that could compromise the representation of gRNAs within the sample.

After the optimal cycle number was determine, a total of twelve 100 μ L PCRs were done with 3 μ L of template per reaction (from the abovementioned elution). The forward primer contained a TruSeq Index that would be subsequently used during NGS analysis. After completion of the PCR, the twelve reactions were pooled together and mixed. 300 μ L of the pooled PCR was taken for subsequent PCR clean-up.

195 μ L of SPRI beads was added to the pooled PCR and incubated at room temperature for 10 minutes. The samples were attached to a DynaMag for 5 minutes. The supernatant (which has the sample) was transferred to a new tube. 300 μ L of SPRI beads were added and incubated for another 10 minutes. The samples were attached to a DynaMag for 5 minutes and the supernatant was discarded (samples attached to the beads). The beads were washed twice with 80% ethanol. After removal of the last supernatant, the beads were spun down, and excess ethanol was removed. The samples were air-dried for 10 minutes and resuspended in 35 μ L of water. DNA concentration was quantified using Qubit Fluorometric Quantitation (Thermo Fisher Scientific) and the samples were pooled proportionally to cell number and sequenced on a HiSeq 2500 such that each sgRNA sequence was covered at least 30 times.

Screening data was analyzed using standard protocols in MaGECK and ScreenProcessing (Horlbeck et al., 2016; Li et al., 2014, 2015). MaGECK was used for the pilot autophagy library, while ScreenProcessing was used for the genome-wide library. Briefly, gRNAs were quantified in each pool of cells based by matching reads back to the appropriate library reference, each pool was normalized by total number of reads, and gRNA distributions were compared to the background. Non-targeting gRNAs were explicitly used in each software package. MaGECK and ScreenProcessing integrate multiple gRNAs into gene-level phenotypes (e.g., log₂-fold-change) and p values using different approaches (Horlbeck et al., 2016; Li et al., 2014, 2015).

sgRNA plasmid cloning procedures for individual plasmids

The sgRNA sequences for genome-wide screening were based on the Weissman CRISPRi-v2 library and contained 5 sgRNAs per gene. The sgRNA sequences for autophagy-related genes used for the pilot-test run were custom-designed to target all reported transcription start site (TSS) of each gene and contained 10 sgRNAs per TSS. sgRNA plasmids were cloned by annealing and ligating sgRNA-containing short oligos to the CRISPRi-v2 vector (addgene 84832) via the previously described protocol (Horlbeck et al., 2016). Brriefly, the forward and reverse primers of each sgRNA were annealed by pre-incubation at 37°C for 30min in the presence of T4 polynucleotide kinase (PNK; NEB) followed by incubation at 95°C for 5 min and then ramp down to 25°C at 5°C /min. The annealed sgRNA inserts were then ligated to CRISPRia-v2 plasmid (digested using BstXI and BlpI) using Quick ligation kit (NEB). Knockdown efficiency of each guide was measured either by western blot or qRT-PCR. All sgRNA constructs used in this study are detailed in Table S3.

shRNA plasmid cloning for DDRGK1 and UFL1

Short hairpin RNA (shRNA) was used to knockdown DDRGK1 in cell lines that do not express dCas9-KRAB constructs. Non-targeting (5'-CCTAAGGTTAAGTCGCCCTCG-3'), DDRGK1-targeting (5'-GGCTCTGCTAGTCGGCTTTAT-3') and UFL1-targeting (5'-GCTTC TTTACTCTGTGCTTGA-3') shRNAs were cloned into pLKO.1 puro construct (Addgene #8453) according to protocol described in Addgene (https://www.addgene.org/protocols/plko/?gclid=Cj0KCQiAm5viBRD4ARIsADGUT25ZCGNPeQSFvLqSwvg2tH DkCc9zOZsLdaUffZzNTRYzI_YOIKFVQdUaAqbfEALw_wcB). Briefly, the shRNAs were cloned by standard annealing (same as sgRNA annealing protocol described in the previous section) and ligated to pLKO.1 construct (digested with AgeI-HF and EcoRI-HF).

cDNA plasmid cloning procedures

Unless stated otherwise, all ORFs described in this article were obtained from PCR amplification of HCT116 cDNA. The ORFs were cloned into pLenti-XI destination vector with neomycin resistance. Briefly, an original pLenti-X1-Neo-eGFP-LC3B vector was first digested with restriction enzymes BamHI and Xbal to remove the eGFP-LC3B insert. Then, Gibson Assembly was used to insert the gene-of-interest and the desired epitope or fluorescent tag into the pLenti-X1 vector (Gibson et al., 2009). All overexpression constructs used in this study are detailed in Table S4.

Cell culture

Cells were cultured at 37 °C with 5% CO₂ in a humidified atmosphere. All cells were cultured in DMEM-GlutaMAX medium supplemented with 10% FBS, 0.1 mM non-essential amino acids (GIBCO), 1 mM sodium pyruvate (GIBCO), 100 U/mL penicillin (GIBCO), and 100 g/mL streptomycin (GIBCO). Cell lines were obtained from the Berkeley Cell Culture Facility and were verified mycoplasma free with MycoAlert Mycoplasma Detection Kit (Lonza).

Cell Treatments

ER-phagy was induced with media starvation using EBSS with calcium, magnesium, and phenol red (Invitrogen e10043). For EATR and CCER assays, cells were plated 48 hours prior to EBSS treatment. EATR expression is induced using 4 µg/ml doxycycline 24hr prior to starvation. Unless otherwise stated, starvation treatment was carried out for 16 hours. Cells in fed conditions indicate incubation in complete DMEM described above.

For all experiments except the Seahorse assay, rotenone was used at a final concentration of 3 μ M, antimycin A was used at a concentration of 0.5 μ M, and oligomycin A was used at a concentration of 3 μ M. Cells were treated with these drugs in two phases for a total of 40 hours. First, cells were treated for 24 hours with complete DMEM, then immediately treated again for 16 hours in EBSS media or complete DMEM. Unless stated otherwise, epoxomicin and folimycin treatments were co-administered with EBSS starvation at 100 nM final concentration.

Lentiviral packaging and transduction

Lentiviral packaging was performed in HEK293T cells using either TransIT-LT1 Transfection Reagent (Mirus) or Lipofectamine 3000 (ThermoFisher Scientific) according to the manufacturer's protocol. Briefly, delta-VPR, VSVG, and the construct of interest were transfected at the ratio of 4:1:5. Lentiviral supernatant was harvested at 48hr post-transfection and HEK293T cells were replenished with fresh media for another harvest at 72hr post-transfection.

Knockout Cell Line Generation

AMPK knockout cell lines were generated using Cas9 RNPs and nucleofection as detailed previously (Lingeman et al., 2017). The sgRNA protospacer sequences were validated and used previously by the Shaw lab (Toyama et al., 2016). The protospacer sequences are as follow: AMPKα1-sgRNA1- GGCTGTCGCCATCTTTCTCC; AMPKα1-sgRNA2- GAAGATCGGCCACTACATTC; AMPKα2-sgRNA1- TCAGCCATCTTCGGCGCGCGC; AMPKα2-sgRNA2- GAAGATCGGACACTACGTGC. After nucleofection, HCT116 cells were serial diluted into 96 well plates such that there was on average of 0.7 cells/well. AMPK KO clones were screened by western blotting. DDRGK1, UFL1 and UFSP2 knockout cell lines were using pSpCas9(BB)-2A-GFP (PX458) (Addgene #48138) plasmids carrying sgRNAs that targets the respective regions close to the transcription start site. For DDRGK1 and UFL1, two guides were used simultaneously to remove the transcription start sites. The knockout of UFSP2 was performed using only one guide based on reported sequence (Walczak et al., 2019). The protospacer sequences are as follow: DDRGK1-sgRNA1- ATGAGATCCCGGCCT CAGGG; DDRGK1-sgRNA2- TAGGAGATGCCGCTGCACCA; UFL1-sgRNA1- CTGACTCGCAGTAGACGCGG; UFL1-sgRNA2-GCCTAATT TGGGCTCCACAA; UFSP2-sgRNA1- AATAAGAGGAGGCCTTGATT. GFP-positive cells were single-cell sorted 48hr post transfection and knockout clones were screened by western blotting and selected clones were further validated by Sanger sequencing.

Flow Cytometry Analysis of EATR cells

Flow cytometry of EATR assay was performed using an Attune NxT Flow Cytometer and subsequent analysis was performed using FlowJo 10.1 (Liang et al., 2018). All EATR experiments were performed using live cells to prevent reversal of eGFP quenching post-fixation. The intensities for both eGFP and mCherry of the EATR cells at fed condition were used as references to define the gate for zero ER-phagy events. Following stimulation, ER-phagy detection is based on the shift of cell population into the ER-phagy gate. On average, 5 to 10,000 cells were analyzed per condition and all statistical analyses were performed using data from at least three biological replicates.

Quantitative real-time PCR (qRT-PCR)

RNA extraction was performed using Directzol RNA miniprep kit (Zymo Research) according to manufacturer's instruction. 1µg of RNA per sample were used for reverse transcription using SuperScript III First-Strand Synthesis System (Invitrogen) according to manufacturer's instruction. qRT-PCR reaction was set up using Fast SYBR Green Mastermix (Applied Biosystems) and run in triplicates using StepOne Plus Real-Time PCR system (Applied Biosystems). A complete list of all primers used are compiled in Table S6.

Western blotting

To prepare samples for western blot, cells were lysed in Radioimmunoprecipitation assay (RIPA) buffer (0.5M Tris-HCI, pH 7.4, 1.5M NaCI, 2.5% deoxycholic acid, 10% NP-40, 10mM EDTA), supplemented with Halt Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktail (both ThermoFisher). Cells were lysed on ice for 10 minutes and spun at 14000 rpm for 10 minutes to remove insoluble debris. Protein concentrations were quantified by Bradford assay. Lysates were normalized based on protein concentration and NuPage LDS Sample Buffer (4x) supplemented with B-mercaptoethanol (5% v/v) was added (Invitrogen). Samples were boiled at 98°C for 5 minutes.

Between 20-40µg of samples were run on NuPAGE Bis-Tris 4%–12% gels in NuPage MES SDS Buffer (Invitrogen) for 40 minutes at 200 V and transferred to 0.4-µm nitrocellulose membranes using a semi-dry transfer system (Bio-Rad Catalog #1704150) at 1.3 A and 25 V for 15 minutes. After transfer, membranes were blocked with 5% (w/v) milk in Tris buffered saline containing 0.1% Tween 20 (TBS-T) for 30 minutes, and subsequently washed with TBS-T three times. Primary antibodies were diluted at the appropriate concentration in 5% BSA (w/v) in TBS-T. The membrane was incubated in primary antibody for either 1-2 hours at room temperature or overnight at 4°C. The membrane was washed with TBS-T three times for five minutes each. The blots were incubated for 30 minutes in the milk solution with a 1:10,000 dilution of Li-Cor near-infrared fluorescence secondary antibodies. The blots were done using Li-Cor's Near-InfraRed fluorescence Odyssey.

Immunoprecipitation

Unless specified otherwise, all immunoprecipitation experiments were performed in HCT116 cells stably-expressing the different HA-tagged UFMylation protein constructs using the Perice Anti-HA Magnetic beads Kits according to manufacturer's protocol. Briefly, cells were harvested and lysed using the IP-lysis buffer supplemented with Halt Protease Inhibitor Cocktail (ThermoFisher). Equal amount of lysates (~5mg) for each condition were mixed with pre-washed 50µl of HA-magnetic bead slurry. Immunoprecipitation was performed at 4'C for 2hr. The beads were then washed twice using 'high-salt' IP lysis buffer (IP lysis buffer supplemented

with 500mM NaCl), with 5min incubation on a rotor. The final wash was performed using regular IP lysis buffer. Immunoprecipitated proteins were eluted by boiling the samples at 98'C in 1x NuPAGE LDS Sample Buffer (ThermoFisher) for 5min supplemented with NU-PAGE sample reducing agent.

Denaturing Immunoprecipitation and tandem-mass spectrometry analysis (IP-MS/MS)

HEK293T cells with either DDRGK1 knockout or DDRGK1 and UFSP2 double knockout were transiently transfected with pRK5-HA-UFM1-dCS for 72hr. Cells were then starved for 4hr in the presence of folimycin (50nM) and lysed using 1X RIPA lysis buffer supplemented with mammalian protease inhibitor for 10min on ice. Insoluble debris and nuclear fractions were removed by centrifugation. The samples were then denatured using final 2% SDS and boiled for 5min at 95°C. After denaturation, the samples were further diluted at 1:20 in 1X RIPA lysis buffer to dilute the SDS concentration to 0.1% prior to immunoprecipitation using anti-HA magnetic beads (Pierce, #88837). Immunoprecipitation was performed at room temperature for 1hr with constant rotation followed by two washes in high-salt RIPA buffer containing 500mM NaCl and a final wash in 1x RIPA buffer.

The immunoprecipitation samples were then processed by the Proteomics group of Functional Genomics Center Zurich (FGCZ) for on-bead tryptic digestion and mass spectrometry analysis. Briefly, beads were washed twice with 50ul of digestion buffer (10 mM Tris/2 mM CaCl₂, pH 8.2). Then, 45µl of digestion buffer and 5µl trypsin (100 ng/ul in 10 mM HCl) were added and samples were microwaved to assist digestion (30 min at 60°C). The supernatant was collected and peptides were extracted from beads with 150ul of 0.1%TFA/50% acetonitrile. Supernatants were then combined and dried, dissolved in 20µl 0.1% formic acid and further diluted 1:10 in 0.1% formic acid and transferred to autosampler vials for LC/MS/MS. Database searches were performed using the Mascot search engine against SwissProt (all species and only human).

Immunofluorescence

Immunofluorescence was conducted as previously described (Liang et al., 2018). Briefly, cells were fixed in 4% (wt/vol) paraformaldehyde for 15 min followed by permeabilization using 0.1% Triton X-100 in PBS for 10 min. Cells were then blocked in 1% BSA in PBS for 20 min. Primary antibodies were incubated for 1hr at room temperature, followed by three PBS washes for 5min each. Alexa Fluor 488/568/660-conjugated goat anti-mouse or anti-rabbit IgG secondary antibodies were incubated for 30 min at room temperature, followed by three PBS washes for 5min each. Coverslips were mounted onto glass slides using ProLong Gold Antifade reagent with or without DAPI addition for nucleus visualization. Images were taken using either Zeiss LSM 710 Axio Observer (in Berkeley) or Leica TCS SP8 confocal microscope (in ETH Zurich) with 63x objective lens and post-processed in Adobe Photoshop for specific inset enlargement and RGB channel separation. Colocalization analysis in Figure 6J was determined by Pearson's Correlation coefficient using ImageJ with colocalization plugin from McMaster Biophotonics Facility (MBF). The frequency scatterplot in Figure S6A was generated using the same plugin.

MitoTracker

The MitoTracker assay was performed according the manufacturer's protocol (ThermoFisher Catalog #M7512). Cells were plated 48 hours before starvation. Cell starvation and drug concentrations was performed according to protocols described above. The MitoTracker Red CMXRos was dissolved in DMSO for a stock concentration of 1 mM. MitoTracker was added to samples such that the concentration in each well was 50 nM. The cells were incubated for 30 minutes, washed with media, and then fixed in 4% formaldehyde. The cells were stained with calnexin according to the immunofluorescence protocol. For flow cytometry measurement, the experiment was performed the same way as mentioned above but the cells were trypsinized after incubation with MitoTracker dye to measure the fluorescence intensity of the staining.

ATP Assay

The assay was performed according to the manufacturer's protocol for the CellTiter-Glo 2.0 Cell Viability Assay (Promega; Cat #: G9241). Briefly, the cells treated with starvation were starved for 25 hours. The cells treated with rotenone or antimycin A were used as positive controls and cells were treated for 1 hour. Cells were harvested, washed with PBS, and counted and normalized. The cells were spun down again and resuspended such that there were 25,000 cells per 50 μ L of PBS. 50 μ L of PBS was added to each well in an opaque-walled 96-well plate. Each sample was done in technical triplicate. Wells with PBS, but no cells, were used as a blank control. 50 μ L of CellTiter-Glo 2.0 reagent was added to each well. The plate was placed on an orbital shake for 2 minutes, followed by a 10 minute bench-top incubation to stabilize the signal. Sample luminescence was determined by the SpectraMax M2 Microplate Reader (Molecular Devices).

Mitochondrial Respiration Measurements

Mitochondrial activity was determined using the Seahorse Flux Analyzer XF24 (Agilent Technology) and the Seahorse XF Cell Mito Stress Test Kit (Agilent; Cat. #:103015-100) according to the manufacturer's protocol. Briefly, 4×10^4 HCT1 16 cells were seeded on XF24-well cell culture microplates. After 24hr, growth medium was exchanged with XF assay base medium supplemented with 1 mM sodium pyruvate (Invitrogen; Cat. #11360-070), 2mM L-glutamine (Invitrogen; Cat. #25030-081), and 10mM D-glucose (pH 7.4) (Invitrogen; Cat. #:D16-500). The microplates were incubated at 37° C without CO₂ for 1hr prior to the assay. Samples were mixed for 3 min, time delayed for 2 min, and measured for 3 min. Oligomycin (1 μ M), FCCP (1 μ M), and rotenone / antimycin

 $(0.5 \mu M)$ were sequentially injected at the indicated time points. OCR data were normalized by protein concentration and the average values were taken for each experiment. Seven replicates were performed for each cell line. The mean \pm SEM was determined and statistical significance was evaluated using the Student's *t* test with a P value < 0.05.

Statistical analysis

All analysis was performed using data from at least three independent biological replicates (exact number of replicates are stated in the figure legend). Unless stated otherwise, all statistical analyses were performed in PRISM6 software using paired Student's t test. P values are indicated as follow: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001. The distribution of the data was assumed to be normal, but this was not formally tested.

DATA AND CODE AVAILABILITY

The accession number for the next generation sequencing data reported in this paper is NCBI-SRA: PRJNA599329. All original western blot data reported in this paper are available at Mendeley Data (https://doi.org/10.17632/ztzfkww2jx.2).

Supplemental Figures




Figure S1. Characterization of ER-phagy and Optimization of CRISPRi Screen, Related to Figure 1

(A) Trial of different ER stress or autophagy stimuli to induce ER-phagy. HCT116 EATR cells were treated with Earl's buffered saline solution (EBSS – amino acid starvation) or the indicated drugs (Thapsigargin: 1µM, Tunicamycin: 0.5µg/ml, Rapamycin: 1µM, Torin1: 1µM) for 16hr. Cells were then harvested for western blotting to check for UPR and autophagy response.

(B) Only amino acid starvation (using EBSS) inhibits ER-phagy. The same cells and treatment conditions in Figure S1A were also subjected to FACS measurement of ER-phagy. Data represents mean ± SD of three biological replicates. P value indicates two-tailed paired t test (**p < 0.01).

(C) EBSS and Torin1 treatments induce general autophagy. HCT116 GR-LC3B cells were treated with the same conditions in (A and B) and were subjected to measurement of general autophagy by FACS. Data represents mean \pm SD of three biological replicates. P value indicates two-tailed paired t test (***p < 0.001). (D) FACS measurement of eGFP and mCherry fluorescence at individual cell level shows about 8% of ER-phagy per cell upon starvation. A representative plot for the eGFP/mCherry fluorescence intensity ratio of each cell was plotted for HCT116 EATR cells to represent the amount of ER-phagy upregulation after 16hr of *(legend continued on next page)*

starvation. A total of 10,000 cells from each condition was shown. Values on top of each condition represents the mean eGFP/mCherry intensity ratio and the associated standard error. P value indicates two-tailed paired t test (****p < 0.0001).

(E) Gating strategy for ER-phagy screen. HCT116 CRISPRi EATR cells transduced with the CRISPRi library of sgRNAs were starved for 16hr and subjected for FACS measurement for ER-phagy. Based on the EATR assay, the top and bottom 25% of cells correspond to sgRNA knockdown that results in 'enhanced' and 'inhibited' ER-phagy, respectively and were processed for next generation sequencing of sgRNA barcode.

(F) Multiple autophagy genes (highlighted in blue) were enriched in the 'inhibited' ER-phagy sort gate. The normalized sgRNA count from the 'Inhibited' ER-phagy sort gate was plotted against the normalized sgRNA count of the background sample. The labeled genes are enriched in the 'Inhibited' ER-phagy gate upon knockdown and indicate active transcription start sites (TSS) that are being used in HCT116 cells.

(G) Autophagy genes (highlighted in blue) that are depleted in the 'enhanced' ER-phagy sort gate corresponds to the genes that are enriched in the 'inhibited' sort gate of (F).


(H) ER-phagy receptor, general autophagy and membrane trafficking genes are hits in the ER-phagy screen. Those genes that are significantly enriched in either the 'inhibited' or 'enriched' gate are indicated in blue. Volcano plot describes data from the genome-wide CRISPRi screen. All negative control sgRNAs are indicated in gray and targeted sgRNAs are indicated in black. Data represent two biological replicates. log2 fold change and Mann-Whitney P value were calculated as described in (Horlbeck et al., 2016).

(I) Knockdown of genes involved in general autophagy also inhibit ER-phagy. HCT116 CRISPRi EATR cells were transduced with sgRNAs targeting the indicated candidate genes reported from the CRISPRi genome wide screen. Cells were starved for 16hr and subjected to FACS measurement for ER-phagy. Data represents mean \pm SD of three biological replicates. P value indicates two-tailed paired t test (*p < 0.05, **p < 0.01; ****p < 0.001).

(J) CCER assay complements the EATR data in Figure S1I. HCT116 CRISPRi CCER cells were also transduced with the same sgRNAs as Figure S1I. Cells were then starved for 16hr and harvested for western blot analysis for the levels of two general autophagy markers, p62 and LC3B.

(K) All sgRNAs efficiently knockdown the respective general autophagy genes. The same cell lines in (J) were harvested for qRT-PCR analysis to measure the knockdown efficiency of individual sgRNAs.

(L) The FAM134B sgRNAs used in this CRISPRi screen do not effectively knock down FAM134B. HCT116-CRISPRi EATR cells stably expressing FAM134B sgRNAs were harvested for qRT-PCR to determine the knockdown efficiency.



Cell

Figure S2. Disruption of Mitochondrial Oxidative Phosphorylation Inhibits ER-phagy, Related to Figure 2

(A) Schematic of the oxidative phosphorylation (OXPHOS) pathway. The genes implicated in ER-phagy regulation are annotated in red in their respective electrontransport chain compartment.

(B) Cells from Figure 2B were harvested to assess the knockdown efficiency of each sgRNA by western blotting.

(C) Knockdown of NDUFB4, NDUFB2 and ATP50 shows ER-phagy inhibition using the CCER assay. HCT116 CRISPRi CCER cells were transduced with the indicated sgRNAs and subjected to 16hr starvation. Cells were then harvested for western blot analysis.

(D) The cleaved and full length mCherry-RAMP4 band intensities in (C) were measured and normalized to starved sgNT sample. Data represents mean \pm SD of three biological replicates. P value represents two-tailed paired t test (**p < 0.001).

(E) Knockdown of NDUFB4, NDUFB2, and ATP5O does not affect general autophagy. HCT116 CRISPRi cells expressing mCherry-eGFP-LC3B were transduced with sgRNAs targeting either ULK1, ATG10, NDUFB4, NDUFB2, or ATP5O. Cells were starved for 16hr before FACS measurement for general autophagy. Data represents mean ± SD of four biological replicates. P value represents two-tailed paired t test (*p < 0.05).

(F) ULK1 protein levels corresponds to the disruption of the OXPHOS complex. Cells from the same experiment as Figure 2C were harvested for western blot analysis to verify the protein levels of ULK1, ATG10, NDUFB4 and NDUFB2.

(G) Re-expression of ATP50 restores ULK1 protein levels. HCT116 CRISPRi EATR cells transduced with sgATP50 were rescued with ATP50 cDNA and harvested for western blot analysis to assess the protein levels of ULK1 and ATP50.

(H) Re-expression of ATP5O rescues ER-phagy. The same cells in (G) were starved for 16hr before FACS measurement for ER-phagy. Data presented as mean \pm SD of three biological replicates. P value indicates two-tailed paired t test (**p < 0.01; ***, p < 0.001).

(I) Schematic of experimental setup for chemical genetic inhibition of electron transport chain function in ER-phagy. HCT116 CRISPRi cells were treated with each inhibitor for 24 hours in complete media, then maintained in inhibitor for another 16 hours in fed or EBSS starvation media. Cells were then harvested for FACS to measure autophagy.

(J) OXPHOS inhibitors disrupt ER-phagy as measured by CCER assay. HCT116 CRISPRi CCER cells were treated with rotenone, antimycin A, and oligomycin A and starved for 16hr. Cells were lysed for western blotting to measure mCherry-RAMP4 cleavage.


(K) Densitometry measurement of the ratio between the cleaved and full length mCherry-RAMP4 bands in (J). Data represents mean \pm SD of three biological replicates. P value indicates two-tailed paired t test (*p < 0.05).


(L) OXPHOS inhibitors disrupt ER-phagy as measured by flow cytometry. HCT116 EATR cells were treated with small molecule inhibitors of rotenone, antimycin A, or oligomycin A, and starved for 16 hours before FACS measurement of ER-phagy. Data presented as mean \pm SD of three biological replicates. P value indicates two-tailed paired t test (*p < 0.05, ****p < 0.0001).

(M) General autophagy is unaffected by antimycin A and oligomycin A treatment in starvation conditions. HCT116 cells were treated with the indicated small molecule inhibitors of antimycin A, or oligomycin A for 24hr and then were subsequently starved for 16hr with treatment of small molecule inhibitors. Cells were lysed for western blot analysis to measure protein levels of LC3B.

(N) NDUFB2, NDUFB4 and ATP50 depletions affect cellular ATP levels. HCT116 CRISPRi cells were transduced with sgRNAs targeting either NDUFB4, NDUFB2, or ATP50 and starved for 16hr or treated with rotenone or oligomycin A. Cells were collected for ATP Glo luminescence assay. Data represents mean \pm SD of three biological replicates.

(0) Oxygen consumption is reduced in NDUFB4, NDUFB2, and ATP50 knockdown cells. HCT116 CRISPRi cells were transduced with sgRNAs targeting either NDUFB2 or ATP50 and the Seahorse Flux Analyzer was conducted to determine the oxygen consumption rate.





В

EBSS

RG

А

DMEM

RGB

Figure S3. ER-phagy Inhibition by Mitochondrial OXPHOS Disruption Is Not Related to Mitophagy, ULK1, or AMPK1 Activities, Related to Figure 2

(A) Disruption of the mitochondrial OXPHOS components does not affect the mitochondrial membrane potential. HCT116 CRISPRi cells were transduced with sgRNAs targeting either NDUFB4, NDUFB2, or ATP50 or treated with indicated small molecule inhibitors. Cells were subsequently treated with MitoTracker, then fixed and immunostained for calnexin (CANX). Representative images are shown. Scale bar represents 10µm.

(B) Quantitative measurement of MitoTracker staining by flow cytometry. Cells from the same experiment in (A) were stained with MitoTracker and then trypsinized from flow cytometry measurement of the staining intensity. Data presented as mean \pm SD of three biological replicates. P value indicates two-tailed paired t test (*p < 0.05, **p < 0.01).

(C) Disruption of the OXPHOS pathway does not induce mitophagy based on the protein levels of MFN2. HCT116 CRISPRi cells were transduced with sgRNAs targeting either NDUFB4, NDUFB2, or ATP50 and starved for 16hr or treated with CCCP. Cells were harvested for western blot analysis and immunoprobed for the indicated proteins. A representative blot is shown.

(D) Densitometry measurement of the ratio between MFN2/actin from (C). Data represents mean \pm SD of two biological replicates.

(E) Starvation does not induce mitophagy in Parkin-overexpressing cells. HCT116 CRISPRi were transduced with YFP-Parkin construct and treated with starvation or CCCP (10 uM) for 16hr. Cells were harvested for western blot analysis and immunoprobed for the indicated Parkin substrates to verify mitophagy in CCCP-treated cells.


(F) OXPHOS disruption does not trigger mitophagy in Parkin-overexpressing cells. HCT116 CRISPRi-YFP-Parkin cells were transduced with sgRNAs targeting either NDUFB4, NDUFB2, or ATP50 and starved for 16hr or treated with CCCP. Cells were harvested for western blot analysis and immunoprobed for the indicated proteins. A representative western blot is shown.

(G) Densitometry measurement of the ratio between MFN2/actin from (E). Data represents mean ± SD of three biological replicates.

- (H) Changes in ULK1 protein levels during starvation correspond to the protein levels of NDUFB4, NDUFB2, and ATP50. HCT116 CRISPRi EATR cells were transduced with NDUFB4, NDUFB4, NDUFB2, or ATP50 cDNA constructs, and then transduced with sgRNAs targeting ULK1, NDUFB4, NDUFB2, or ATP50. Cells were lysed for western blotting and immunoprobed for the indicated proteins.
- (I) ULK1 overexpression does not rescue ER-phagy. HCT116 CRISPRI EATR cells with or without ULK1 overexpression were transduced with sgRNAs targeting ULK1, NDUFB4, NDUFB2, or ATP50 and starved for 16hr before FACS measurement for ER-phagy. Data presented as mean \pm SD of four biological replicates. (*p < 0.05, ***p < 0.001).
- (J) Western blot validation of AMPKa knockout and cDNA re-expression. Parental represents HCT116 CRISPRi EATR cells. AMPK KO (knockout) cells were generated using CRISPR. GST-AMPKa cDNAs were re-expressed in the AMPK KO cells. The catalytically active (GST-AMPKa-CA) form is a truncation of full length AMPKa, resulting in the smaller size. GST-AMPKa-KD (kinase dead) has a K47R point mutation in the CA construct.

(K) Phosphorylation status of downstream AMPKa targets were analyzed to verify the catalytically active (CA) and kinase dead (KD) AMPKa constructs. AMPKa knockout HCT116 EATR clone from (I) were starved for 16 hours and samples were lysed for western blotting and immunoprobed for known target proteins of AMPK phosphorylation.

(L) Catalytically active (CA) AMPKa does not inhibit ER-phagy. AMPKa knockout HCT116 EATR cells stably expressing catalytically active (CA) AMPKa, or kinase dead (KD) AMPKa were starved for 16hr before FACS measurement of ER-phagy. Data presented as mean ± SD of three biological replicates.



Cell

(legend on next page)

Figure S4. DDRGK1-Dependent ER-phagy Specifically Affects ER Sheet Degradation, Related to Figures 3 and 4

(A) Densitometry measurement of the ratio between the cleaved and full length mCherry-RAMP4 in Figure 3C. Data represents mean ± SD of five biological replicates. P value indicates two-tailed paired t test (**p < 0.01, ***p < 0.001).

(B) UFL1 protein expression prevents proteasomal degradation of DDRGK1. HCT116 CRISPRi cells were transduced with sgRNA targeting UFL1. Cells were treated with Epoxomicin (100nM) or Folimycin (100nM) for 6hr and then harvested for western blot analysis. p53 and LC3B were used as positive controls for proteasomal and lysosomal inhibitions, respectively.

(C) UBA5 knockdown inhibits ER-phagy. HCT116 CRISPRi EATR cells were transduced with the indicated sgRNA and then starved for 16hr before FACS analysis for ER-phagy. Data represents mean \pm SD of three biological replicates. Statistical significance was determined based on two-tailed paired t test. (**p < 0.01; ****p < 0.0001).

(D) UFL1 and DDRGK1 act in series during ER-phagy. HCT116 CRISPRi EATR cells were transduced with the indicated sgRNAs and then starved for 16hr before FACS analysis for ER-phagy. Data represents mean ± SD of three biological replicates. Statistical significance was determined based on two-tailed paired t test. (E) The same cell lines in (D) were harvested for western blotting to verify the knockdown of targeted genes.

(F) DDRGK1 knockdown prevents ER lumen protein degradation. HCT116 cells stably expressing mCherry-KDEL were transduced with shRNA against either DDRGK1 or UFL1. Cells were then starved for 16hr and harvested for western blot analysis to assess mCherry-KDEL cleavage. A representative blot is shown. (G) Densitometry analysis of mCherry-KDEL cleavage from (F). Data represents mean \pm SD of three biological replicates. P value indicates two-tailed paired t test (*p < 0.05; **p < 0.01).

(H) The stable cell lines from Figure 4G were harvested for western blot to verify the knockdown of DDRGK1 and UFL1.

(I) Representative FACS scatterplots from Figure 4G for the measurement of eGFP and mCherry fluorescence using either TetOn-REEP5-mCherry-eGFP or TetOn-CLIMP63-mCherry-eGFP.

(J) Knockdown of DDRGK1 impedes FAM134B-mediated ER-phagy. HCT116 CRISPRi EATR cells stably expressing HA-FAM134B were transduced with sgDDRGK1. Cells were starved for 16hr and subjected for ER-phagy measurement by FACS analysis. Data represents mean \pm SD of three biological replicates. P value indicates two-tailed paired t test (***p < 0.001; ****p < 0.0001).

(K) HCT116 CRISPRi CCER cells stably expressing HA-FAM134B were transduced with sgDDRGK1. Cells were starved for 16hr and then harvested for western blot analysis of ER protein levels.

(L) Densitometry analysis of mCherry-RAMP4 cleavage from (K). Data represents mean \pm SD of three biological replicates. P value indicates two-tailed paired t test (*p < 0.05).




Figure S5. DDRGK1 Is Not a Substrate of UFMylation, Related to Figure 5

(A) Knockdown of UFM1 does not prevent the appearance of higher molecular weight species of DDRGK1. HCT116 CRISPRi cells stably expressing DDRGK1-HA construct were transduced with sgRNA targeting UFM1. Cells were then harvested for HA-immunoprecipitation and western blotted for the indicated proteins. (B) Knockdown of UFL1 but not UFM1 reduces DDRGK1 protein levels. HCT116 CRISPRi EATR cells transeduced with the indicated sgRNAs were harvested for western blotting to assess the protein levels of DDRGK1 upon knockdown of the targeted genes.

(C) The cDNA of DDRGK1-HA mutant variants in Figure 5C were stably expressed in HCT116 cells to verify their respective protein sizes in DDRGK1 knockdown cells.

(D) All individual Lysine mutant constructs of DDRGK1 are able to rescue ER-phagy in DDRGK1 knockdown cells. HCT116 CRISPRi EATR cells with sgDDRGK1 were transduced with the indicated DDRGK1-HA mutant constructs. Cells were then starved for 16hr before FACS measurement of ER-phagy. Data represents mean \pm SD of three biological replicates. P value indicates two-tailed paired t test. (*p < 0.05, **p < 0.01).

(E) The cell lines generated for (D) were harvested for western blotting to verify the expression of the indicated DDRGK1-HA mutant constructs.




Figure S6. DDRGK1 Acts as an ER Surface Adaptor for UFL1, Related to Figure 6

RPN1 Is an ER Surface UFMylation Substrate

(A) Additional colocalization data analysis of Figure 6F for DDRGK1, UFL1 and the ER marker, RAMP4 based on frequency of colocalization. Conditions with good or near perfect colocalization have good correlation between the X- and Y-axes. Representative frequency scatterplot from each condition is shown.
(B) The cell lines generated for Figure 5H were harvested for western blotting to verify the expression of the indicated DDRGK1-HA mutant constructs.
(C) Schematic for the different DDRGK1 and UFL1 mutant constructs. UFL1 is tethered to the ER surface by synthetic fusion with RAMP4 at the C-terminal of UFL1.

(D) Western blot validation of the expression levels of each mutant constructs of DDRGK1 and UFL1 shown in (C). Dotted line represents cropped images from the same blots but with irrelevant lanes removed.

(E) Immunofluorescence analysis to confirm that the RAMP4-fused constructs localize to the ER surface. Scale bar represents 10µm. Insets represent three-fold enlargement of the boxed areas.

(H) The same cell lines used in (G) were harvested for qRT-PCR to assess the knockdown efficiency of each sgRNA.

⁽F) None of the synthetic fusion of UFL1 or DDRGK1 to the ER surface rescued ER-phagy in sgDDRGK1 cells. HCT116 cells stably expressing sgDDRGK1 were transduced with the indicated cDNAs. Cells were starved for 16hr before FACS measurement for ER-phagy. Data represents mean \pm SD of three biological replicates. P value indicates two-tailed paired t test (**p < 0.01).

⁽G) None of the previously reported targets of UFMylation are involved in ER-phagy regulation. HCT116 CRISPRi EATR cells were transduced with sgRNAs targeting CDK5RAP3, Sox9 or ASC1 and starved for 16hr before FACS measurement of ER-phagy. Data represents mean ± SD of three biological replicates. P value indicates two-tailed paired t test (**p < 0.01).

⁽I) RPN1 localizes to the ER. U2OS cells were transfected with cDNAs for RPN1-GFP and mCherry-KDEL for 48hr. Scale bar represents 10µm. Inset represents 4x enlargement of the boxed area.




Figure S7. Disruption of UFMylation Results in Elevated ER Stress and ER Expansion, Related to Figure 7

(A) IRE1 α is not a target of DDRGK1-mediated UFMylation. HCT116 CRISPRi cells stably expressing HA-UFM1 were transduced with sgRNA targeting DDRGK1. Cells were starved for 16hr before being lysed in non-denaturing condition for HA-immunoprecipitation of UFM1 and western blot analysis of its interaction with IRE1 α and DDRGK1.

(B) The same experiment shown in Figure S5B were further probed for the indicated ER or UPR markers. The densitometry measurements for IRE1α, BiP, CANX, CLIMP63 and REEP5 from three biological replicates are shown in Figure 7A.

(C) DDRGK1 depletion results in the upregulation of UPR markers in various cell lines. HepG2 and MCF7 cells were transduced with shRNAs targeting DDRGK1. Cells were then harvested for western blot analysis of DDRGK1 knockdown efficiency and UPR response.

(D) HeLa cells with CRISPR/Cas9-KO of DDRGK1 were harvested for western blot analysis of IRE1a protein levels.

(E) Loss of DDRGK1 results in increased ER content. The same HeLa cell lines generated in (D) were fixed and stained for an ER marker (CANX). Scale bar represents 20µm.

(F) IRE1 α depletion prevents UPR response in DDRGK1 knockdown cells. The same cell lines in Figure 7C were harvested for western blotting to measure the protein levels of the indicated UPR genes.

Cell, Volume 180

Supplemental Information

A Genome-wide ER-phagy Screen

Highlights Key Roles of Mitochondrial

Metabolism and ER-Resident UFMylation

Jin Rui Liang, Emily Lingeman, Thao Luong, Saba Ahmed, Matthias Muhar, Truc Nguyen, James A. Olzmann, and Jacob E. Corn

ULK1ENSG0000177169ULK2ENSG0000083290ATG13ENSG0000175224FIP200ENSG0000023287ATG101ENSG0000123395ATG9AENSG0000198925ATG9BENSG000007540WIP1ENSG0000157954PIK3R4ENSG0000198455VPS34ENSG0000126581ATG14ENSG000016775UVRAGENSG000018445ATG4AENSG0000144488ATG4AENSG000018445ATG4AENSG000018445ATG4AENSG000016775UVRAGENSG0000184468ATG4AENSG0000184468ATG4AENSG000018447ATG4AENSG0000184468ATG4AENSG000018447ATG4BENSG000018447ATG4BENSG0000197548LC3AENSG0000197548LC3AENSG0000197548LC3AENSG000014941LC3B2ENSG0000170296GABARAPL1ENSG0000170296GABARAPL2ENSG000017234ATG10ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG16L1ENSG0000152348	Gene Name	Ensembl No.
ATG13ENSG0000175224FIP200ENSG0000023287ATG101ENSG0000123395ATG9AENSG0000198925ATG9BENSG0000181652WIP11ENSG0000017540WIP12ENSG0000157954PK3R4ENSG0000196455VPS34ENSG0000126581ATG14ENSG0000118822ATG4AENSG0000184488ATG4AENSG0000184488ATG4BENSG000018457ATG4CENSG00001844ATG4DENSG000013734ATG5ENSG0000197548LC3AENSG000011460LC3BENSG0000140941LC3B2ENSG0000170296GABARAPL1ENSG0000145782ATG10ENSG0000145782ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG16L1ENSG0000055978	ULK1	ENSG00000177169
FIP200ENSG0000023287ATG101ENSG0000123395ATG9AENSG0000198925ATG9BENSG00000181652WIP11ENSG0000070540WIP12ENSG0000157954PIK3R4ENSG0000196455VPS34ENSG0000126781BECNENSG0000126775UVRAGENSG00001126775UVRAGENSG000011844ATG4AENSG000011844ATG4BENSG0000125703ATG4CENSG0000125703ATG4DENSG000013734ATG5ENSG0000197548LC3AENSG00001460LC3BENSG0000140941LC3B2ENSG0000170296GABARAPL1ENSG000015782ATG10ENSG000015782ATG10ENSG000015782ATG12ENSG000015782ATG12ENSG000015782	ULK2	ENSG0000083290
ATG101ENSG0000123395ATG9AENSG0000198925ATG9BENSG0000181652WiP11ENSG0000070540WiP12ENSG0000157954PIK3R4ENSG0000196455VPS34ENSG0000126581ATG14ENSG0000126775UVRAGENSG0000198382ATG3ENSG000011844ATG4AENSG0000168397ATG4DENSG0000125703ATG4DENSG0000125703ATG5ENSG000013734ATG5ENSG0000197548LC3AENSG000014460LC3BENSG0000170296GABARAPL1ENSG000015734ATG10ENSG0000170296GABARAPL2ENSG000015782ATG12ENSG000014782	ATG13	ENSG00000175224
ATG9AENSG0000198925ATG9BENSG0000181652WIP11ENSG000070540WIP12ENSG0000157954PIK3R4ENSG0000196455VPS34ENSG0000078142BECNENSG0000126581ATG14ENSG0000126775UVRAGENSG000018448ATG3ENSG000018449ATG4AENSG000018449ATG4AENSG000018449ATG4CENSG000018397ATG4DENSG0000130734ATG5ENSG0000197548LC3AENSG0000140941LC3BENSG0000140941LC3B2ENSG0000170296GABARAPL1ENSG0000152348ATG10ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000152348ATG12ENSG0000145782ATG16L1ENSG0000145782	FIP200	ENSG0000023287
ATG9B ENSG0000181652 WIP11 ENSG0000070540 WIP12 ENSG0000157954 PIK3R4 ENSG0000078142 BECN ENSG00000126581 ATG14 ENSG0000126775 UVRAG ENSG000018482 ATG3 ENSG000018448 ATG3 ENSG00001844 ATG4 ENSG00001844 ATG4 ENSG00001844 ATG4 ENSG00001844 ATG4 ENSG00001844 ATG4 ENSG00001844 ATG4 ENSG0000168397 ATG4 ENSG000015703 ATG4D ENSG0000130734 ATG5 ENSG00000197548 LC3A ENSG0000140941 LC3B ENSG0000170296 GABARAP ENSG0000170296 GABARAPL1 ENSG00000139112 GABARAPL2 ENSG00000152348 ATG10 ENSG0000145782 ATG12 ENSG0000145782	ATG101	ENSG0000123395
WIP11 ENSG0000070540 WIP12 ENSG0000157954 PIK3R4 ENSG0000078142 BECN ENSG0000078142 BECN ENSG00000126581 ATG14 ENSG0000126775 UVRAG ENSG0000198382 ATG3 ENSG000011844 ATG4 ENSG0000125703 ATG4B ENSG0000125703 ATG4D ENSG0000125703 ATG4D ENSG0000130734 ATG5 ENSG0000197548 LC3A ENSG0000140941 LC3B ENSG0000170296 GABARAPL1 ENSG000013713 GABARAPL2 ENSG0000132573 ATG7 ENSG0000197548 LC3B ENSG0000197548 LC3B ENSG0000197548 LC3B ENSG0000170296 GABARAPL ENSG0000170296 GABARAPL2 ENSG0000132348 ATG10 ENSG0000152348 ATG12 ENSG0000145782 ATG1611 ENSG0000085978	ATG9A	ENSG0000198925
WIP12 ENSG0000157954 PIK3R4 ENSG00000196455 VPS34 ENSG0000078142 BECN ENSG0000126581 ATG14 ENSG0000126775 UVRAG ENSG0000198382 ATG3 ENSG000011844 ATG4A ENSG0000188397 ATG4D ENSG0000125703 ATG4D ENSG0000130734 ATG5 ENSG0000197548 LC3A ENSG000014460 LC3B ENSG0000170296 GABARAPL ENSG0000170296 GABARAPL2 ENSG0000152348 ATG10 ENSG0000152348 ATG12 ENSG0000152348	ATG9B	ENSG0000181652
PIK3R4 ENSG00000196455 VPS34 ENSG0000078142 BECN ENSG0000126581 ATG14 ENSG0000126775 UVRAG ENSG0000198382 ATG3 ENSG0000198382 ATG4 ENSG000011844 ATG4A ENSG0000168397 ATG4D ENSG0000125703 ATG4D ENSG0000130734 ATG5 ENSG000013734 ATG5 ENSG0000197548 LC3A ENSG0000144941 LC3B ENSG0000170296 GABARAPL ENSG0000170296 GABARAPL2 ENSG0000152348 ATG10 ENSG0000145782 ATG12 ENSG0000145782	WIPI1	ENSG0000070540
VPS34 ENSG0000078142 BECN ENSG0000126581 ATG14 ENSG0000126775 UVRAG ENSG0000198382 ATG3 ENSG0000198382 ATG3 ENSG000014848 ATG4A ENSG000011844 ATG4B ENSG0000168397 ATG4C ENSG0000125703 ATG4D ENSG0000130734 ATG5 ENSG000013734 ATG5 ENSG0000197548 LC3A ENSG0000140941 LC3B ENSG0000170296 GABARAPL ENSG0000170296 GABARAPL2 ENSG0000152348 ATG10 ENSG0000145782 ATG12 ENSG0000145782	WIPI2	ENSG00000157954
BECN ENSG0000126581 ATG14 ENSG0000126775 UVRAG ENSG0000198382 ATG3 ENSG0000144848 ATG4 ENSG0000101844 ATG4A ENSG0000168397 ATG4C ENSG0000125703 ATG4D ENSG0000130734 ATG5 ENSG0000197548 LC3A ENSG0000140941 LC3B ENSG0000170296 GABARAPL1 ENSG0000139112 GABARAPL2 ENSG0000152348 ATG10 ENSG0000152348 ATG12 ENSG0000152348 ATG16L1 ENSG0000185978	PIK3R4	ENSG0000196455
ATG14 ENSG0000126775 UVRAG ENSG00000198382 ATG3 ENSG0000014848 ATG4A ENSG0000101844 ATG4B ENSG00000168397 ATG4C ENSG00000125703 ATG4D ENSG00000130734 ATG5 ENSG00000197548 LC3A ENSG0000101460 LC3B ENSG0000140941 LC3B2 ENSG00000170296 GABARAPL1 ENSG00000139112 GABARAPL2 ENSG00000152348 ATG10 ENSG0000140941 LC3B2 ENSG0000170296 GABARAPL1 ENSG0000170296 GABARAPL3 ENSG00001839112 GABARAPL4 ENSG0000034713 ATG10 ENSG0000152348 ATG12 ENSG0000145782 ATG16L1 ENSG0000085978	VPS34	ENSG0000078142
UVRAG ENSG0000198382 ATG3 ENSG000014848 ATG4A ENSG0000101844 ATG4B ENSG0000168397 ATG4C ENSG0000125703 ATG4D ENSG0000130734 ATG5 ENSG0000197563 ATG7 ENSG0000197548 LC3A ENSG0000140941 LC3B2 ENSG0000170296 GABARAPL1 ENSG0000139112 GABARAPL2 ENSG0000152348 ATG10 ENSG0000145782 ATG12 ENSG0000152348	BECN	ENSG0000126581
ATG3 ENSG0000144848 ATG4A ENSG0000101844 ATG4B ENSG0000168397 ATG4C ENSG0000125703 ATG4D ENSG0000130734 ATG5 ENSG0000057663 ATG7 ENSG0000197548 LC3A ENSG0000140941 LC3B ENSG0000170296 GABARAP ENSG000013713 GABARAPL1 ENSG0000034713 ATG10 ENSG0000152348 ATG12 ENSG00000145782	ATG14	ENSG0000126775
ATG4A ENSG0000101844 ATG4B ENSG0000168397 ATG4C ENSG0000125703 ATG4D ENSG0000130734 ATG5 ENSG0000057663 ATG7 ENSG0000197548 LC3A ENSG000011460 LC3B ENSG0000140941 LC3B2 ENSG0000170296 GABARAP ENSG0000139112 GABARAPL1 ENSG0000152348 ATG10 ENSG0000145782 ATG12 ENSG0000145782	UVRAG	ENSG0000198382
ATG4B ENSG0000168397 ATG4C ENSG0000125703 ATG4D ENSG0000130734 ATG5 ENSG0000057663 ATG7 ENSG0000197548 LC3A ENSG0000140941 LC3B ENSG00000170296 GABARAPL1 ENSG0000139112 GABARAPL2 ENSG00000152348 ATG10 ENSG0000152348 ATG12 ENSG0000085978	ATG3	ENSG0000144848
ATG4C ENSG0000125703 ATG4D ENSG0000130734 ATG5 ENSG0000057663 ATG7 ENSG0000197548 LC3A ENSG0000140941 LC3B2 ENSG0000170296 GABARAPL1 ENSG0000170296 GABARAPL2 ENSG000034713 ATG12 ENSG0000152348 ATG12 ENSG0000145782	ATG4A	ENSG0000101844
ATG4D ENSG0000130734 ATG5 ENSG0000057663 ATG7 ENSG00000197548 LC3A ENSG0000101460 LC3B ENSG0000140941 LC3B2 ENSG0000170296 GABARAP ENSG0000139112 GABARAPL1 ENSG000034713 ATG10 ENSG0000152348 ATG12 ENSG0000145782 ATG16L1 ENSG0000085978	ATG4B	ENSG0000168397
ATG5 ENSG0000057663 ATG7 ENSG0000197548 LC3A ENSG0000101460 LC3B ENSG0000140941 LC3B2 ENSG0000258102 GABARAP ENSG0000170296 GABARAPL1 ENSG0000139112 GABARAPL2 ENSG0000034713 ATG10 ENSG0000152348 ATG12 ENSG0000145782 ATG16L1 ENSG0000085978	ATG4C	ENSG0000125703
ATG7 ENSG0000197548 LC3A ENSG0000101460 LC3B ENSG0000140941 LC3B2 ENSG0000258102 GABARAP ENSG0000170296 GABARAPL1 ENSG0000139112 GABARAPL2 ENSG0000034713 ATG10 ENSG0000152348 ATG12 ENSG0000145782 ATG16L1 ENSG0000085978	ATG4D	ENSG0000130734
LC3A ENSG0000101460 LC3B ENSG0000140941 LC3B2 ENSG0000258102 GABARAP ENSG0000170296 GABARAPL1 ENSG0000139112 GABARAPL2 ENSG0000034713 ATG10 ENSG0000152348 ATG12 ENSG0000145782 ATG16L1 ENSG000085978	ATG5	ENSG0000057663
LC3B ENSG0000140941 LC3B2 ENSG0000258102 GABARAP ENSG0000170296 GABARAPL1 ENSG0000139112 GABARAPL2 ENSG0000034713 ATG10 ENSG0000152348 ATG12 ENSG0000145782 ATG16L1 ENSG000085978	ATG7	ENSG0000197548
LC3B2 ENSG0000258102 GABARAP ENSG0000170296 GABARAPL1 ENSG0000139112 GABARAPL2 ENSG0000034713 ATG10 ENSG0000152348 ATG12 ENSG0000145782 ATG16L1 ENSG0000085978	LC3A	ENSG0000101460
GABARAP ENSG0000170296 GABARAPL1 ENSG0000139112 GABARAPL2 ENSG0000034713 ATG10 ENSG00000152348 ATG12 ENSG0000145782 ATG16L1 ENSG0000085978	LC3B	ENSG0000140941
GABARAPL1 ENSG0000139112 GABARAPL2 ENSG0000034713 ATG10 ENSG00000152348 ATG12 ENSG0000145782 ATG16L1 ENSG000085978	LC3B2	ENSG0000258102
GABARAPL2 ENSG0000034713 ATG10 ENSG0000152348 ATG12 ENSG0000145782 ATG16L1 ENSG0000085978	GABARAP	ENSG0000170296
ATG10 ENSG0000152348 ATG12 ENSG0000145782 ATG16L1 ENSG0000085978	GABARAPL1	ENSG0000139112
ATG12 ENSG0000145782 ATG16L1 ENSG0000085978	GABARAPL2	ENSG0000034713
ATG16L1 ENSG0000085978	ATG10	ENSG0000152348
	ATG12	ENSG00000145782
ATG16L2 ENSG00000168010	ATG16L1	ENSG0000085978
	ATG16L2	ENSG0000168010

Table S1 – List of general autophagy genes that are targeted in the pilot autophagy gene

 screen. Related to Fig 1 and Supplemental Fig 1.

FSMAS Cyto 0.263 1.152 0.042 2.597 0.003 4.4 PREB E/Flyso 0.045 1.151 0.022 2.902 0.006 4.4 NRC3A nuc 0.045 1.153 0.019 1.567 0.006 4.3 RCM2A nuc 0.0412 0.740 0.079 2.325 0.001 -3. NRP11A nuc 0.018 -3.305 0.086 1.501 0.004 -3. RP13A nuc 0.018 -3.327 0.181 1.242 0.000 -3. NUDF82 mito 0.452 -2.580 0.033 1.051 0.001 -3. NMM24 gog/exra 0.033 -3.140 0.036 -3.31 0.006 -3.31 PMS65 cyto 0.033 -2.727 0.144 0.318 0.003 -3. PMS15 mito 0.030 -2.277 0.144 0.313 0.006 -2. PMS15	gene	Localization	Enhanced(P-	Enhanced(log2 Fold change)		Inhibit (log2 Fold change)	Enh/Inh (P- value)	Enh/Inh (Fold change)
PREB Ek/lyso 0.045 1.513 0.023 2.902 0.006 4. ATPSD mito 0.156 -3.428 0.007 6.37 0.008 -3. CONDA cyto 0.238 -1.363 0.019 1.567 0.004 -3. RRC14 nuc 0.018 -3.305 0.086 1.501 0.004 -3. RV113A nuc 0.018 -3.372 0.181 1.242 0.004 -3. RPL3 cyto 0.032 -275 0.328 3.722 0.000 -3. NUDFE2 mito 0.043 2.731 0.046 0.381 0.003 -3. FSIDT810 mito 0.006 2.272 0.422 0.895 0.006 -3. FAST nito 0.033 2.717 0.143 0.346 -3. 3. FDIT810 mito 0.035 2.757 0.424 0.895 0.756 2.0000 -3.	VPS16	lyso	0.077	-4.578	0.002	1.338	0.001	-5.368
RTPSO mito 0.015 3.328 0.007 0.637 0.008 3.33 COR02A oyto 0.238 1.363 0.019 1.367 0.006 3.3 PRF4 nuc 0.018 -3.305 0.086 1.501 0.004 -3.3 PRF3 nuc 0.018 -3.352 0.181 1.242 0.004 -3.3 NUF82 mito 0.452 -2.475 0.328 3.792 0.0001 -3.3 MMP24 gojgl/ctra 0.033 -3.440 0.066 0.338 0.003 -3.4 PSM85 cyto 0.003 -2.272 0.143 0.313 0.006 -3.3 PICK1 mito 0.030 -2.272 0.143 0.313 0.005 -2.2 PR451 cyto 0.046 0.331 0.006 -3.2 PICK1 mito 0.031 -2.277 0.134 0.374 0.003 -2.2 PR51 cyto 0.183			0.263	-1.152				-4.701
CORO2A oyto 0.238 1.363 0.019 1.567 0.006 3. RRF24 nuc 0.018 -3.305 0.0075 1.2325 0.001 -3.3 RVF13A nuc 0.018 -3.305 0.086 1.511 0.004 -3.3 RVP12A cvto 0.0756 2.475 0.328 3.792 0.000 -3.3 NDUF82 mito 0.053 3.40 0.096 0.518 0.000 -3.3 PSMB5 cyto 0.003 2.790 0.140 0.381 0.003 -3.3 PMSD131D mito 0.006 -2.277 0.242 0.895 0.006 -3.3 RAS2 mito 0.035 -2.573 0.026 0.706 0.003 -2.2 DR1 nuc 0.019 -2.757 0.134 0.374 0.004 -2.2 SCRINC2 extracell 0.316 -1.540 0.055 0.053 0.004 -2.2 <td< td=""><td>PREB</td><td>ER/lyso</td><td>0.045</td><td>-1.513</td><td>0.023</td><td>2.902</td><td>0.006</td><td>-4.177</td></td<>	PREB	ER/lyso	0.045	-1.513	0.023	2.902	0.006	-4.177
IRRC24 nuc 0.018 -3.305 0.026 1.501 0.004 -3.305 RPF13A nuc 0.018 -3.305 0.086 1.501 0.004 -3.305 RPL32 cvto 0.756 2.475 0.228 3.792 0.0004 -3.305 MUP42 golg/vetra 0.033 -3.140 0.066 0.358 0.003 -3.305 MMP24 golg/vetra 0.033 -3.140 0.066 0.358 0.003 -3.305 PSM55 cvto 0.005 -2.277 0.140 0.381 0.008 -3.33 PGK1 mito 0.005 -2.272 0.143 0.374 0.003 -2.22 DL1 nuc 0.019 -2.572 0.026 0.776 0.003 -2.22 DL1 nuc 0.019 -2.248 0.037 -2.24 0.044 -2.248 0.231 -0.242 0.232 0.221 D.12 D.124 D.134 0.360 -2.248	ATP5O	mito	0.156	-3.428	0.007	0.637	0.003	-3.862
PRPF4 nuc 0.018 3.302 0.086 1.501 0.004 3.3 RPL23 cvto 0.018 3.372 0.181 1.242 0.000 3.3 NDUF82 mto 0.452 2.580 0.033 1.051 0.001 3.3 NMP24 golg/extra 0.033 3.140 0.046 0.338 0.003 3.3 PSMB5 cyto 0.003 2.790 0.140 0.381 0.000 3.3 PLST810 mito 0.000 2.797 0.242 0.895 0.008 3.3 PCK1 mito 0.035 2.777 0.242 0.895 0.006 3.3 PCK1 mito 0.035 2.737 0.026 0.006 0.003 2.2 DL mito 0.034 0.320 0.341 0.039 2.2 3.10 0.341 0.004 2.2 DL mito 0.044 0.800 0.461 1.466 0.402 <t< td=""><td>CORO2A</td><td>cyto</td><td>0.238</td><td>-1.363</td><td>0.019</td><td>1.567</td><td>0.006</td><td>-3.796</td></t<>	CORO2A	cyto	0.238	-1.363	0.019	1.567	0.006	-3.796
RNF113A nuc 0.018 -3.572 0.181 1.242 0.004 -3. NDUF92 mito 0.0756 2.2475 0.328 3.792 0.000 -3. NDUF92 mito 0.0432 -2.580 0.003 1.051 0.003 -3. MMP24 golg/extra 0.033 -3.140 0.096 0.358 0.003 -3. PKM55 Cyto 0.000 -2.930 0.039 0.492 0.000 -3. PAFS51 Cyto 0.066 -2.272 0.143 0.313 0.006 -3. TARS2 mito 0.035 -2.722 0.143 0.314 0.005 -2. DLD mito 0.036 -2.573 0.013 0.374 0.000 -2. RINC extracell 0.316 -1.540 0.066 1.456 0.009 -2. RINC extracell 0.316 -1.540 0.021 -2. MMAA 0.002 -2. </td <td>LRRC34</td> <td>nuc</td> <td>0.473</td> <td>-0.740</td> <td>0.079</td> <td>2.325</td> <td>0.001</td> <td>-3.783</td>	LRRC34	nuc	0.473	-0.740	0.079	2.325	0.001	-3.783
EPL3 cyto 0.756 2.475 0.328 3.792 0.0001 -3. NMP24 gplg/extra 0.452 -2.580 0.003 1.051 0.001 -3. PSMB5 cyto 0.003 -2.790 0.140 0.381 0.003 -3. PSMB5 cyto 0.066 -2.777 0.242 0.895 0.008 -3. PAPS51 cyto 0.066 -2.777 0.242 0.895 0.006 -3. TABS2 mito 0.035 2.573 0.026 0.706 0.005 -2. DR1 nuc 0.019 -2.757 0.134 0.374 0.004 -2. SERINC2 extracell 0.316 -1.540 0.065 0.553 0.004 -2. SERINC2 extracell 0.316 -1.540 0.026 0.002 -2. SERINC2 extracell 0.316 -1.540 0.026 0.020 -2. Cyto 0.001 -2.	PRPF4	nuc	0.018	-3.305	0.086	1.501	0.004	-3.662
NDLFR2 mito 0.432 2.880 0.003 1.051 0.001 3.3 MMP24 golg/extra 0.033 -3.140 0.096 0.358 0.003 -3.3 HSD17B10 mito 0.000 -2.790 0.414 0.381 0.003 -3.3 PAPSS1 cyto 0.003 -2.722 0.4143 0.313 0.006 -3.3 PICK1 mito 0.030 -2.722 0.143 0.313 0.006 -3.3 TARS2 mito 0.019 -2.757 0.134 0.374 0.003 -2.2 DLD mito 0.044 -0.800 0.046 1.446 0.009 -2.5 SRINC2 extracell 0.318 -0.806 0.392 2.432 0.004 -2.2 MMAA mito 0.004 2.450 0.230 0.021 -2.2 MMAA mito 0.004 2.450 0.350 0.206 0.002 -2.2 MAAA	RNF113A	nuc	0.018	-3.572	0.181	1.242	0.004	-3.607
MMP24 golg/j.extra 0.033 -3.140 0.096 0.388 0.003 -3.3 PSMB5 cyto 0.000 -2.930 0.140 0.381 0.003 -3.3 PAPSS1 cyto 0.066 -2.277 0.2421 0.895 0.000 -3.3 PAPSS1 cyto 0.066 -2.277 0.2421 0.895 0.000 -3.3 TARS2 mito 0.033 -2.573 0.026 0.706 0.005 -2.2 DLD mito 0.044 0.800 0.046 1.446 0.004 -2.2 SERINC2 extracell 0.316 -1.540 0.065 0.553 0.000 -2. ATF5 cyto 0.183 -0.806 0.392 2.432 0.004 -2.2 RPSK82 cyto/u 0.099 -2.248 0.231 1.759 0.010 -2. MAA mito 0.002 -2.23 0.191 0.949 0.001 -2.	RPL23	cyto		-2.475	0.328	3.792		-3.602
PSMBS cyto 0.003 -2.790 0.140 0.381 0.003 -3. HSD17B10 mito 0.000 -2.390 0.039 0.492 0.000 -3. PICK1 mito 0.030 -2.277 0.242 0.143 0.313 0.006 -3. PICK1 mito 0.033 -2.573 0.134 0.374 0.005 -2.2 DR1 nuc 0.019 -2.757 0.134 0.374 0.004 -2. SERINC2 extracell 0.316 1.540 0.065 0.553 0.009 -2. ATF5 cyto 0.183 -0.806 0.392 2.432 0.001 -2. MMAA mito 0.004 -2.450 0.290 0.291 0.001 -2. MMRP24 mito 0.025 -2.025 0.130 0.206 0.020 -2. NDFS8 mito 0.025 -2.026 0.390 0.001 -2. SG011 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-3.504</td>								-3.504
HSD17B10 mto 0.000 2.330 0.039 0.492 0.000 -3. PAPS51 cyto 0.066 -2.277 0.242 0.895 0.000 -3. TARS2 mito 0.033 -2.737 0.026 0.706 0.005 -2. DID mito 0.019 2.757 0.134 0.347 0.003 -2. DLD mito 0.044 0.800 0.046 1.446 0.004 -2. SERINC2 extracell 0.316 -1.540 0.065 0.553 0.009 -2. ATF5 cyto 0.138 0.860 0.392 2.432 0.004 -2. MMAA mito 0.002 2.553 0.330 0.206 0.002 -2. VBSB mito 0.017 -2.444 0.128 0.467 0.001 -2. VDUFS8 mito 0.022 2.033 0.057 0.379 0.000 -2. SCGL1		golgi/extra					0.003	-3.433
PAPSS1 Cyto 0.066 -2.277 0.242 0.895 0.008 -3.3 PICK1 mito 0.030 -2.723 0.143 0.313 0.006 -3.3 TARS2 mito 0.035 -2.573 0.026 0.706 0.003 -2.2 DID mito 0.044 -0.800 0.464 0.446 0.004 -2.2 SERINC2 extracell 0.316 -1.540 0.065 0.553 0.009 -2.2 NPS6KB2 cyto/nuc 0.099 -2.248 0.231 1.759 0.001 -2.2 MMAA mito 0.004 -2.450 0.290 0.291 0.004 -2. MRP124 mito 0.007 -2.444 0.128 0.977 0.202 -2.23 SGOL1 cyto/nuc 0.028 -2.059 0.598 0.667 0.001 -2.2 SGOL1 cyto/nuc 0.028 -2.597 0.330 0.047 0.003 -2.2	PSMB5		0.003				0.003	-3.176
IPICK1 mito 0.030 -2.722 0.143 0.313 0.006 -3.33 TARS2 mito 0.035 -2.757 0.026 0.706 0.005 -2.7 DLD mito 0.044 -0.800 0.046 1.446 0.004 -2.7 SERINC2 extracell 0.313 -1.540 0.065 0.553 0.009 -2.2 RPS6KB2 cyto/nuc 0.099 -2.248 0.231 1.759 0.001 -2. NMAA mito 0.004 -2.450 0.290 0.291 0.004 -2. NMAA mito 0.009 -2.653 0.350 0.206 0.002 -2. NDUF88 mito 0.001 -1.838 0.452 0.647 0.001 -2. SGOL1 cyto/nuc 0.028 -2.090 0.598 0.669 0.007 -2. NDUF84 mito 0.002 -2.233 0.057 0.379 0.0001 -2.	HSD17B10	mito	0.000	-2.930	0.039	0.492	0.000	-3.150
TARS2 mito 0.035 -2.573 0.026 0.706 0.005 -2.2 DR1 mito 0.019 -2.757 0.134 0.374 0.003 -2.2 DR1 mito 0.044 -0.800 0.046 1.446 0.004 -2.2 SERINC2 extracell 0.316 -1.540 0.065 0.553 0.009 -2.2 RPS6KB2 cyto/nuc 0.099 -2.248 0.231 1.759 0.001 -2. MMAA mito 0.004 -2.450 0.290 0.291 0.004 -2. NMPP124 mito 0.007 -2.444 0.128 0.197 0.002 -2. SGOL1 cyto/nuc 0.028 -2.050 0.198 0.969 0.001 -2. SGOL1 cyto/nuc 0.028 -2.059 0.390 0.001 -2. SGOL1 cyto/nuc 0.028 -2.059 0.390 0.001 -2. SGOL1 cyto/nuc </td <td></td> <td>cyto</td> <td></td> <td></td> <td>0.242</td> <td></td> <td>0.008</td> <td>-3.114</td>		cyto			0.242		0.008	-3.114
DR1 nuc 0.019 -2.757 0.134 0.374 0.003 -2.2 DLD mito 0.044 -0.800 0.046 1.446 0.004 -2.2 SRINC2 extracell 0.313 -0.806 0.332 2.432 0.004 -2.2 ATF5 Cyto 0.183 -0.806 0.332 2.432 0.004 -2. MMAA mito 0.004 -2.450 0.290 0.291 0.004 -2. MRPL24 mito 0.009 -2.653 0.350 0.206 0.002 -2. NDUFS8 mito 0.012 -2.233 0.611 0.940 0.001 -2. SGOL1 Cyto/ruc 0.028 -2.030 0.047 0.003 -2. CCAR1 nuc 0.071 -2.976 0.230 0.047 0.003 -2. DDX52 nuc 0.127 -1.969 0.215 0.228 0.000 -2. SIC7A9 PM <td>PICK1</td> <td>mito</td> <td></td> <td>-2.722</td> <td></td> <td>0.313</td> <td>0.006</td> <td>-3.041</td>	PICK1	mito		-2.722		0.313	0.006	-3.041
DLD mito 0.044 -0.800 0.046 1.446 0.004 -2: SERINC2 extracell 0.316 -1.540 0.065 0.553 0.009 -2: ATF5 cyto 0.183 -0.806 0.392 2.432 0.004 -2: RPS6K82 cyto/nuc 0.099 -2.248 0.231 1.759 0.001 -2: MMAA mito 0.009 -2.653 0.350 0.206 0.002 -2: MPL24 mito 0.001 -2.444 0.128 0.197 0.002 -2: MDUFS8 mito 0.021 -2.233 0.057 0.379 0.0001 -2: SGOL1 cyto/nuc 0.028 -2.233 0.057 0.379 0.000 -2: SCTA9 PM 0.019 -2.104 0.225 0.390 0.010 -2: SUC7A9 PM 0.012 -2.144 0.022 0.137 0.002 -2: V	TARS2	mito	0.035	-2.573	0.026	0.706	0.005	-2.983
SERING2 extracell 0.316 -1.540 0.065 0.553 0.009 -2.2 ATF5 Cyto 0.183 -0.806 0.332 2.432 0.004 -2. MMAA mito 0.004 -2.488 0.231 1.759 0.001 -2. MMPL24 mito 0.009 -2.653 0.350 0.206 0.002 -2. NDUFS8 mito 0.017 -2.444 0.128 0.197 0.001 -2. SGDL1 cyto/nuc 0.022 -2.025 0.119 0.940 0.001 -2. SGDL1 cyto/nuc 0.028 -2.509 0.598 0.969 0.007 -2. SGDL1 cyto/nuc 0.021 -2.233 0.047 0.003 -2. SGDL3 nuc 0.127 -1.969 0.215 0.228 0.000 -2. SLC7A9 PM 0.019 -2.104 0.073 0.601 0.002 -2. VARS2	DR1	nuc	0.019	-2.757	0.134	0.374	0.003	-2.967
ATF5 cyto 0.183 -0.806 0.392 2.432 0.004 -2.2 RPS6K82 cyto/nuc 0.099 -2.248 0.231 1.759 0.001 -2. MMAA mito 0.009 -2.653 0.350 0.206 0.002 -2. CYB58 mito 0.017 -2.444 0.128 0.197 0.002 -2. CYB58 mito 0.001 -1.838 0.452 0.647 0.001 -2. SGOL1 cyto/nuc 0.028 -2.509 0.598 0.969 0.007 -2. SGOL1 cyto/nuc 0.028 -2.509 0.538 0.969 0.000 -2. CGAR1 nuc 0.071 -2.976 0.230 0.047 0.003 -2. DDX52 nuc 0.125 -2.144 0.723 0.000 -2. VARS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. VARS2 mi	DLD	mito	0.044	-0.800	0.046	1.446	0.004	-2.956
PPS6R92 cyto/nuc 0.099 -2.248 0.231 1.759 0.001 -2. MMAA mito 0.004 -2.450 0.230 0.291 0.004 -2. MMRPL24 mito 0.001 -2.443 0.128 0.197 0.002 -2. NDUFS8 mito 0.025 -2.025 0.119 0.940 0.001 -2. SGOL1 cyto/nuc 0.028 -2.509 0.598 0.969 0.007 -2. SGOL1 cyto/nuc 0.028 -2.509 0.598 0.969 0.001 -2. SGOL1 cyto/nuc 0.021 -2.976 0.230 0.047 0.003 -2. CCAR1 nuc 0.071 -2.976 0.230 0.010 -2. DX52 nuc 0.127 -1.969 0.215 0.228 0.900 0.010 -2. VARS2 mito 0.032 -2.144 0.073 0.601 0.002 -2.	SERINC2	extracell	0.316	-1.540	0.065	0.553	0.009	-2.944
MMAA mito 0.004 -2.450 0.290 0.291 0.004 -2. MRPL24 mito 0.009 -2.653 0.350 0.206 0.002 -2. NDUFS8 mito 0.025 -2.025 0.119 0.940 0.001 -2. NDUFS8 mito 0.025 -2.025 0.119 0.940 0.001 -2. NDUF84 mito 0.002 -2.233 0.057 0.379 0.000 -2. NDUF84 mito 0.002 -2.233 0.057 0.379 0.000 -2. SLC7A9 PM 0.019 -2.146 0.228 0.008 -2. SLC7A9 PM 0.019 -2.144 0.073 0.601 0.003 -2. VARS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. VARS2 mito 0.0059 -1.866 0.984 0.169 0.002 -2. VARS2 cyto/lyso<								-2.895
MRPL24 mito 0.009 -2.653 0.350 0.206 0.002 -2. CYB5B mito 0.017 -2.444 0.128 0.197 0.002 -2. MAP4 cyto 0.001 -1.838 0.452 0.647 0.001 -2. SG0L1 cyto/nuc 0.028 -2.509 0.598 0.669 0.007 -2. SG0L1 cyto/nuc 0.021 -2.23 0.057 0.379 0.000 -2. CCAR1 nuc 0.071 -2.976 0.230 0.047 0.003 -2. DDX52 nuc 0.127 -1.969 0.215 0.228 0.390 0.010 -2. DAS5 nuc 0.022 -2.744 0.073 0.661 0.003 -2. VARS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. LOC441155 nuc 0.058 -2.106 0.221 0.215 0.003 -2. <	RPS6KB2	cyto/nuc	0.099	-2.248	0.231	1.759	0.001	-2.780
CYB5B mito 0.017 -2.444 0.128 0.197 0.002 -2. NDUFSA mito 0.025 -2.025 0.119 0.940 0.001 -2. SG0L1 cyto/nuc 0.028 -2.059 0.598 0.667 0.001 -2. SG0L1 cyto/nuc 0.028 -2.509 0.598 0.969 0.007 -2. NDUFB4 mito 0.002 -2.233 0.057 0.379 0.000 -2. DDX52 nuc 0.127 -1.969 0.215 0.228 0.008 -2. DDX52 nuc 0.127 -1.969 0.215 0.228 0.008 -2. MGL ER 0.125 -2.144 0.073 0.601 0.003 -2. MAPA 0.029 -1.866 0.984 0.169 0.004 -2. VARS2 mito 0.038 -2.106 0.221 0.215 0.003 -2. LOC41155 nu <td>MMAA</td> <td>mito</td> <td>0.004</td> <td>-2.450</td> <td>0.290</td> <td>0.291</td> <td>0.004</td> <td>-2.736</td>	MMAA	mito	0.004	-2.450	0.290	0.291	0.004	-2.736
NDUFS8 mito 0.025 -2.025 0.119 0.940 0.001 -2. MAP4 cyto 0.001 -1.838 0.452 0.647 0.001 -2. SGOL1 cyto/nuc 0.028 -2.509 0.598 0.969 0.007 -2. NDUFB4 mito 0.002 -2.233 0.057 0.379 0.000 -2. CCAR1 nuc 0.017 -1.969 0.215 0.228 0.008 -2. SLC7A9 PM 0.019 -2.104 0.225 0.390 0.010 -2. VARS2 mito 0.002 -1.740 0.03 0.660 0.000 -2. VARS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. VARS2 mito 0.018 -2.204 0.984 0.169 0.004 -2. LOC441155 nuc 0.058 -2.106 0.221 0.215 0.03 -2. ABHD8 <td>MRPL24</td> <td>mito</td> <td>0.009</td> <td>-2.653</td> <td>0.350</td> <td>0.206</td> <td>0.002</td> <td>-2.701</td>	MRPL24	mito	0.009	-2.653	0.350	0.206	0.002	-2.701
MAP4 cyto 0.001 -1.838 0.452 0.647 0.001 -2. SGOL1 cyto/nuc 0.028 -2.509 0.598 0.969 0.007 -2. NDUFB4 mito 0.002 -2.233 0.057 0.379 0.000 -2. DXDS2 nuc 0.017 -2.976 0.230 0.047 0.003 -2. DX52 nuc 0.127 -1.969 0.215 0.228 0.008 -2. SLC7A9 PM 0.012 -2.144 0.073 0.601 0.003 -2. VRS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. VRS2 mito 0.002 -1.740 0.030 0.660 0.000 -2. VRS3 nuto 0.008 -1.150 0.046 1.094 0.002 -2. ABHD8 extracell 0.018 -2.066 0.221 0.215 0.003 -2. ADAM18	CYB5B	mito	0.017	-2.444	0.128	0.197	0.002	-2.647
SGOL1 cyto/nuc 0.028 -2.509 0.598 0.969 0.007 -2. NDUFB4 mito 0.002 -2.233 0.057 0.379 0.000 -2. CCAR1 nuc 0.071 -2.976 0.230 0.047 0.003 -2. DDX52 nuc 0.127 -1.969 0.215 0.228 0.008 -2. SLC7A9 PM 0.012 -2.144 0.073 0.601 0.003 -2. VARS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. LOC441155 nuc 0.059 -1.866 0.984 0.169 0.004 -2. PIK3C3 cyto/lyso 0.115 -1.250 0.046 1.094 0.002 -2. ABH08 extracell 0.018 -2.204 0.988 0.055 0.008 -2. ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. <t< td=""><td>NDUFS8</td><td>mito</td><td>0.025</td><td>-2.025</td><td>0.119</td><td>0.940</td><td>0.001</td><td>-2.514</td></t<>	NDUFS8	mito	0.025	-2.025	0.119	0.940	0.001	-2.514
NDUFB4 mito 0.002 -2.233 0.057 0.379 0.000 -2. CCAR1 nuc 0.071 -2.976 0.230 0.047 0.003 -2. DDX52 nuc 0.127 -1.969 0.215 0.228 0.008 -2. SLC7A9 PM 0.019 -2.104 0.225 0.390 0.010 -2. PLD4 ER 0.022 -1.740 0.003 0.660 0.000 -2. VARS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. VARS2 mito 0.002 -1.740 0.004 1.094 0.002 -2. LOC441155 nuc 0.059 -1.866 0.984 0.169 0.004 -2. LOC41155 nuc 0.058 -2.106 0.221 0.215 0.003 -2. DFFA cyto/nuc 0.058 -2.106 0.221 0.216 0.003 -2. CANL	MAP4	cyto	0.001	-1.838	0.452	0.647	0.001	-2.489
CCAR1 nuc 0.071 -2.976 0.230 0.047 0.003 -2. DDX52 nuc 0.127 -1.969 0.215 0.228 0.008 -2. SLC7A9 PM 0.019 -2.104 0.225 0.390 0.010 -2. MGLL ER 0.125 -2.144 0.073 0.601 0.003 -2. VARS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. UCC441155 nuc 0.059 -1.866 0.984 0.169 0.002 -2. ABHD8 extracell 0.018 -2.204 0.988 0.056 0.008 -2. DFFA cyto/nuc 0.058 -2.106 0.221 0.215 0.003 -2. ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. RACGAP1 cyto 0.008 -1.752 0.179 0.296 0.005 -2. GTAS <td>SGOL1</td> <td>cyto/nuc</td> <td>0.028</td> <td>-2.509</td> <td>0.598</td> <td>0.969</td> <td>0.007</td> <td>-2.474</td>	SGOL1	cyto/nuc	0.028	-2.509	0.598	0.969	0.007	-2.474
DDX52 nuc 0.127 -1.969 0.215 0.228 0.008 -2. SLC7A9 PM 0.019 -2.104 0.225 0.390 0.010 -2. PLD4 ER 0.125 -2.144 0.073 0.601 0.003 -2. WAS2 mito 0.002 -1.740 0.003 0.666 0.000 -2. VARS2 mito 0.0059 -1.866 0.984 0.169 0.004 -2. LOC441155 nuc 0.059 -1.866 0.984 0.169 0.002 -2. ABHD8 extracell 0.018 -2.204 0.988 0.056 0.008 -2. ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. AKGAP1 cyto 0.009 -1.760 0.750 1.216 0.003 -2. QXA1L mito 0.003 -1.752 0.179 0.296 0.005 -2. GNAS	NDUFB4	mito	0.002	-2.233	0.057	0.379	0.000	-2.449
SLC7A9 PM 0.019 -2.104 0.225 0.390 0.010 -2. PLD4 FR 0.125 -2.144 0.073 0.601 0.003 -2. MGLL ER 0.032 -2.244 0.252 0.197 0.002 -2. VARS2 mito 0.002 -1.740 0.003 0.666 0.000 -2. LOC441155 nuc 0.059 -1.866 0.984 0.169 0.004 -2. ABHD8 extracell 0.018 -2.204 0.988 0.056 0.008 -2. ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. ACGAP1 cyto 0.009 -1.750 0.750 1.216 0.003 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. GGRAS cyto/nuc 0.031 -1.752 0.179 0.296 0.0002 -2. RBM2	CCAR1	nuc	0.071	-2.976	0.230	0.047	0.003	-2.418
PLD4 ER 0.125 -2.144 0.073 0.601 0.003 -2. MGLL ER 0.032 -2.244 0.252 0.197 0.002 -2. VARS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. UCC441155 nuc 0.059 -1.866 0.984 0.169 0.004 -2. ABH08 extracell 0.018 -2.204 0.988 0.056 0.008 -2. ABH08 extracell 0.018 -2.204 0.988 0.056 0.008 -2. ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. ACGAP1 cyto 0.009 -1.760 0.750 1.216 0.003 -2. GNA11 mito 0.008 -1.531 0.008 0.772 0.001 -2. GNA11 mito 0.037 -1.752 0.179 0.296 0.005 -2. FGFBP3	DDX52	nuc	0.127	-1.969	0.215	0.228	0.008	-2.408
MGLL ER 0.032 -2.244 0.252 0.197 0.002 -2. VARS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. LOC441155 nuc 0.059 -1.866 0.984 0.169 0.004 -2. ABHD8 extracell 0.015 -1.250 0.046 1.094 0.002 -2. ABHD8 extracell 0.018 -2.204 0.988 0.056 0.008 -2. ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. ACGAP1 cyto 0.009 -1.760 0.750 1.216 0.003 -2. OXA1L mito 0.008 -1.531 0.008 0.772 0.001 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. RBM28 nuc 0.011 -1.583 0.210 0.360 0.009 -2. M	SLC7A9	PM	0.019	-2.104	0.225	0.390	0.010	-2.404
VARS2 mito 0.002 -1.740 0.003 0.660 0.000 -2. LOC441155 nuc 0.059 -1.866 0.984 0.169 0.004 -2. PIK3C3 cyto/lyso 0.115 -1.250 0.046 1.094 0.002 -2. ABHD8 extracell 0.018 -2.204 0.988 0.056 0.008 -2. ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. RAGGAP1 cyto 0.009 -1.760 0.750 1.216 0.003 -2. QXA1L mito 0.008 -1.531 0.008 0.772 0.001 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. NUDCD1 cyto 0.021 -0.913 0.276 0.589 0.002 -2. NUB28 nuc 0.011 -1.838 0.210 0.360 0.099 -2.	PLD4	ER	0.125	-2.144	0.073	0.601	0.003	-2.238
LOC441155 nuc 0.059 -1.866 0.984 0.169 0.004 -2. PIK3C3 cyto/lyso 0.115 -1.250 0.046 1.094 0.002 -2. ABHD8 extracell 0.018 -2.204 0.988 0.056 0.008 -2. DFFA cyto/nuc 0.058 -2.106 0.221 0.215 0.003 -2. RACGAP1 cyto 0.009 -1.760 0.750 1.216 0.003 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. GRAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. NUDCD1 cyto 0.021 -0913 0.276 0.589 0.002 -2. NUBCD1 cyto 0.011 -1.583 0.210 0.360 0.009 -2. NUBC1 cyto 0.071 -1.422 0.117 0.202 0.007 -1.	MGLL	ER	0.032	-2.244	0.252	0.197	0.002	-2.235
PIK3C3 cyto/lyso 0.115 -1.250 0.046 1.094 0.002 -2. ABH08 extracell 0.018 -2.204 0.988 0.056 0.008 -2. DFFA cyto/nuc 0.058 -2.106 0.221 0.215 0.003 -2. ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. ACGAP1 cyto 0.009 -1.760 0.750 1.216 0.003 -2. OXA1L mito 0.008 -1.531 0.008 0.772 0.001 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. NUDCD1 cyto 0.021 -0.913 0.276 0.589 0.002 -2. MBM28 nuc 0.011 -1.583 0.210 0.360 0.009 -2. MINR1A PM 0.146 -1.006 0.057 1.024 0.007 -1. <	VARS2	mito	0.002	-1.740	0.003	0.660	0.000	-2.184
ABHD8 extracell 0.018 -2.204 0.988 0.056 0.008 -2. DFFA cyto/nuc 0.058 -2.106 0.221 0.215 0.003 -2. ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. RACGAP1 cyto 0.009 -1.760 0.750 1.216 0.003 -2. QXA1L mito 0.008 -1.531 0.008 0.772 0.001 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. NUDCD1 cyto 0.021 -0.913 0.276 0.589 0.002 -2. NUDCD1 cyto 0.011 -1.583 0.210 0.360 0.009 -2. RBM28 nuc 0.011 -1.583 0.210 0.360 0.009 -2. SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1. <t< td=""><td>LOC441155</td><td>nuc</td><td>0.059</td><td>-1.866</td><td>0.984</td><td>0.169</td><td>0.004</td><td>-2.163</td></t<>	LOC441155	nuc	0.059	-1.866	0.984	0.169	0.004	-2.163
DFFA cyto/nuc 0.058 -2.106 0.221 0.215 0.003 -2. ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. RACGAP1 cyto 0.009 -1.760 0.750 1.216 0.003 -2. OXA1L mito 0.008 -1.531 0.008 0.772 0.001 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. NUDCD1 cyto 0.021 -0.913 0.276 0.589 0.002 -2. NUDCD1 cyto 0.011 -1.583 0.210 0.360 0.009 -2. NTNR1A PM 0.146 -1.006 0.057 1.024 0.007 -1. SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1. GDI1 cyto 0.071 -1.422 0.117 0.202 0.007 -1. MR2C	PIK3C3	cyto/lyso	0.115	-1.250	0.046	1.094	0.002	-2.135
ADAM18 PM 0.070 -2.343 0.969 0.045 0.002 -2. RACGAP1 cyto 0.009 -1.760 0.750 1.216 0.003 -2. QXA1L mito 0.008 -1.531 0.008 0.772 0.001 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. FGFBP3 extracell 0.096 -1.818 0.047 0.466 0.006 -2. NUDCD1 cyto 0.021 -0.913 0.276 0.589 0.002 -2. MTNR1A PM 0.146 -1.006 0.057 1.024 0.007 -1. SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1. GD11 cyto 0.071 -1.422 0.117 0.202 0.005 -1. FMOD lyso 0.329 -0.293 0.119 1.756 0.008 -1. NDU	ABHD8	extracell	0.018	-2.204	0.988	0.056	0.008	-2.129
RACGAP1 cyto 0.009 -1.760 0.750 1.216 0.003 -2. OXA1L mito 0.008 -1.531 0.008 0.772 0.001 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. RBTRS extracell 0.096 -1.818 0.047 0.466 0.006 -2. NUDCD1 cyto 0.021 -0.913 0.276 0.589 0.002 -2. RBM28 nuc 0.011 -1.583 0.210 0.360 0.009 -2. SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1. SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1. NR2C1 nuc 0.030 -1.907 0.801 0.028 0.005 -1. <	DFFA	cyto/nuc	0.058	-2.106	0.221	0.215	0.003	-2.122
OXA1L mito 0.008 -1.531 0.008 0.772 0.001 -2. GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. FGFBP3 extracell 0.096 -1.818 0.047 0.466 0.006 -2. NUDCD1 cyto 0.021 -0.913 0.276 0.589 0.002 -2. RBM28 nuc 0.011 -1.583 0.210 0.360 0.009 -2. MTNR1A PM 0.146 -1.006 0.057 1.024 0.007 -1. SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1. GD11 cyto 0.071 -1.422 0.117 0.202 0.007 -1. GN21 nuc 0.030 -1.907 0.801 0.028 0.005 -1. NR221 nuc 0.030 -1.696 0.314 0.422 0.000 -1. RPL01 </td <td>ADAM18</td> <td>PM</td> <td>0.070</td> <td>-2.343</td> <td>0.969</td> <td>0.045</td> <td>0.002</td> <td>-2.113</td>	ADAM18	PM	0.070	-2.343	0.969	0.045	0.002	-2.113
GNAS cyto/nuc 0.037 -1.752 0.179 0.296 0.005 -2. FGFBP3 extracell 0.096 -1.818 0.047 0.466 0.006 -2. NUDCD1 cyto 0.021 -0.913 0.276 0.589 0.002 -2. RBM28 nuc 0.011 -1.583 0.210 0.360 0.009 -2. MTNR1A PM 0.146 -1.006 0.057 1.024 0.007 -1. SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1. GD11 cyto 0.071 -1.422 0.117 0.202 0.007 -1. RPZC1 nuc 0.030 -1.907 0.801 0.028 0.005 -1. FMOD lyso 0.329 -0.293 0.119 1.756 0.008 -1. NDUFA8 mito 0.003 -1.686 0.508 0.285 0.006 -1. LEO1<	RACGAP1	cyto	0.009	-1.760	0.750	1.216	0.003	-2.110
FGFBP3 extracell 0.096 -1.818 0.047 0.466 0.006 -2. NUDCD1 cyto 0.021 -0.913 0.276 0.589 0.002 -2. RBM28 nuc 0.011 -1.583 0.210 0.360 0.009 -2. MTNR1A PM 0.146 -1.006 0.057 1.024 0.007 -1. SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1. GD11 cyto 0.071 -1.422 0.117 0.202 0.007 -1. NR2C1 nuc 0.030 -1.907 0.801 0.028 0.005 -1. FMOD lyso 0.329 -0.293 0.119 1.756 0.008 -1. NDUFA8 mito 0.003 -1.696 0.314 0.422 0.000 -1. RPL10L cyto 0.265 -1.688 0.508 0.285 0.006 -1. LEO1 <td>OXA1L</td> <td>mito</td> <td>0.008</td> <td>-1.531</td> <td>0.008</td> <td>0.772</td> <td>0.001</td> <td>-2.107</td>	OXA1L	mito	0.008	-1.531	0.008	0.772	0.001	-2.107
NUDCD1 cyto 0.021 -0.913 0.276 0.589 0.002 -2.4 RBM28 nuc 0.011 -1.583 0.210 0.360 0.009 -2.4 MTNR1A PM 0.146 -1.006 0.057 1.024 0.007 -1.4 SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1.4 GD11 cyto 0.071 -1.422 0.117 0.202 0.007 -1.4 NR2C1 nuc 0.030 -1.907 0.801 0.028 0.005 -1.4 NMDUFA8 mito 0.003 -1.696 0.314 0.422 0.000 -1.4 NDUFA8 mito 0.003 -1.688 0.508 0.285 0.006 -1.4 LEO1 nuc 0.102 -1.726 0.184 0.414 0.005 -1.4 HLTF nuc 0.142 -1.838 0.534 0.396 0.003 -1.4 KCNN3	GNAS	cyto/nuc	0.037	-1.752	0.179	0.296	0.005	-2.102
RBM28 nuc 0.011 -1.583 0.210 0.360 0.009 -2. MTNR1A PM 0.146 -1.006 0.057 1.024 0.007 -1. SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1. GD1 cyto 0.071 -1.422 0.117 0.202 0.007 -1. NR2C1 nuc 0.030 -1.907 0.801 0.028 0.005 -1. FMOD lyso 0.329 -0.293 0.119 1.756 0.008 -1. NDUFA8 mito 0.003 -1.696 0.314 0.422 0.000 -1. RPL10L cyto 0.265 -1.688 0.508 0.285 0.006 -1. LEO1 nuc 0.102 -1.726 0.184 0.414 0.005 -1. HLTF nuc 0.142 -1.838 0.534 0.396 0.003 -1. KCNN3	FGFBP3	extracell	0.096	-1.818	0.047	0.466	0.006	-2.078
MTNR1APM0.146-1.0060.0571.0240.007-1.1SUPV3L1mito0.120-0.8480.0430.9370.007-1.1GD1cyto0.071-1.4220.1170.2020.007-1.1NR2C1nuc0.030-1.9070.8010.0280.005-1.1FMODlyso0.329-0.2930.1191.7560.008-1.1NDUFA8mito0.003-1.6960.3140.4220.000-1.1RPL10Lcyto0.265-1.6880.5080.2850.006-1.1LEO1nuc0.102-1.7260.1840.4140.005-1.1HLTFnuc0.142-1.8380.5340.3960.003-1.1MRPL33mito0.001-1.5160.4180.2620.001-1.1KCNN3PM0.297-1.4760.0950.4640.009-1.1CUL9cyto0.031-2.4300.2000.6680.007-1.1GDAP2lyso0.080-1.5190.3380.4770.007-1.1RIMBP2PM0.705-0.8170.0030.8360.006-1.1ENPP3PM0.014-1.1390.0890.5210.003-1.1	NUDCD1	cyto	0.021	-0.913	0.276	0.589	0.002	-2.031
SUPV3L1 mito 0.120 -0.848 0.043 0.937 0.007 -1.4 GD11 cyto 0.071 -1.422 0.117 0.202 0.007 -1.4 NR2C1 nuc 0.030 -1.907 0.801 0.028 0.005 -1.4 FMOD lyso 0.329 -0.293 0.119 1.756 0.008 -1.4 NDUFA8 mito 0.003 -1.696 0.314 0.4222 0.000 -1.4 RPL10L cyto 0.265 -1.688 0.508 0.285 0.006 -1.4 LEO1 nuc 0.102 -1.726 0.184 0.414 0.005 -1.4 HLTF nuc 0.142 -1.838 0.534 0.396 0.003 -1.4 MRPL33 mito 0.001 -1.516 0.418 0.262 0.001 -1.4 CU19 cyto 0.031 -2.430 0.200 0.668 0.007 -1.4 GDAP2	RBM28	nuc	0.011	-1.583	0.210	0.360	0.009	-2.025
GDI1 cyto 0.071 -1.422 0.117 0.202 0.007 -1.1 NR2C1 nuc 0.030 -1.907 0.801 0.028 0.005 -1.1 FMOD lyso 0.329 -0.293 0.119 1.756 0.008 -1.1 NDUFA8 mito 0.003 -1.696 0.314 0.422 0.000 -1.1 RPL10L cyto 0.265 -1.688 0.508 0.285 0.006 -1.1 LEO1 nuc 0.102 -1.726 0.184 0.414 0.005 -1.1 HLTF nuc 0.142 -1.838 0.534 0.396 0.003 -1.1 MRPL33 mito 0.001 -1.516 0.418 0.262 0.001 -1.1 KCNN3 PM 0.297 -1.476 0.095 0.464 0.009 -1.1 CUL9 cyto 0.031 -2.430 0.200 0.668 0.007 -1.4 GDAP2	MTNR1A	PM	0.146	-1.006	0.057	1.024	0.007	-1.962
NR2C1 nuc 0.030 -1.907 0.801 0.028 0.005 -1.1 FMOD lyso 0.329 -0.293 0.119 1.756 0.008 -1.1 NDUFA8 mito 0.003 -1.696 0.314 0.422 0.000 -1.1 RPL10L cyto 0.265 -1.688 0.508 0.285 0.006 -1.1 LEO1 nuc 0.102 -1.726 0.184 0.414 0.005 -1.1 HLTF nuc 0.142 -1.838 0.534 0.396 0.003 -1.1 MRPL33 mito 0.001 -1.516 0.418 0.262 0.001 -1.1 KCNN3 PM 0.297 -1.476 0.095 0.464 0.009 -1.1 CUL9 cyto 0.031 -2.430 0.200 0.668 0.007 -1.4 GDAP2 lyso 0.080 -1.519 0.338 0.477 0.007 -1.4 RIMBP2 <td>SUPV3L1</td> <td>mito</td> <td>0.120</td> <td>-0.848</td> <td>0.043</td> <td>0.937</td> <td>0.007</td> <td>-1.929</td>	SUPV3L1	mito	0.120	-0.848	0.043	0.937	0.007	-1.929
FMODlyso0.329-0.2930.1191.7560.008-1.1NDUFA8mito0.003-1.6960.3140.4220.000-1.1RPL10Lcyto0.265-1.6880.5080.2850.006-1.1LEO1nuc0.102-1.7260.1840.4140.005-1.1HLTFnuc0.142-1.8380.5340.3960.003-1.1MRPL33mito0.001-1.5160.4180.2620.001-1.1KCNN3PM0.297-1.4760.0950.4640.009-1.1CUL9cyto0.031-2.4300.2000.6680.007-1.1GDAP2lyso0.080-1.5190.3380.4770.007-1.1RIMBP2PM0.705-0.8170.0030.8360.006-1.1MS4A3PM0.456-1.3090.4410.4960.009-1.1ENPP3PM0.014-1.1390.0890.5210.003-1.1	GDI1	cyto	0.071	-1.422	0.117	0.202	0.007	-1.920
FMODlyso0.329-0.2930.1191.7560.008-1.1NDUFA8mito0.003-1.6960.3140.4220.000-1.1RPL10Lcyto0.265-1.6880.5080.2850.006-1.1LEO1nuc0.102-1.7260.1840.4140.005-1.1HLTFnuc0.142-1.8380.5340.3960.003-1.1MRPL33mito0.001-1.5160.4180.2620.001-1.1KCNN3PM0.297-1.4760.0950.4640.009-1.1CUL9cyto0.031-2.4300.2000.6680.007-1.1GDAP2lyso0.080-1.5190.3380.4770.007-1.1RIMBP2PM0.705-0.8170.0030.8360.006-1.1MS4A3PM0.456-1.3090.4410.4960.009-1.1ENPP3PM0.014-1.1390.0890.5210.003-1.1	NR2C1	nuc	0.030	-1.907	0.801	0.028	0.005	-1.903
NDUFA8 mito 0.003 -1.696 0.314 0.422 0.000 -1.4 RPL10L cyto 0.265 -1.688 0.508 0.285 0.006 -1.4 LEO1 nuc 0.102 -1.726 0.184 0.414 0.005 -1.4 HLTF nuc 0.142 -1.838 0.534 0.396 0.003 -1.4 MRPL33 mito 0.001 -1.516 0.418 0.262 0.001 -1. KCNN3 PM 0.297 -1.476 0.095 0.464 0.009 -1. MRPL34 mito 0.012 -1.232 0.013 0.521 0.001 -1. CUL9 cyto 0.031 -2.430 0.200 0.668 0.007 -1. GDAP2 lyso 0.080 -1.519 0.338 0.477 0.007 -1. RIMBP2 PM 0.705 -0.817 0.003 0.836 0.006 -1. MS4A3	FMOD	lyso	0.329	-0.293	0.119	1.756	0.008	-1.870
LEO1 nuc 0.102 -1.726 0.184 0.414 0.005 -1. HLTF nuc 0.142 -1.838 0.534 0.396 0.003 -1. MRPL33 mito 0.001 -1.516 0.418 0.262 0.001 -1. KCNN3 PM 0.297 -1.476 0.095 0.464 0.009 -1. MRPL34 mito 0.012 -1.232 0.013 0.521 0.001 -1. CUL9 cyto 0.031 -2.430 0.200 0.668 0.007 -1. GDAP2 lyso 0.080 -1.519 0.338 0.477 0.007 -1. RIMBP2 PM 0.705 -0.817 0.003 0.836 0.006 -1. MS4A3 PM 0.456 -1.309 0.441 0.496 0.009 -1. ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	NDUFA8		0.003	-1.696	0.314	0.422	0.000	-1.853
LEO1 nuc 0.102 -1.726 0.184 0.414 0.005 -1. HLTF nuc 0.142 -1.838 0.534 0.396 0.003 -1. MRPL33 mito 0.001 -1.516 0.418 0.262 0.001 -1. KCNN3 PM 0.297 -1.476 0.095 0.464 0.009 -1. MRPL34 mito 0.012 -1.232 0.013 0.521 0.001 -1. CUL9 cyto 0.031 -2.430 0.200 0.668 0.007 -1. GDAP2 lyso 0.080 -1.519 0.338 0.477 0.007 -1. RIMBP2 PM 0.705 -0.817 0.003 0.836 0.006 -1. MS4A3 PM 0.456 -1.309 0.441 0.496 0.009 -1. ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	RPL10L	cyto	0.265	-1.688	0.508	0.285	0.006	-1.844
HLTF nuc 0.142 -1.838 0.534 0.396 0.003 -1. MRPL33 mito 0.001 -1.516 0.418 0.262 0.001 -1. KCNN3 PM 0.297 -1.476 0.095 0.464 0.009 -1. MRPL34 mito 0.012 -1.232 0.013 0.521 0.001 -1. CUL9 cyto 0.031 -2.430 0.200 0.668 0.007 -1. GDAP2 lyso 0.080 -1.519 0.338 0.477 0.007 -1. RIMBP2 PM 0.705 -0.817 0.003 0.836 0.006 -1. MS4A3 PM 0.456 -1.309 0.441 0.496 0.009 -1. ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	LEO1		0.102	-1.726	0.184	0.414	0.005	-1.801
MRPL33 mito 0.001 -1.516 0.418 0.262 0.001 -1. KCNN3 PM 0.297 -1.476 0.095 0.464 0.009 -1. MRPL34 mito 0.012 -1.232 0.013 0.521 0.001 -1. CUL9 cyto 0.031 -2.430 0.200 0.668 0.007 -1. GDAP2 lyso 0.080 -1.519 0.338 0.477 0.007 -1. RIMBP2 PM 0.705 -0.817 0.003 0.836 0.006 -1. MS4A3 PM 0.456 -1.309 0.441 0.496 0.009 -1. ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	HLTF	nuc	0.142			0.396	0.003	-1.773
MRPL34 mito 0.012 -1.232 0.013 0.521 0.001 -1. CUL9 cyto 0.031 -2.430 0.200 0.668 0.007 -1. GDAP2 lyso 0.080 -1.519 0.338 0.477 0.007 -1. RIMBP2 PM 0.705 -0.817 0.003 0.836 0.006 -1. MS4A3 PM 0.456 -1.309 0.441 0.496 0.009 -1. ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	MRPL33	mito	0.001	-1.516	0.418	0.262	0.001	-1.771
CUL9 cyto 0.031 -2.430 0.200 0.668 0.007 -1. GDAP2 lyso 0.080 -1.519 0.338 0.477 0.007 -1. RIMBP2 PM 0.705 -0.817 0.003 0.836 0.006 -1. MS4A3 PM 0.456 -1.309 0.441 0.496 0.009 -1. ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	KCNN3	PM	0.297	-1.476	0.095	0.464	0.009	-1.728
CUL9 cyto 0.031 -2.430 0.200 0.668 0.007 -1. GDAP2 lyso 0.080 -1.519 0.338 0.477 0.007 -1. RIMBP2 PM 0.705 -0.817 0.003 0.836 0.006 -1. MS4A3 PM 0.456 -1.309 0.441 0.496 0.009 -1. ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	MRPL34	mito	0.012	-1.232	0.013	0.521	0.001	-1.698
GDAP2 Iyso 0.080 -1.519 0.338 0.477 0.007 -1. RIMBP2 PM 0.705 -0.817 0.003 0.836 0.006 -1. MS4A3 PM 0.456 -1.309 0.441 0.496 0.009 -1. ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	CUL9	cyto	0.031				0.007	-1.675
RIMBP2 PM 0.705 -0.817 0.003 0.836 0.006 -1. MS4A3 PM 0.456 -1.309 0.441 0.496 0.009 -1. ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	GDAP2		0.080			0.477	0.007	-1.635
MS4A3 PM 0.456 -1.309 0.441 0.496 0.009 -1. ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	-							-1.551
ENPP3 PM 0.014 -1.139 0.089 0.521 0.003 -1.	MS4A3	PM	0.456					-1.541
		PM			0.089			-1.527
								-1.513
								-1.493

CDA3 mito 0.021 0.427 0.204 0.540 0.007 1.374 MAGEA11 mito 0.201 0.613 0.504 0.849 0.004 1.342 BC3L mito 0.201 0.613 0.502 0.765 0.005 1.327 BPL30 mito 0.005 0.976 0.0481 1.168 0.009 1.214 APR331 nuc 0.067 0.422 0.424 0.635 0.004 1.249 RNF146 cyto 0.013 1.152 0.390 0.181 0.006 1.243 ATGIO tyso/cyto 0.133 0.152 0.001 1.217 NDUFS5 mito 0.002 1.036 0.048 0.458 0.001 1.217 NDUFS5 mito 0.021 -0.702 0.047 0.563 0.022 1.103 NUFUS5 mito 0.025 -1.274 0.456 0.571 0.002 1.157 TRCPRL tyso		Ι.						
ARSA Nov[ER 0.007 1.156 0.197 0.222 0.003 1.464 XIPF11 nuc 0.005 1.100 0.008 0.552 0.001 1.443 XRPS1 RR 0.005 1.139 0.642 0.077 0.001 1.413 AARS2 mito 0.003 1.128 0.376 0.314 0.001 1.413 AARS2 mito 0.001 1.428 0.376 0.540 0.007 1.374 AMSE01 (701 0.021 -0.637 0.002 0.765 0.000 1.342 REX14 R/Rydgl 0.304 -0.613 0.512 0.001 1.327 REX14 0.740 0.325 -0.076 0.431 1.000 1.243 MR1430 mite 0.057 0.000 1.242 0.422 0.422 0.423 1.434 MR1446 vfto 0.131 0.477 0.020 0.635 0.000 1.2429 SULT122								
MRPLIS mito 0.009 1.1000 0.008 0.552 0.001 1.446 TOR3A FR 0.009 1.319 0.642 0.057 0.003 1.413 ANAS2 mito 0.003 1.218 0.376 0.144 0.006 1.413 ANAS2 mito 0.021 0.827 0.204 0.540 0.006 1.408 COA3 mito 0.021 0.551 0.002 0.765 0.006 1.322 EX4 mito 0.035 0.676 0.009 0.512 0.005 1.272 MRP33 mito 0.035 0.676 0.099 0.512 0.006 1.223 MRP33 mito 0.035 0.676 0.002 0.661 1.245 MRP34 mito 0.0467 0.423 0.618 0.066 1.249 MR146 Oyto 0.131 1.152 0.390 0.161 0.066 1.243 MI7130 Nyoto 0.14								
ZNF711 nuc 0.009 1.308 0.494 0.0216 0.008 1.443 AARS2 nito 0.003 1.238 0.376 0.344 0.001 1.403 AARS2 nito 0.022 0.951 0.706 0.501 0.006 1.403 AARS2 nito 0.021 0.827 0.204 0.840 0.000 1.324 BCSL mite 0.005 0.450 0.002 0.765 0.000 1.327 BCAL EK/golgi 0.532 0.001 1.327 0.002 0.651 0.000 1.244 RP130 mito 0.065 0.076 0.021 0.326 0.000 1.243 RV1331 nuc 0.067 0.013 1.185 0.006 1.243 RV140 0.134 0.541 0.039 0.675 0.001 1.214 RV140 0.100 0.477 0.039 0.675 0.001 1.214 RV110 0.118 <t< td=""><td></td><td>· · ·</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		· · ·						
TORBA ER 0.003 1.1319 0.642 0.007 0.003 1.413 ANAS2 mito 0.023 -0.551 0.706 0.501 0.006 1.403 ANAFC mito 0.022 -0.551 0.706 0.501 0.006 1.408 CAR1 myto 0.022 -0.551 0.005 1.600 0.004 -1.327 EX14 EV/kolgi 0.544 -0.557 0.005 -0.601 -1.327 MRP130 muto 0.005 -0.976 0.483 1.185 0.009 -1.247 RNF146 cyto 0.013 -1.152 0.330 0.181 0.006 -1.248 NUDES mito 0.100 0.877 0.009 0.675 0.001 -1.242 SULT3C cyto 0.013 -1.152 0.330 0.375 0.000 -1.243 NUDES mito 0.020 -1.046 0.048 0.468 0.001 -1.243 SULT3C		mito						
AARS2 Into 0.003 1.298 0.376 0.144 0.001 1.400 CDA3 mito 0.022 -0.551 0.206 0.540 0.007 1.374 MAGEA11 mito 0.005 -2.550 0.059 1.000 0.004 1.327 BCS1 mito 0.005 -2.550 0.050 0.512 0.002 1.327 BCS1 mito 0.005 -0.976 0.009 0.512 0.002 1.327 BCS1 modesome 0.255 -0.076 0.483 1.185 0.006 1.249 NRF36 cyto 0.013 -1.52 0.306 0.006 1.249 NRF16 cyto 0.013 -0.877 0.009 0.675 0.001 -1.249 NUTC2 cyto 0.019 -0.840 0.136 0.666 0.001 -1.217 NUTC2 cyto 0.010 -0.871 0.003 -1.212 NUTC2 cyto 0.000			0.009	-1.308	0.949	0.216	0.008	-1.443
ANAPCID bytg/nuc 0.229 -0.551 0.706 0.501 0.006 -1.408 COA3 mito 0.021 -0.627 0.204 0.540 0.007 -1.342 MGEAL11 (yto 0.005 -2.550 0.055 1.000 0.014 -1.342 BCS1L mito 0.021 -0.613 0.039 0.512 0.001 -1.327 BCMP2A endosome 0.255 -0.076 0.483 1.188 0.009 -1.244 APF134D (yto 0.013 -1.152 0.390 0.181 0.066 -1.242 NUFS3 mito 0.020 -0.034 0.048 0.475 0.001 -1.214 NUFS3 mito 0.020 -0.048 0.0475 0.001 -1.214 NUFS5 1.016 0.022 -0.072 0.047 0.563 0.002 -1.721 NUFS5 1.010 0.012 -0.725 0.454 0.577 0.001 -1.127	TOR3A	ER	0.005	-1.319	0.642	0.057	0.003	-1.413
CDA3 mino 0.021 0.2827 0.204 0.540 0.007 1.374 MAGEAII mtho 0.201 0.613 0.056 1.000 0.004 1.342 BC3L mtho 0.201 0.613 0.002 0.765 0.005 1.322 MRP130 mto 0.005 0.976 0.483 1.185 0.000 1.244 RNF144 erdosome 0.255 -0.076 0.483 1.185 0.006 1.244 NRF144 cyto 0.013 -1.522 0.990 0.181 0.006 1.245 NG10 tysol/cyto 0.133 -1.527 0.093 0.675 0.001 1.217 NUESS mito 0.020 -1.036 0.048 0.458 0.001 1.217 NUESS mito 0.021 -0.702 0.047 0.563 0.002 1.101 NUESS mito 0.025 -1.281 0.456 0.571 0.002 1.163 <t< td=""><td>AARS2</td><td>mito</td><td>0.003</td><td>-1.298</td><td>0.376</td><td>0.144</td><td>0.001</td><td>-1.410</td></t<>	AARS2	mito	0.003	-1.298	0.376	0.144	0.001	-1.410
MAGEAL1 tyto 0.005 2.550 0.055 1.000 0.004 1.342 BCS1L mito 0.201 0.613 0.504 0.849 0.005 1.322 B14 EK/golgi 0.504 0.976 0.090 0.512 0.001 1.327 CMMP2A endosome 0.255 0.076 0.483 1.185 0.009 1.242 XNF33 nuc 0.067 0.482 0.0483 0.531 0.066 1.243 NUESS mito 0.100 0.877 0.009 0.675 0.001 1.223 SULTC2 Vto 0.019 -0.844 0.336 0.696 0.001 1.214 NUESS mito 0.020 1.036 0.454 0.537 0.003 1.152 SULTIC2 Vto 0.010 -1.248 0.337 0.001 1.217 NUESS mito 0.022 -0.702 0.444 0.537 0.009 1.163 STMTO	ANAPC10	cyto/nuc	0.229	-0.551	0.706	0.501	0.006	-1.408
BCS1L mino 0.201 0.613 0.504 0.567 0.002 0.765 0.005 1.322 MRP30 mito 0.005 -0.957 0.002 0.765 0.005 1.327 CMMP2A endosome 0.255 -0.076 0.483 1.185 0.009 1.274 RNF14C erdosome 0.255 -0.076 0.483 1.185 0.006 1.224 RNF14C erdo 0.013 -1.512 0.390 0.675 0.006 -1.240 RVG10 vsc/cyto 0.013 -0.237 0.009 0.675 0.001 -1.217 NDUFSS mito 0.020 -1.036 0.048 0.438 0.001 -1.217 NDUFSS mito 0.021 -1.072 0.047 0.558 0.002 -1.218 NUFSS mito 0.022 -1.032 0.454 0.371 0.002 -1.158 MRP141 mito 0.055 -1.241 0.057 -1.161	COA3	mito	0.021	-0.827	0.204	0.540	0.007	-1.374
BCSL mito 0.201 0.613 0.504 0.567 0.002 0.765 0.005 1.327 CHMP2A endsome 0.255 0.0076 0.483 1.185 0.009 1.274 CHMP2A endsome 0.255 0.076 0.483 1.185 0.009 1.274 NRF146 CYC 0.013 1.152 0.390 0.181 0.006 -1.240 NRF146 CYC 0.013 -1.512 0.390 0.181 0.006 -1.240 PGIG2 mito 0.010 -0.377 0.009 0.675 0.001 -1.217 NUTCS mito 0.020 -0.021 0.0247 0.653 0.002 -1.217 NUTCS MM 0.012 -0.702 0.047 0.531 0.002 -1.217 NUTC 0.066 -0.795 0.454 0.371 0.002 -1.163 RPH10 0.065 -0.784 0.272 0.371 0.003 -1.142	MAGEA11	cyto	0.005	-2.550	0.055	1.000	0.004	-1.342
EP24 EF4 (golgi 0.564 0.9576 0.002 0.765 0.005 1.322 MPRJ30 mico 0.005 -0.076 0.089 0.512 0.001 -1.307 CHMP2A endosome 0.255 -0.076 0.482 1.185 0.009 -1.243 NRF146 Cyto 0.013 -1.152 0.390 0.181 0.006 -1.243 ATG10 Vyco/vito 0.134 0.047 0.009 0.675 0.001 -1.214 NUFS5 mito 0.020 -1.036 0.048 0.358 0.001 -1.214 NUFS5 mito 0.021 -0.702 0.047 0.563 0.001 -1.141 KCNR13 PM 0.012 -0.702 0.047 0.563 0.002 -1.163 TRMF146 Intic 0.053 -1.291 0.246 0.337 0.001 -1.175 MRP411 mito 0.053 -1.291 0.246 0.337 0.001 -1.163 </td <td>BCS1L</td> <td></td> <td>0.201</td> <td></td> <td>0.504</td> <td>0.849</td> <td>0.004</td> <td>-1.327</td>	BCS1L		0.201		0.504	0.849	0.004	-1.327
MRP130 mito 0.005 0.076 0.090 0.512 0.001 -1.277 CHMP2A endosome 0.255 -0.076 0.483 1.185 0.009 -1.274 RNF146 Cyto 0.013 -1.152 0.900 0.161 0.006 -1.249 RNF146 Cyto 0.013 -0.127 0.009 0.675 0.001 -1.220 VITC12 Cyto 0.019 0.804 0.028 0.665 0.001 -1.217 NUUTS5 mito 0.020 -1.036 0.048 0.488 0.001 -1.217 NUUTS5 mito 0.020 -1.036 0.047 0.031 -1.217 NUUT12 Cyto 0.060 -0.725 0.0471 0.003 -1.121 NUUT12 Cyto 0.060 -0.795 0.454 0.507 0.009 -1.161 MP41 mito 0.012 -1.038 0.221 0.331 0.001 -1.127 RMF144								
CHMP2A endosome 0.255 0.076 0.483 1.185 0.009 -1.274 RNF146 cyto 0.067 0.822 0.042 0.635 0.006 -1.243 ATG10 lysa/cyto 0.113 -0.152 0.390 0.0161 -1.245 DF062 mito 0.100 0.637 0.009 0.675 0.001 -1.229 SUTTC2 cyto 0.010 -0.304 0.036 0.666 0.001 -1.214 NUFS5 mito 0.020 -1.036 0.048 0.458 0.001 -1.214 KCNH3 PM 0.012 -0.702 0.047 0.563 0.009 -1.163 TRMT10C mito 0.056 -1.244 0.337 0.001 -1.175 TRMT10C 0.030 -0.745 0.221 0.331 0.007 -1.163 GF91 PM 0.032 -1.033 0.523 0.184 0.334 0.000 -1.133 RVF14								
ZNF33 nuc 0.067 -0.222 0.042 0.635 0.006 -1.249 RNF146 (yto 0.013 -1.152 0.390 0.181 0.006 -1.249 POLG2 mito 0.010 -0.877 0.009 0.675 0.001 -1.220 NDUFSS mito 0.020 -1.036 0.048 0.458 0.002 -1.217 NDUFSS mito 0.021 -0.702 0.047 0.563 0.002 -1.210 CHAFIA nuc 0.099 -1.011 0.170 0.731 0.003 -1.175 TRCR1 lyso 0.0660 -0.725 0.454 0.507 0.001 -1.175 TRMT10C mito 0.053 -1.291 0.248 0.337 0.001 -1.175 TRMT10C mito 0.005 -0.745 0.211 0.331 0.002 -1.165 ZNF414 nuc 0.030 -1.424 0.002 -1.165 0.003 -1.132 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
RNF146 cyto 0.013 -1.152 0.390 0.181 0.006 -1.245 ATG10 lyso/cyto 0.143 -0.541 0.023 0.876 0.006 -1.249 ATG10 lyso/cyto 0.119 -0.804 0.136 0.6675 0.001 -1.219 SULTC2 cyto 0.019 -0.304 0.048 0.458 0.001 -1.214 KCNR13 PM 0.012 -0.702 0.047 0.563 0.002 -1.201 CRNF14 nuc 0.059 -1.411 0.003 -1.121 0.003 -1.121 TRMF10C mito 0.053 -1.291 0.248 0.337 0.001 -1.163 TRMF10C mito 0.053 -1.291 0.248 0.337 0.001 -1.163 GPS PM 0.335 -0.388 0.011 1.073 0.002 -1.163 GPSF1 mito 0.012 -1.333 0.798 0.191 0.002 -1.134								
ATG10 yps/(yto 0.143 -0.541 0.023 0.875 0.000 -1.240 POL62 mito 0.100 -0.877 0.009 0.675 0.001 -1.220 NDUFSS mito 0.012 -0.702 0.048 0.488 0.001 -1.211 NDUFSS mito 0.012 -0.702 0.047 0.563 0.002 -1.201 CHAF1A nuc 0.099 -1.011 0.170 0.731 0.003 -1.187 TRMTIOC mito 0.053 -1.291 0.248 0.337 0.001 -1.175 TRMTIOC mito 0.005 -0.784 0.211 0.331 0.002 -1.165 ZNF41 nuc 0.030 -0.745 0.211 0.331 0.003 -1.142 GSF1 mito 0.012 -1.033 0.523 0.184 0.005 -1.143 ALYREF cyto/nuc 0.032 -1.121 0.334 0.000 -1.130								
PD162 mito 0.100 -0.877 0.009 0.675 0.001 -1.229 SULT1C2 cyto 0.019 -0.804 0.136 0.696 0.001 -1.217 NUDFS5 mito 0.012 -0.702 0.047 0.563 0.002 -1.214 KCNR13 PM 0.012 -0.702 0.047 0.563 0.0003 -1.214 KCNR13 PM 0.012 -1.702 0.0447 0.563 0.0009 -1.185 TECPR1 lyso 0.066 -7.795 0.454 0.337 0.001 -1.175 TMT10C mito 0.196 0.640 0.041 0.716 0.002 -1.165 SUF414 nuc 0.033 -1.323 0.001 -1.163 3.0007 -1.163 GXP414 nuc 0.031 -1.333 0.798 0.191 0.003 -1.124 GXP414 nuc 0.021 -0.331 0.331 -1.033 0.002 -1.033 </td <td></td> <td>· ·</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		· ·						
SulTic2 cyto 0.019 -0.804 0.136 0.696 0.001 -1.217 NDUFS5 mito 0.020 -1.036 0.048 0.458 0.001 -1.214 KNN13 PM 0.012 -0.702 0.731 0.003 -1.201 CHAF1A nuc 0.099 -1.101 0.170 0.731 0.0003 -1.137 MRPL41 mito 0.053 -1.291 0.248 0.337 0.001 -1.175 TMTIOC mito 0.053 -0.744 0.272 0.371 0.002 -1.165 ZINF414 nuc 0.030 -0.745 0.211 0.331 0.007 -1.163 GP9 PM 0.835 0.381 0.011 1.073 0.003 -1.184 COA mito 0.012 -1.033 0.523 0.184 0.334 0.006 -1.100 MPL55 mito 0.082 -1.005 0.184 0.334 0.000 -1.012 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>								
NDUFSS mito 0.020 1.036 0.048 0.458 0.001 1-1244 KCNR13 PM 0.012 -0.702 0.047 0.563 0.0002 -1.201 CMAF1A nuc 0.099 -1.101 0.731 0.003 -1.1291 TECPRI Iyso 0.066 -0.795 0.454 0.537 0.009 -1.1375 TRMTIOC mito 0.055 -0.784 0.271 0.331 0.007 -1.165 STR414 nuc 0.033 -0.784 0.271 0.331 0.007 -1.163 GRS1 mito 0.012 -1.033 0.798 0.191 0.003 -1.143 COA4 mito 0.082 -1.005 0.184 0.334 0.006 -1.100 CA4 mito 0.082 -1.030 0.921 0.155 0.002 -0.991 MPL55 mito 0.085 -1.030 0.921 0.155 0.002 -0.991 MRPL1								
KCNL13 PM 0.012 -0.702 0.047 0.563 0.002 -1.201 CHAF1A nuc 0.099 -1.101 0.170 0.731 0.003 -1.195 TECPR1 Iyso 0.066 0.795 0.454 0.337 0.0001 -1.175 MRPL41 mito 0.055 -0.744 0.272 0.371 0.002 -1.165 ZMF414 nuc 0.030 -0.745 0.211 0.331 0.007 -1.163 GP9 PM 0.835 0.738 0.011 1.073 0.003 -1.148 ALYEF cyto/nuc 0.031 -1.353 0.798 0.191 0.003 -1.138 COA4 mito 0.062 -1.005 0.184 0.334 0.006 -1.005 COA4 mito 0.065 -1.030 0.921 0.152 0.002 -1.018 MRPL17 mito 0.065 -1.031 0.042 -0.022 -1.018 MR		- · · · · · · · · · · · · · · · · · · ·						
CHAFLA nuc 0.099 -1.101 0.170 0.731 0.003 -1.195 TECPR1 lyso 0.060 -0.795 0.454 0.507 0.009 -1.187 TRMT10C mito 0.016 -0.640 0.041 0.716 0.009 -1.163 WBSCN16 mito 0.030 -0.745 0.211 0.331 0.007 -1.163 GP9 PM 0.835 -0.388 0.011 1.073 0.003 -1.142 GR\$1 mito 0.012 -1.033 0.523 0.184 0.005 -1.133 ALYREF cyto/ruc 0.031 -1.353 0.798 0.191 0.002 -1.039 CNTF extracell 0.044 -0.881 0.479 0.165 0.003 -1.020 CNTF extracell 0.044 -0.835 0.412 0.184 0.003 -0.991 PTCD1 mito 0.010 -0.835 0.412 0.184 0.003 -0.9919								
TECPRI lyso 0.060 -0.795 0.454 0.507 0.009 -1.187 MRPL41 mito 0.053 -1.291 0.248 0.337 0.001 -1.175 MRPL51 mito 0.005 -0.784 0.272 0.371 0.002 -1.165 SVF414 nuc 0.035 -0.784 0.271 0.311 0.007 -1.163 GRSF1 mito 0.012 -1.033 0.523 0.184 0.003 -1.138 AVREF Cyto/nuc 0.032 -1.133 0.798 0.191 0.003 -1.138 COA4 mito 0.042 -1.005 0.184 0.334 0.006 -1.009 MRPL55 mito 0.088 0.616 0.007 0.571 0.002 -1.039 CNTF extracell 0.040 -0.881 0.479 0.165 0.003 -1.021 MRPL17 mito 0.022 -0.931 0.016 -1.030 -1.021 0.056		PM						
MRPL41 mito 0.033 -1.291 0.248 0.337 0.001 -1.175 TRMT10C mito 0.196 -0.640 0.041 0.716 0.009 -1.165 ZNFA14 nuc 0.030 -0.745 0.211 0.331 0.007 -1.163 GP9 PM 0.835 -0.388 0.011 1.073 0.003 -1.142 GRSF1 mito 0.012 -1.033 0.523 0.184 0.005 -1.138 ALYREF cyto/nuc 0.031 -1.1353 0.798 0.191 0.003 -1.118 COA4 mito 0.088 -0.616 0.007 0.571 0.002 -1.039 CNTF extracell 0.004 -0.881 0.472 0.002 -1.018 MPPL17 mito 0.022 -0.393 0.651 0.242 0.002 -0.991 MPIC11 mito 0.010 -0.835 0.412 0.184 0.002 -0.997		nuc						-1.195
TRMTIOC mito 0.096 -0.640 0.041 0.716 0.009 -1.168 WBSCR16 mito 0.005 -0.784 0.272 0.371 0.002 -1.165 GP9 PM 0.835 -0.388 0.011 1.073 0.003 -1.142 GRSF1 mito 0.012 -1.033 0.774 0.211 0.331 0.003 -1.133 ALYREF cyto/nuc 0.031 -1.353 0.798 0.191 0.003 -1.138 CAM mito 0.082 -1.005 0.184 0.334 0.006 -1.030 MRPL55 mito 0.082 -1.015 0.002 -1.033 RMPL17 mito 0.065 -1.030 0.921 0.155 0.002 -0.991 PTCD1 mito 0.012 -0.993 0.651 0.242 0.002 -0.991 PTCD1 mito 0.012 -0.932 0.079 0.931 0.006 -0.979 P								
WBSCR16 mito 0.005 -0.784 0.272 0.371 0.002 -1.165 ZNF414 nuc 0.030 -0.745 0.211 0.331 0.007 -1.163 GP9 PM 0.335 -0.388 0.011 1.073 0.003 -1.142 GRSF1 mito 0.012 -1.033 0.523 0.184 0.005 -1.138 ALYREF cyto/nuc 0.031 -1.152 0.798 0.191 0.003 -1.118 COA4 mito 0.082 -1.005 0.184 0.334 0.006 -1.100 MRPL17 mito 0.065 -1.030 0.921 0.152 0.002 -0.991 PTCD1 mito 0.010 -0.835 0.412 0.184 0.003 -0.980 C16orf45 nuc 0.017 -0.900 0.611 0.197 0.004 -0.931 MRPL22 mito 0.149 -0.378 0.024 0.641 0.008 -0.994 <td>MRPL41</td> <td>mito</td> <td>0.053</td> <td>-1.291</td> <td>0.248</td> <td>0.337</td> <td>0.001</td> <td>-1.175</td>	MRPL41	mito	0.053	-1.291	0.248	0.337	0.001	-1.175
ZNF414 nuc 0.030 -0.745 0.211 0.331 0.007 -1.163 GP9 PM 0.835 -0.388 0.011 1.073 0.003 -1.142 GRS1 mito 0.003 -1.135 0.798 0.191 0.003 -1.118 COA4 mito 0.082 -1.005 0.184 0.334 0.002 -1.019 CNTF extracell 0.004 -0.881 0.479 0.165 0.003 -1.012 RPU1 mito 0.002 -1.013 0.921 0.152 0.008 -0.991 RPU1 mito 0.010 -0.835 0.412 0.184 0.002 -0.991 VIPI1 endosome 0.012 -0.993 0.651 0.242 0.002 -0.991 C1Cort45 nuc 0.017 -0.900 0.611 0.197 0.004 -0.979 RNL22 mito 0.028 -0.771 0.276 0.184 0.007 -9.949	TRMT10C	mito	0.196	-0.640	0.041	0.716	0.009	-1.168
GP9 PM 0.835 -0.388 0.011 1.073 0.003 -1.142 GRSF1 mito 0.012 -1.033 0.523 0.184 0.005 -1.138 CAA mito 0.082 -1.005 0.184 0.334 0.006 -1.100 MRPL55 mito 0.088 -0.616 0.007 0.571 0.002 -1.030 CNTF extracell 0.004 -0.881 0.479 0.165 0.003 -1.030 RPL17 mito 0.005 -1.030 0.921 0.152 0.002 -0.991 MRPL17 mito 0.005 -1.030 0.921 0.152 0.008 -0.991 Clfor/45 nuc 0.017 -0.900 0.651 0.242 0.002 -0.917 PRUNE2 cyto 0.404 -0.322 0.079 0.931 0.009 -0.929 PRUNE2 cyto 0.404 -0.323 0.881 0.009 -0.929 SL	WBSCR16	mito	0.005	-0.784	0.272	0.371	0.002	-1.165
GRSF1 mito 0.012 -1.033 0.523 0.184 0.005 -1.138 ALYREF cyto/nuc 0.031 -1.353 0.798 0.191 0.003 -1.118 ALYREF cyto/nuc 0.032 -1.005 0.184 0.0334 0.006 -1.009 MRPL55 mito 0.088 -0.616 0.007 0.571 0.002 -1.039 CNTF extracell 0.004 -0.881 0.479 0.165 0.002 -1.018 MRPL17 mito 0.065 -1.030 0.921 0.152 0.008 -0.991 WIP11 endosome 0.012 -0.933 0.651 0.242 0.002 -0.991 WIP12 mito 0.010 0.835 0.412 0.024 -0.004 -0.979 PRUNE2 cyto 0.404 -0.392 0.079 0.931 0.008 -0.949 SL26AA PM 0.042 -0.771 0.276 0.184 0.007 -9.94	ZNF414	nuc	0.030	-0.745	0.211	0.331	0.007	-1.163
GRSF1 mito 0.012 -1.033 0.523 0.184 0.005 -1.138 ALYREF cyto/nuc 0.031 -1.333 0.798 0.191 0.003 -1.118 ALYREF cyto/nuc 0.031 -1.333 0.798 0.191 0.003 -1.118 ALYREF cyto/nuc 0.032 -1.030 0.334 0.0002 -1.039 CNTF extracell 0.004 -0.881 0.479 0.165 0.002 -1.039 MRPL17 mito 0.065 -1.030 0.921 0.152 0.008 -0.991 WIP11 endosome 0.012 -0.933 0.651 0.242 0.002 -0.991 WIP12 mito 0.010 0.835 0.412 0.018 -0.939 0.651 0.242 0.002 -0.991 PRUNE2 cyto 0.404 -0.392 0.079 0.931 0.008 -0.992 PRUNE2 cyto 0.404 -0.794 0.578 <td< td=""><td>GP9</td><td>PM</td><td>0.835</td><td>-0.388</td><td>0.011</td><td>1.073</td><td>0.003</td><td>-1.142</td></td<>	GP9	PM	0.835	-0.388	0.011	1.073	0.003	-1.142
ALYREF cyto/nuc 0.031 -1.353 0.798 0.191 0.003 -1.118 COA4 mito 0.082 -1.005 0.184 0.334 0.006 -1.100 MRPLS5 mito 0.088 -0.616 0.007 0.571 0.002 1.039 CNTF extracell 0.004 -0.881 0.479 0.165 0.003 -1.023 ETV1 nuc 0.007 -1.217 0.784 0.210 0.002 -1.018 MRPL17 mito 0.010 -0.835 0.412 0.148 0.003 -0.991 VIP11 endosome 0.017 -0.900 0.611 0.197 0.004 -0.892 Clfort45 nuc 0.017 -0.900 0.611 0.197 0.004 -0.937 RNPL22 mito 0.028 -0.771 0.276 0.184 0.007 -9.949 SL26A4 PM 0.004 -0.823 0.881 0.009 -0.924	GRSF1	mito	0.012		0.523	0.184	0.005	-1.138
COA4 mito 0.082 -1.005 0.184 0.334 0.006 -1.100 MRPLS5 mito 0.088 -0.616 0.007 0.571 0.002 -1.039 ETV1 nuc 0.027 -1.217 0.784 0.210 0.002 -1.018 MRPL17 mito 0.065 -1.030 0.921 0.152 0.008 -0.991 PTCD1 mito 0.010 -0.835 0.412 0.184 0.003 -0.980 C16orf45 nuc 0.017 -0.900 0.611 0.197 0.004 -0.979 MRPL22 mito 0.149 -0.378 0.024 0.641 0.008 -0.950 MRPL22 mito 0.149 -0.378 0.024 0.641 0.008 -0.949 DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.949 DDRGK1 ER 0.013 -0.715 0.117 0.388 0.009 -0.924	ALYREF	cvto/nuc	0.031		0.798		0.003	
MRPL55 mito 0.088 -0.616 0.007 0.571 0.002 -1.039 CNTF extracell 0.004 -0.881 0.479 0.165 0.003 -1.033 MRPL17 mito 0.065 -1.030 0.921 0.152 0.002 -0.991 MTPL1 endosome 0.012 -0.993 0.651 0.242 0.002 -0.991 PTCD1 mito 0.010 -0.835 0.412 0.148 0.003 -0.980 Cl6or45 nuc 0.017 -0.900 0.611 0.197 0.004 -0.979 PRUNE2 cyto 0.404 -0.392 0.079 0.931 0.008 -0.949 SL26A4 PM 0.004 -0.823 0.881 0.009 0.008 -0.949 DLF2 nuc 0.136 -0.715 0.117 0.388 0.006 -0.944 POL52 nuc 0.188 -0.686 0.708 0.055 -0.924 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>								
CNTF extracell 0.004 -0.881 0.479 0.165 0.003 -1.023 ETV1 nuc 0.027 -1.217 0.784 0.210 0.002 -1.018 MRPL17 mito 0.065 -1.030 0.921 0.152 0.008 -0.991 MIP1 endosome 0.012 -0.993 0.651 0.242 0.003 -0.991 PTCD1 mito 0.010 -0.835 0.412 0.184 0.003 -0.9979 PRUNE2 cyto 0.404 -0.322 0.079 0.931 0.009 -0.975 MRPL22 mito 0.028 -0.771 0.276 0.184 0.007 -0.949 SLC26A4 PM 0.004 -0.732 0.881 0.009 0.008 -0.949 DDRGK1 ER 0.014 -0.745 0.117 0.388 0.009 -0.922 ZDHC2 ER/golgi 0.716 -0.239 0.003 0.777 0.005 -0.914								
ETV1 nuc 0.027 -1.217 0.784 0.210 0.002 -1.018 MRPL17 mito 0.065 -1.030 0.921 0.152 0.008 -0.991 PTCD1 mito 0.010 -0.835 0.412 0.184 0.003 -0.991 PTCD1 mito 0.010 -0.835 0.412 0.184 0.004 -0.979 PRUNE2 cyto 0.404 -0.392 0.079 0.931 0.009 -0.957 MRPL22 mito 0.128 -0.771 0.276 0.184 0.007 -0.949 SL26A4 PM 0.004 -0.823 0.881 0.009 -0.088 -0.944 PDE2 nuc 0.136 -0.715 0.117 0.388 0.009 -0.949 DDR6X1 ER 0.014 -0.794 0.578 0.166 0.005 -0.912 DDR6X1 ER 0.018 -0.566 0.535 0.122 0.038 0.006 -0.992								
MRPL17 mito 0.065 -1.030 0.921 0.152 0.008 -0.991 WIP11 endosome 0.012 -0.993 0.6511 0.242 0.002 -0.991 PTCD1 mito 0.010 -0.835 0.412 0.184 0.003 -0.980 Caforf45 nuc 0.017 -0.900 0.611 0.197 0.004 -0.979 PRUNE2 cyto 0.404 -0.392 0.079 0.931 0.009 -0.957 MRPL22 mito 0.149 -0.378 0.024 -0.641 0.008 -0.939 SLC26A4 PM 0.004 -0.823 0.881 0.009 0.008 -0.949 DLG2 nuc 0.136 -0.715 0.117 0.388 0.009 -0.929 DHC2 ER/goigi 0.716 -0.239 0.003 0.777 0.005 -0.924 DHC4 Iyso 0.025 -0.566 0.535 0.182 0.006 -0.868								
WIP11 endosome 0.012 -0.993 0.651 0.242 0.002 -0.991 PTCD1 mito 0.010 -0.835 0.412 0.184 0.003 -0.980 C16orf45 nuc 0.017 -0.900 0.611 0.197 0.004 -0.979 PRUNE2 cyto 0.0404 -0.392 0.079 0.931 0.009 -0.957 MRPL22 mito 0.028 -0.771 0.276 0.184 0.007 -0.949 SL266A4 PM 0.004 -0.823 0.881 0.009 0.008 -0.949 DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.944 POLE2 nuc 0.136 -0.715 0.117 0.388 0.005 -0.914 POLE2 nuc 0.136 -0.750 0.117 0.388 0.005 -0.914 PMEM2 Sologiti 0.716 -0.530 0.122 0.318 0.005 -0.912								
PTCD1 mito 0.010 -0.835 0.412 0.184 0.003 -0.980 C16orf45 nuc 0.017 -0.900 0.611 0.197 0.004 -0.979 PRUNE2 cyto 0.404 -0.392 0.079 0.931 0.009 -0.957 MRPL22 mito 0.028 -0.771 0.276 0.184 0.007 -0.949 SLC26A4 PM 0.004 -0.823 0.881 0.009 -0.08 -0.949 DRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.949 DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.944 POL2 nuc 0.138 -0.368 0.066 0.708 0.005 -0.929 ZDHHC2 ER/golgi 0.716 -0.329 0.003 0.777 0.005 -0.905 WDFY3 cyto/nuc 0.118 -0.650 0.430 0.456 0.008 -0.929 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
C16orf45 nuc 0.017 -0.900 0.611 0.197 0.004 -0.979 PRUNE2 cyto 0.404 -0.332 0.079 0.931 0.009 -0.957 MRPL22 mito 0.149 -0.378 0.024 0.641 0.008 -0.950 MRPL2 mito 0.028 -0.771 0.276 0.184 0.007 -0.949 SLC26A4 PM 0.004 -0.823 0.881 0.009 0.008 -0.949 DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.944 POLE2 nuc 0.136 -0.715 0.117 0.388 0.009 -0.929 DDHC2 ER/golgi 0.716 -0.239 0.003 0.777 0.005 -0.924 EPG5 nuc 0.188 -0.368 0.066 0.708 0.005 -0.914 TMEM74 lyso 0.025 -0.566 0.535 0.182 0.006 -0.868								
PRUNE2 cyto 0.404 -0.392 0.079 0.931 0.009 -0.957 MRPL22 mito 0.149 -0.378 0.024 0.641 0.008 -0.950 ATP512 mito 0.028 -0.771 0.276 0.184 0.007 -0.949 SLC26A4 PM 0.004 -0.823 0.881 0.009 0.008 -0.949 DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.944 POLE2 nuc 0.136 -0.715 0.117 0.388 0.009 -0.929 ZDHHC2 ER/golgi 0.716 -0.239 0.003 0.777 0.005 -0.924 EPG5 nuc 0.188 -0.666 0.535 0.182 0.005 -0.905 WDFY3 cyto/nuc 0.118 -0.650 0.430 0.456 0.008 -0.838 INF2 mito 0.052 -0.848 0.473 0.106 0.007 -0.828 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
MRPL22 mito 0.149 -0.378 0.024 0.641 0.008 -0.950 ATP512 mito 0.028 -0.771 0.276 0.184 0.007 -0.949 SLC26A4 PM 0.004 -0.823 0.881 0.009 0.008 -0.949 DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.949 DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.949 DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.944 POL2 nuc 0.136 -0.715 0.117 0.388 0.005 -0.924 EPG5 nuc 0.188 -0.368 0.066 0.708 0.005 -0.914 TMEM74 lyso 0.025 -0.566 0.535 0.182 0.006 -0.868 RNF183 ER 0.031 -0.635 0.129 0.445 0.004 -0.829								
ATP5J2 mito 0.028 -0.771 0.276 0.184 0.007 -0.949 SLC26A4 PM 0.004 -0.823 0.881 0.009 0.008 -0.949 DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.944 POLE2 nuc 0.136 -0.715 0.117 0.388 0.009 -0.929 ZDHC2 ER/golgi 0.716 -0.239 0.003 0.777 0.005 -0.924 EPG5 nuc 0.188 -0.368 0.066 0.708 0.005 -0.914 TMEM74 lyso 0.025 -0.566 0.535 0.182 0.006 -0.905 WDFY3 cyto/nuc 0.118 -0.650 0.430 0.445 0.006 -0.868 RNF183 ER 0.031 -0.635 0.129 0.445 0.006 -0.868 TRAPC12 cyto/nuc 0.116 -0.533 0.044 0.449 0.008 -0.829		- · · · · · · · · · · · · · · · · · · ·						
SLC26A4 PM 0.004 -0.823 0.881 0.009 0.008 -0.949 DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.944 POLE2 nuc 0.136 -0.715 0.117 0.388 0.009 -0.929 ZDHHC2 ER/golgi 0.716 -0.239 0.003 0.777 0.005 -0.924 EPG5 nuc 0.188 -0.368 0.066 0.708 0.005 -0.914 TMEM74 lyso 0.025 -0.566 0.535 0.182 0.005 -0.905 WDFY3 cyto/nuc 0.118 -0.650 0.430 0.456 0.008 -0.868 RNF183 ER 0.031 -0.635 0.129 0.445 0.004 -0.868 RNF183 ER 0.031 -0.633 0.044 0.449 0.008 -0.838 LIPT2 mito 0.052 -0.848 0.473 0.106 0.007 -0.829								
DDRGK1 ER 0.014 -0.794 0.578 0.166 0.006 -0.944 POLE2 nuc 0.136 -0.715 0.117 0.388 0.009 -0.929 ZDHHC2 ER/golgi 0.716 -0.239 0.003 0.777 0.005 -0.924 EPG5 nuc 0.188 -0.368 0.066 0.708 0.005 -0.914 TMEM74 lyso 0.025 -0.566 0.535 0.182 0.005 -0.905 WDFY3 cyto/nuc 0.118 -0.650 0.430 0.456 0.008 -0.902 KLK6 mito/nuc 0.119 -1.015 0.922 0.318 0.006 -0.868 RNF183 ER 0.031 -0.635 0.129 0.445 0.004 -0.866 TRAPPC12 cyto/nuc 0.116 -0.533 0.044 0.449 0.008 -0.838 LIPT2 mito 0.052 -0.848 0.473 0.106 0.007 -0.829								
POLE2 nuc 0.136 -0.715 0.117 0.388 0.009 -0.929 ZDHHC2 ER/golgi 0.716 -0.239 0.003 0.777 0.005 -0.924 EPG5 nuc 0.188 -0.368 0.066 0.708 0.005 -0.914 TMEM74 lyso 0.025 -0.566 0.535 0.182 0.005 -0.905 WDFY3 cyto/nuc 0.118 -0.650 0.430 0.456 0.008 -0.902 KLK6 mito/nuc 0.119 -1.015 0.922 0.318 0.006 -0.868 RNF183 ER 0.031 -0.635 0.129 0.445 0.004 -0.866 TRAPPC12 cyto/nuc 0.116 -0.533 0.044 0.449 0.008 -0.829 ASB16 cyto 0.320 -0.103 0.103 0.739 0.009 -0.821 FZD6 PM 0.196 -0.579 0.202 0.469 0.006 -0.808	SLC26A4	PM						
ZDHHC2 ER/golgi 0.716 -0.239 0.003 0.777 0.005 -0.924 EPG5 nuc 0.188 -0.368 0.066 0.708 0.005 -0.914 TMEM74 lyso 0.025 -0.566 0.535 0.182 0.005 -0.905 WDFY3 cyto/nuc 0.118 -0.650 0.430 0.456 0.008 -0.902 KLK6 mito/nuc 0.119 -1.015 0.922 0.318 0.006 -0.868 RNF183 ER 0.031 -0.635 0.129 0.445 0.004 -0.866 TRAPPC12 cyto/nuc 0.116 -0.533 0.044 0.449 0.008 -0.829 ASB16 cyto 0.052 -0.848 0.473 0.106 0.007 -0.829 ASB16 cyto 0.320 -0.103 0.103 0.739 0.009 -0.786 CDK5RAP3 cyto 0.043 -0.764 0.308 0.208 0.004 -0.782	DDRGK1	ER	0.014	-0.794	0.578	0.166	0.006	-0.944
EPGS nuc 0.188 -0.368 0.066 0.708 0.005 -0.914 TMEM74 lyso 0.025 -0.566 0.535 0.182 0.005 -0.905 WDFY3 cyto/nuc 0.118 -0.650 0.430 0.456 0.008 -0.902 KLK6 mito/nuc 0.119 -1.015 0.922 0.318 0.006 -0.868 RNF183 ER 0.031 -0.635 0.129 0.445 0.004 -0.866 TRAPPC12 cyto/nuc 0.116 -0.533 0.044 0.449 0.008 -0.838 LIPT2 mito 0.052 -0.848 0.473 0.106 0.007 -0.829 ASB16 cyto 0.320 -0.103 0.103 0.739 0.009 -0.821 RABSC lyso 0.073 -0.573 0.100 0.263 0.009 -0.766 DCLK2 cyto 0.361 -0.278 0.175 0.580 0.010 -0.782	POLE2	nuc	0.136	-0.715		0.388	0.009	-0.929
TMEM74lyso0.025-0.5660.5350.1820.005-0.905WDFY3cyto/nuc0.118-0.6500.4300.4560.008-0.902KLK6mito/nuc0.119-1.0150.9220.3180.006-0.868RNF183ER0.031-0.6350.1290.4450.004-0.866TRAPPC12cyto/nuc0.116-0.5330.0440.4490.008-0.838LIPT2mito0.052-0.8480.4730.1060.007-0.829ASB16cyto0.320-0.1030.1030.7390.009-0.821RAD5CIyso0.073-0.5730.1000.2630.009-0.796CDKSRAP3cyto0.043-0.7640.3080.2080.004-0.785DCLK2cyto0.361-0.2780.1750.5800.010-0.792PIGFER0.181-0.2540.1330.4610.008-0.798KIAA0391mito0.030-0.6090.3620.2100.009-0.700CEACAM5PM0.084-0.8270.3580.0150.007-0.679LIR1nuc0.282-0.1990.1290.5230.009-0.594LIRB4PM0.0600.8100.140-0.3580.0100.616SCUBE1PM0.0390.6370.693-0.1120.0100.620TMC4PM0.0680.536-0.2550	ZDHHC2	ER/golgi	0.716	-0.239	0.003	0.777	0.005	-0.924
WDFY3 cyto/nuc 0.118 -0.650 0.430 0.456 0.008 -0.902 KLK6 mito/nuc 0.119 -1.015 0.922 0.318 0.006 -0.868 RNF183 ER 0.031 -0.635 0.129 0.445 0.004 -0.868 TRAPPC12 cyto/nuc 0.116 -0.533 0.044 0.449 0.008 -0.838 LIPT2 mito 0.052 -0.848 0.473 0.106 0.007 -0.829 ASB16 cyto 0.320 -0.103 0.103 0.739 0.009 -0.821 FZD6 PM 0.196 -0.559 0.202 0.469 0.006 -0.808 RAB5C lyso 0.073 -0.573 0.100 0.263 0.009 -0.796 DCLK2 cyto 0.361 -0.278 0.175 0.580 0.010 -0.782 PIGF ER 0.181 -0.254 0.133 0.461 0.008 -0.758 <td>EPG5</td> <td>nuc</td> <td>0.188</td> <td>-0.368</td> <td>0.066</td> <td>0.708</td> <td>0.005</td> <td>-0.914</td>	EPG5	nuc	0.188	-0.368	0.066	0.708	0.005	-0.914
KLK6 mito/nuc 0.119 -1.015 0.922 0.318 0.006 -0.868 RNF183 ER 0.031 -0.635 0.129 0.445 0.004 -0.866 TRAPPC12 cyto/nuc 0.116 -0.533 0.044 0.449 0.008 -0.838 LIPT2 mito 0.052 -0.848 0.473 0.106 0.007 -0.829 ASB16 cyto 0.320 -0.103 0.103 0.739 0.009 -0.821 FZD6 PM 0.196 -0.559 0.202 0.469 0.006 -0.808 RAB5C lyso 0.073 -0.573 0.100 0.263 0.009 -0.796 CDKSRAP3 cyto 0.043 -0.764 0.308 0.208 0.004 -0.782 DCLK2 cyto 0.361 -0.278 0.175 0.580 0.010 -0.782 PIGF ER 0.181 -0.254 0.133 0.461 0.008 -0.758 <td>TMEM74</td> <td>lyso</td> <td>0.025</td> <td>-0.566</td> <td>0.535</td> <td>0.182</td> <td>0.005</td> <td>-0.905</td>	TMEM74	lyso	0.025	-0.566	0.535	0.182	0.005	-0.905
KLK6 mito/nuc 0.119 -1.015 0.922 0.318 0.006 -0.868 RNF183 ER 0.031 -0.635 0.129 0.445 0.004 -0.866 TRAPPC12 cyto/nuc 0.116 -0.533 0.044 0.449 0.008 -0.838 LIPT2 mito 0.052 -0.848 0.473 0.106 0.007 -0.829 ASB16 cyto 0.320 -0.103 0.103 0.739 0.009 -0.821 FZD6 PM 0.196 -0.559 0.202 0.469 0.006 -0.808 RAB5C lyso 0.073 -0.573 0.100 0.263 0.009 -0.796 CDK5RAP3 cyto 0.043 -0.764 0.308 0.208 0.004 -0.782 DCLK2 cyto 0.361 -0.278 0.175 0.580 0.010 -0.782 PIGF ER 0.181 -0.254 0.133 0.461 0.008 -0.758 <td>WDFY3</td> <td>cyto/nuc</td> <td>0.118</td> <td>-0.650</td> <td>0.430</td> <td>0.456</td> <td>0.008</td> <td>-0.902</td>	WDFY3	cyto/nuc	0.118	-0.650	0.430	0.456	0.008	-0.902
RNF183 ER 0.031 -0.635 0.129 0.445 0.004 -0.866 TRAPPC12 cyto/nuc 0.116 -0.533 0.044 0.449 0.008 -0.838 LIPT2 mito 0.052 -0.848 0.473 0.106 0.007 -0.829 ASB16 cyto 0.320 -0.103 0.103 0.739 0.009 -0.821 FZD6 PM 0.196 -0.559 0.202 0.469 0.006 -0.808 RAB5C lyso 0.073 -0.573 0.100 0.263 0.009 -0.796 CDK5RAP3 cyto 0.043 -0.764 0.308 0.208 0.004 -0.785 DCLK2 cyto 0.361 -0.278 0.175 0.580 0.010 -0.782 PIGF ER 0.181 -0.254 0.133 0.461 0.008 -0.758 KIAA0391 mito 0.030 -0.609 0.362 0.210 0.007 -0.679 <td>KLK6</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.006</td> <td>-0.868</td>	KLK6						0.006	-0.868
TRAPPC12 cyto/nuc 0.116 -0.533 0.044 0.449 0.008 -0.838 LIPT2 mito 0.052 -0.848 0.473 0.106 0.007 -0.829 ASB16 cyto 0.320 -0.103 0.103 0.739 0.009 -0.821 FZD6 PM 0.196 -0.559 0.202 0.469 0.006 -0.808 RAB5C lyso 0.073 -0.573 0.100 0.263 0.009 -0.796 CDK5RAP3 cyto 0.043 -0.764 0.308 0.208 0.004 -0.785 DCLK2 cyto 0.361 -0.278 0.175 0.580 0.010 -0.782 PIGF ER 0.181 -0.254 0.133 0.461 0.008 -0.782 KIAA0391 mito 0.030 -0.609 0.362 0.210 0.009 -0.700 CEACAM5 PM 0.084 -0.827 0.358 0.015 0.007 -0.679 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.004</td> <td></td>							0.004	
LIPT2mito0.052-0.8480.4730.1060.007-0.829ASB16cyto0.320-0.1030.1030.7390.009-0.821FZD6PM0.196-0.5590.2020.4690.006-0.808RAB5Clyso0.073-0.5730.1000.2630.009-0.796CDKSRAP3cyto0.043-0.7640.3080.2080.004-0.785DCLK2cyto0.361-0.2780.1750.5800.010-0.782PIGFER0.181-0.2540.1330.4610.008-0.700CEACAM5PM0.084-0.8270.3580.0150.007-0.679LR1nuc0.282-0.1990.1290.5230.009-0.594LILR84PM0.0600.8100.140-0.3580.0100.616SCUBE1PM0.1680.5060.184-0.4850.0100.620TMC4PM0.1680.5060.184-0.4850.0100.649LOH12CR1lyso0.0140.8130.893-0.0140.0090.726PNISRcyto/nuc0.0070.6450.536-0.2550.0020.748C1orf194nuc0.0240.8840.846-0.1700.0090.751								
ASB16cyto0.320-0.1030.1030.7390.009-0.821FZD6PM0.196-0.5590.2020.4690.006-0.808RAB5CIyso0.073-0.5730.1000.2630.009-0.796CDK5RAP3cyto0.043-0.7640.3080.2080.004-0.785DCLK2cyto0.361-0.2780.1750.5800.010-0.782PIGFER0.181-0.2540.1330.4610.008-0.700CEACAM5PM0.084-0.8270.3580.0150.007-0.679LRR1nuc0.282-0.1990.1290.5230.009-0.594LILR84PM0.0600.8100.140-0.3580.0100.616SCUBE1PM0.1680.5060.184-0.4850.0100.620TMC4PM0.1680.5060.184-0.4850.0100.649LOH12CR1Iyso0.0140.8130.893-0.0140.0090.726PNISRcyto/nuc0.0070.6450.536-0.2550.0020.748C1orf194nuc0.0240.8840.846-0.1700.0090.751								
FZD6PM0.196-0.5590.2020.4690.006-0.808RAB5Clyso0.073-0.5730.1000.2630.009-0.796CDK5RAP3cyto0.043-0.7640.3080.2080.004-0.785DCLK2cyto0.361-0.2780.1750.5800.010-0.782PIGFER0.181-0.2540.1330.4610.008-0.758KIAA0391mito0.030-0.6090.3620.2100.009-0.700CEACAM5PM0.084-0.8270.3580.0150.007-0.679LRR1nuc0.282-0.1990.1290.5230.009-0.594LILRB4PM0.0600.8100.140-0.3580.0100.616SCUBE1PM0.1680.5060.184-0.4850.0100.620TMC4PM0.1680.5060.184-0.4850.0100.649LOH12CR1lyso0.0140.8130.893-0.0140.0090.726PNISRcyto/nuc0.0070.6450.536-0.2550.0020.748C1orf194nuc0.0240.8840.846-0.1700.0090.751								
RAB5C lyso 0.073 -0.573 0.100 0.263 0.009 -0.796 CDK5RAP3 cyto 0.043 -0.764 0.308 0.208 0.004 -0.785 DCLK2 cyto 0.361 -0.278 0.175 0.580 0.010 -0.782 PIGF ER 0.181 -0.254 0.133 0.461 0.008 -0.782 KIAA0391 mito 0.030 -0.609 0.362 0.210 0.009 -0.700 CEACAM5 PM 0.084 -0.827 0.358 0.015 0.007 -0.679 LRR1 nuc 0.282 -0.199 0.129 0.523 0.009 -0.594 LILRB4 PM 0.060 0.810 0.140 -0.358 0.010 0.616 SCUBE1 PM 0.039 0.637 0.693 -0.112 0.010 0.620 TMC4 PM 0.168 0.506 0.184 -0.485 0.010 0.649								
CDK5RAP3 cyto 0.043 -0.764 0.308 0.208 0.004 -0.785 DCLK2 cyto 0.361 -0.278 0.175 0.580 0.010 -0.782 PIGF ER 0.181 -0.254 0.133 0.461 0.008 -0.758 KIAA0391 mito 0.030 -0.609 0.362 0.210 0.009 -0.700 CEACAM5 PM 0.084 -0.827 0.358 0.015 0.007 -0.679 LRR1 nuc 0.282 -0.199 0.129 0.523 0.009 -0.594 LILRB4 PM 0.060 0.810 0.140 -0.358 0.010 0.616 SCUBE1 PM 0.039 0.637 0.693 -0.112 0.010 0.620 TMC4 PM 0.168 0.506 0.184 -0.485 0.010 0.649 LOH12CR1 Iyso 0.014 0.813 0.893 -0.014 0.009 0.726	-							
DCLK2 cyto 0.361 -0.278 0.175 0.580 0.010 -0.782 PIGF ER 0.181 -0.254 0.133 0.461 0.008 -0.782 KIAA0391 mito 0.030 -0.609 0.362 0.210 0.009 -0.700 CEACAM5 PM 0.084 -0.827 0.358 0.015 0.007 -0.679 LR1 nuc 0.282 -0.199 0.129 0.523 0.009 -0.594 LILRB4 PM 0.060 0.810 0.140 -0.358 0.010 0.616 SCUBE1 PM 0.039 0.637 0.693 -0.112 0.010 0.620 TMC4 PM 0.168 0.506 0.184 -0.485 0.010 0.649 LOH12CR1 Iyso 0.014 0.813 0.893 -0.014 0.009 0.726 PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748		1						
PIGF ER 0.181 -0.254 0.133 0.461 0.008 -0.758 KIAA0391 mito 0.030 -0.609 0.362 0.210 0.009 -0.700 CEACAM5 PM 0.084 -0.827 0.358 0.015 0.007 -0.679 LR1 nuc 0.282 -0.199 0.129 0.523 0.009 -0.594 LILR84 PM 0.060 0.810 0.140 -0.358 0.010 0.616 SCUBE1 PM 0.039 0.637 0.693 -0.112 0.010 0.620 TMC4 PM 0.168 0.506 0.184 -0.485 0.010 0.649 LOH12CR1 Iyso 0.014 0.813 0.893 -0.014 0.009 0.726 PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748 C1orf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751		· ·						
KIAA0391 mito 0.030 -0.609 0.362 0.210 0.009 -0.700 CEACAM5 PM 0.084 -0.827 0.358 0.015 0.007 -0.679 LRR1 nuc 0.282 -0.199 0.129 0.523 0.009 -0.594 LILRB4 PM 0.060 0.810 0.140 -0.358 0.010 0.616 SCUBE1 PM 0.039 0.637 0.693 -0.112 0.010 0.620 TMC4 PM 0.168 0.506 0.184 -0.485 0.010 0.649 LOH12CR1 Iyso 0.014 0.813 0.893 -0.014 0.009 0.726 PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748 C1orf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751								
CEACAM5 PM 0.084 -0.827 0.358 0.015 0.007 -0.679 LRR1 nuc 0.282 -0.199 0.129 0.523 0.009 -0.594 LILRB4 PM 0.060 0.810 0.140 -0.358 0.010 0.616 SCUBE1 PM 0.039 0.637 0.693 -0.112 0.010 0.620 TMC4 PM 0.168 0.506 0.184 -0.485 0.010 0.649 LOH12CR1 Iyso 0.014 0.813 0.893 -0.014 0.009 0.726 PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748 C1orf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751								
LRR1 nuc 0.282 -0.199 0.129 0.523 0.009 -0.594 LILRB4 PM 0.060 0.810 0.140 -0.358 0.010 0.616 SCUBE1 PM 0.039 0.637 0.693 -0.112 0.010 0.620 TMC4 PM 0.168 0.506 0.184 -0.485 0.010 0.649 LOH12CR1 lyso 0.014 0.813 0.893 -0.014 0.009 0.726 PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748 Clorf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751								
LILRB4 PM 0.060 0.810 0.140 -0.358 0.010 0.616 SCUBE1 PM 0.039 0.637 0.693 -0.112 0.010 0.620 TMC4 PM 0.168 0.506 0.184 -0.485 0.010 0.649 LOH12CR1 lyso 0.014 0.813 0.893 -0.014 0.009 0.726 PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748 Clorf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751		PM						
SCUBE1 PM 0.039 0.637 0.693 -0.112 0.010 0.620 TMC4 PM 0.168 0.506 0.184 -0.485 0.010 0.649 LOH12CR1 lyso 0.014 0.813 0.893 -0.014 0.009 0.726 PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748 Clorf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751								-0.594
TMC4 PM 0.168 0.506 0.184 -0.485 0.010 0.649 LOH12CR1 lyso 0.014 0.813 0.893 -0.014 0.009 0.726 PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748 C1orf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751	LILRB4	PM	0.060	0.810	0.140	-0.358	0.010	0.616
LOH12CR1 lyso 0.014 0.813 0.893 -0.014 0.009 0.726 PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748 Clorf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751	SCUBE1	PM	0.039	0.637	0.693	-0.112	0.010	0.620
LOH12CR1 lyso 0.014 0.813 0.893 -0.014 0.009 0.726 PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748 Clorf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751	TMC4	PM	0.168	0.506	0.184	-0.485	0.010	0.649
PNISR cyto/nuc 0.007 0.645 0.536 -0.255 0.002 0.748 C1orf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751		lyso		0.813	0.893	-0.014	0.009	0.726
C1orf194 nuc 0.024 0.884 0.846 -0.170 0.009 0.751		,						
								0.751
		ER/lyso	0.100	0.485	0.064	-0.425	0.005	0.754

WDR64	cyto	0.030	0.822	0.812	-0.119	0.009	0.767
UQCRC2	mito	0.030	0.822	0.812	-0.008	0.009	0.707
DOCK2	cyto	0.552	0.176	0.029	-0.787	0.005	0.770
CSTB	cyto	0.420	0.265	0.023	-0.776	0.008	0.795
C10orf32	lyso	0.462	0.377	0.045	-0.705	0.007	0.818
ITIH3	extracell	0.146	0.619	0.056	-0.599	0.003	0.824
FOXK2	nuc	0.008	0.658	0.710	-0.180	0.007	0.832
OR5A2	PM	0.025	0.470	0.047	-0.372	0.002	0.835
LYVE1	extracell	0.226	0.399	0.008	-0.520	0.005	0.841
ZPBP2	nuc	0.320	0.092	0.010	-0.669	0.006	0.842
DMXL2	extracell	0.794	0.028	0.010	-0.904	0.008	0.848
SHOC2	cyto/nuc	0.141	0.498	0.037	-0.687	0.001	0.856
COG7	golgi/nuc	0.699	0.046	0.056	-1.041	0.006	0.858
тнос6	nuc	0.974	0.188	0.012	-0.898	0.009	0.867
CRYGS	cyto/nuc	0.054	0.444	0.158	-0.646	0.004	0.871
TMTC4	PM	0.015	0.625	0.335	-0.477	0.003	0.871
TRABD2B	extracell	0.051	0.797	0.864	-0.449	0.006	0.873
PRSS33	extracell	0.015	0.780	0.714	-0.124	0.010	0.876
TC2N	nuc	0.074	0.491	0.128	-0.536	0.007	0.879
SERPINA3	lyso	0.031	0.677	0.277	-0.443	0.002	0.889
S100A6	cyto	0.062	0.664	0.215	-0.392	0.010	0.903
OR7E24	PM	0.497	0.239	0.128	-0.881	0.008	0.919
CBLB	cyto/nuc	0.590	0.182	0.007	-1.475	0.003	0.924
IRS1	cyto	0.460	0.229	0.163	-1.056	0.007	0.926
C21orf91	MTs	0.159	0.418	0.184	-0.656	0.007	0.928
TMEM170A	ER	0.110	0.665	0.180	-0.403	0.009	0.941
NLRP1	cyto	0.118	0.411	0.021	-0.621	0.004	0.945
UBE2O	nuc	0.017	0.818	0.380	-0.264	0.006	0.979
CUL3	cyto	0.013	1.047	0.888	-0.058	0.004	0.993
KRTAP2-3	cyto	0.056	0.740	0.244	-0.278	0.009	0.998
C17orf85	nuc	0.337	0.416	0.062	-0.856	0.009	1.018
NOL11	nuc	0.361	0.448	0.062	-0.921	0.001	1.024
ITPK1	cyto	0.599	0.022	0.008	-0.948	0.005	1.026
SEMA4G	PM	0.072	0.648	0.033	-0.483	0.007	1.052
LACTBL1	cyto	0.105	0.651	0.263	-0.500	0.009	1.057
РТК2	cyto	0.010	0.940	0.436	-0.188	0.005	1.068
NMD3	nuc	0.025	1.211	0.841	-0.051	0.005	1.069
ASCC3	cyto/nuc	0.038	0.815	0.121	-0.625	0.002	1.073
MED21	nuc	0.611	0.160	0.002	-1.058	0.001	1.074
CDR2	nuc	0.499	0.451	0.007	-0.620	0.007	1.114
E2F8	cyto	0.476	0.256	0.005	-0.866	0.004	1.117
GPR133	PM	0.039	0.651	0.032	-0.743	0.001	1.121
SCG5	extracell	0.230	0.229	0.003	-0.722	0.003	1.122
UBE2J1	ER	0.573	0.139	0.018	-1.086	0.002	1.144
TWIST2	nuc	0.024	0.776	0.248	-0.509	0.006	1.187
PFDN5	nuc	0.002	0.950	0.791	-0.279	0.006	1.192
LY96	endosome	0.073	0.750	0.073	-0.822	0.005	1.214
SCD	ER	0.351	0.334	0.091	-1.164	0.008	1.228
BIK C17orf82	mito	0.052	1.192 0.424	0.383	-0.248 -1.260	0.008	1.285 1.362
C17orf82 CALCOCO2	nuc					0.004	
GCA	cyto/nuc	0.175 0.216	0.707	0.030	-1.057 -1.217	0.009	1.398 1.410
	cyto DM	0.216				0.001	
OR56A1	PM		0.685	0.305	-0.734		1.476
CCDC130	nuc FR	0.012	0.935		-0.734	0.006	1.494
	ER outo/puc	0.062	0.909	0.037	-1.199	0.000 0.008	1.497
INTS7 TPTE2	cyto/nuc ER	0.211 0.195	0.391 0.546	0.022	-1.201 -0.701	0.008	<u>1.513</u> 1.545
ABCB9	lyso	0.276	0.222	0.194	-0.287	0.007	1.633
NUCKS1	nuc	0.250	0.442	0.143	-1.325	0.008	1.709
JUNB FAP	nuc	0.004		0.055	-1.155	0.001	1.783
	PM	0.013	1.166	0.812	-1.038	0.001	1.855
MMS22L	nuc	0.180	0.307	0.015	-1.753		1.923
RPL7A	cyto	0.428	0.927	0.004	-2.293	0.004	2.152
CCNC	nuc mito	0.006	1.945 1.290	0.576 0.059	-0.172		2.172
			1 790	0.059	-1.414	0.002	3.005
RAF1							2.264
SNW1	nuc	0.017	3.081	0.209	-0.269	0.003	3.204
							3.204 3.355 3.619

Alternate	Molecular	DDKO-	DDKO-	DDKO-	DD-	DD-	DD-	DDKO/DD-
ID	Weight	1	2	3	HA-1	HA-2	HA-3	HA*
UFL1	90 kDa	0	0	0	61	53	50	0
DDRGK1	36 kDa	0	0	0	50	42	41	0
MYBBP1A	149 kDa	2	0	0	17	15	17	0.666666667
IRS4	134 kDa	0	0	0	6	5	3	0
PABPC1	71 kDa	0	0	0	8	3	2	0
RPL7A	30 kDa	2	0	2	11	13	10	1.333333333
GNL2	84 kDa	0	0	0	6	4	2	0
LTV1	55 kDa	0	0	0	6	2	4	0
NAT10	116 kDa	0	0	0	5	5	2	0
EMD	29 kDa	2	0	0	6	8	6	0.666666667
DHX9	141 kDa	0	0	0	8	2	0	0
CHMP4B	25 kDa	0	0	0	3	4	3	0
RRP12	144 kDa	0	0	0	3	3	4	0
RPLP0	34 kDa	0	0	2	7	5	6	0.666666667
BANF1	10 kDa	0	0	0	3	3	3	0
RCN2	37 kDa	0	0	0	6	3	0	0
HSPA1A	70 kDa	0	2	0	7	5	4	0.666666667
NOP56	66 kDa	0	0	2	7	4	5	0.666666667
LYAR	44 kDa	0	0	0	3	2	3	0
RPL10A	25 kDa	2	2	2	9	9	9	2
RFC1	128 kDa	0	0	0	3	2	2	0
RRP1	53 kDa	0	0	0	3	2	2	0
FCF1	23 kDa	0	0	0	2	2	3	0
RPL15	24 kDa	2	0	2	7	7	6	1.3333333333
TEX10	106 kDa	0	2	0	5	3	5	0.666666667
NOP58	60 kDa	0	0	2	5	4	3	0.666666667
RPL22L1	15 kDa	0	0	0	4	2	0	0
RPL30	13 kDa	0	0	0	2	2	2	0
AIMP1	34 kDa	0	0	0	2	2	2	0
CDC20	55 kDa	0	0	0	2	2	2	0
TUBG1	51 kDa	0	0	0	2	2	2	0
HNRNPF	46 kDa	3	0	2	7	7	6	1.666666667
KPNB1	97 kDa	2	0	2	7	2	7	1.333333333
HEATR3	75 kDa	0	0	0	3	0	2	0
KIFC1	74 kDa	0	0	0	3	0	2	0
BRIX1	41 kDa	0	0	0	5	0	0	0
USP10	87 kDa	0	0	0	2	0	3	0
MYH9	227 kDa	3	0	0	4	0	9	1
PNO1	28 kDa	0	0	2	3	2	5	0.666666667
HNRNPM	78 kDa	7	5	8	25	18	13	6.666666667
RPL8	28 kDa	4	0	2	8	6	6	2
NPM1	33 kDa	0	2	0	9	0	0	0.666666667
SREK1IP1	18 kDa	0	0	2	3	2	4	0.666666667

Table S3 – Immunoprecipitation-mass spectrometry analysis of DDRGK1 interactors. Related to Fig 6.

						UFSP2	UFSP2	UFSP2	UFSP2 KO/
Alternate	Molecular	HEK293T	UFSP2+DDRGK1	UFSP2+DDRGK1	UFSP2+DDRGK1	KO-	KO-	KO-	UFSP2+DDRGK1
ID	Weight	Neg Ctrl	KO-Biorep1	KO-Biorep2	KO-Biorep3	Biorep1	Biorep2	Biorep3	KO*
ACLY	121 kDa	0	2	0	0	7	9	10	5.8
EPRS	171 kDa	0	0	0	0	6	2	5	5.333333333
ASNS	64 kDa	0	0	0	0	5	4	2	4.666666667
RACK1	35 kDa	0	0	0	2	4	3	4	2.8
RPN1	69 kDa	0	3	4	3	8	10	10	2.384615385
CLTC	192 kDa	4	5	8	7	17	17	16	2.304347826
GOT2	48 kDa	0	2	2	3	4	5	4	1.6
RPL26	17 kDa	2	9	9	9	14	14	13	1.466666667
GANAB	107 kDa	2	7	10	7	13	13	13	1.555555556
HNRNPU	91 kDa	4	6	7	5	11	10	13	1.761904762
FASN	273 kDa	11	18	16	14	24	21	25	1.431372549
UFM1	9 kDa	0	14	12	12	13	14	13	1.048780488
RPL7A	30 kDa	4	6	7	8	7	8	10	1.166666667
RPL10A	25 kDa	0	2	3	2	3	2	3	1.1
UFC1	19 kDa	0	4	5	5	4	3	4	0.823529412
STRAP	38 kDa	0	3	2	2	2	2	2	0.9
UBA5	45 kDa	0	9	8	10	8	9	8	0.933333333

 Table S4 – Immunoprecipitation-mass spectrometry analysis of DDRGK1-dependent UFMylation substrates. Related to Fig 6.

* +1 inflation was performed for the average peptide count of both UFSP2+DDRGK1 KO and UFSP2 KO conditions before ratio count.

Table S5 – CRISPR cutting and CRISPRi sgRNA sequences used in this study. Relatedto STAR methods in the generation of cell lines with gene knockout or knockdown.

Construct	Protospacer	Source
AMPKα1-sgRNA1(RNP cutting		
guide)	GGCTGTCGCCATCTTTCTCC	This study
AMPKα1-sgRNA2 (RNP cutting guide)	GAAGATCGGCCACTACATTC	This study
AMPKα2-sgRNA1 (RNP cutting guide)	TCAGCCATCTTCGGCGCGCG	This study
AMPKα2-sgRNA2 (RNP cutting guide)	GAAGATCGGACACTACGTGC	This study
pX458-DDRGK1*sgRNA1	ATGAGATCCCGGCCTCAGGG	This study
pX458- UFL1-sgRNA1	TAGGAGATGCCGCTGCACCA	This study
pX458- UFL1-sgRNA2	CTGACTCGCAGTAGACGCGG	This study
pX458-UFSP2-sgRNA	GCCTAATT TGGGCTCCACAA	This study
pX458-pLG1-puro NT sgRNA	AATAAGAGGAGGCCTTGATT	Walczak et al. 2019
pLG1-puro NT sgRNA	GCGCCAAACGTGCCCTGACGG	Addgene #109002
pLG1-puro ULK1 sgRNA	GGCGGCGGCACAGAGACCGT	Addgene #109004
pLG1-puro ATG10 sgRNA	GAGGCCGCGGACCTGACTGA	Horlback et al. 2016
pLG1-puro VPS16 sgRNA	GAAAGGCAGAGTCCCCGAGT	Horlback et al. 2016
pLG1-puro El24 sgRNA	GACGGGGCCGCTGGGAAGTC	Horlback et al. 2016
pLG1-puro NDUFB4 sgRNA	GGGCCTCCCAGGCGGGAATA	Horlback et al. 2016
pLG1-puro NDUFB2 sgRNA	GGGGGAAGCGAAGTAGGCAG	Horlback et al. 2016
pLG1-puro ATP5O sgRNA	GGTCCCCCGGGATGCCTACG	Horlback et al. 2016
pLG1-puro DDRGK1 sgRNA-1	GCCGCTACCAAGTACCACAC	Horlback et al. 2016
pLG1-puro DDRGK1 sgRNA-2	GGCGGCGCGACGGTCCACAA	Horlback et al. 2016
pLG1-puro DDRGK1 sgRNA-3	GTGCACTGAGGCCCTCGTCA	Horlback et al. 2016
pLG1-hygro DDRGK1 sgRNA-3	GTGCACTGAGGCCCTCGTCA	Horlback et al. 2016
pLG1-puro UFL1 sgRNA-1	GGCCTGACTCGCAGTAGACG	Horlback et al. 2016
pLG1-puro UFL1 sgRNA-2	GCGCCTGGGAAGAGATTAGG	Horlback et al. 2016
pLG1-puro UFM1 sgRNA-1	GAAGAGATGAAGACTGCGTG	Horlback et al. 2016
pLG1-puro UFM1 sgRNA-2	GGGAAGTCGTGCTACCCCCG	Horlback et al. 2016
pLG1-puro UBA5 sgRNA-1	GCGCTGGGTGCACGTCCCCA	Horlback et al. 2016
pLG1-puro IRE1a sgRNA-1	GGGCGGTGACCGAGCCTCAG	Horlback et al. 2016
pLG1-puro IRE1a sgRNA-2	GAGCGGACGCAGAACTGACT	Horlback et al. 2016
pLG1-puro FAM134B sgRNA-1	GGGACTGGAGAGAGAATGCG	Horlback et al. 2016
pLG1-puro FAM134B sgRNA-2	GAGGTGAAGTCATCCAATGA	Horlback et al. 2016
pLG1-puro FAM134B sgRNA-3	GTCCTAGCTTCATTCAAGGG	Horlback et al. 2016
pLG1-puro FAM134B sgRNA-4	GCTCCCAGTACTGTGACAGG	Horlback et al. 2016
pLG1-puro FAM134B sgRNA-5	GGCACGAACTCACTCAAGAG	Horlback et al. 2016
pLG1-puro CDK5RAP3 sgRNA-1	GGAGTCGAGATGCTGACCAC	Horlback et al. 2016
pLG1-puro CDK5RAP3 sgRNA-2	GGGAGGGAGACCGGAGACAC	Horlback et al. 2016
pLG1-puro Sox9 sgRNA-3	GGGAGTTGGAGAGCCGAAAG	Horlback et al. 2016
pLG1-puro Sox9 sgRNA-4	GGTCCGAGCCGGAGCCCGAC	Horlback et al. 2016
pLG1-puro ASC1 sgRNA-1	GTAGTCCGGTGCAGGACGTG	Horlback et al. 2016
pLG1-puro ASC1 sgRNA-2	GTGGTTCCGGCTGGGGAAGA	Horlback et al. 2016

Target	Primer 1	Primer 2
EI24	AGTGTTGTGCTTGGAATGGTGG	GCCACGACCAAACATCTCCATG
VPS16	ACTCGGGGACTCTGCCTTTTAC	GGCAATCCCTGAGTTCCTCCTT
ULK1	GTCGCCGTCAAGTGCATTAACA	CGTACAGGGCCACGATGTTTTC
ATG10	GTGATAGTTGGGAATGGAGACC	GGTAGATGCTCCTAGATGTGAC
sXBP1	TGCTGAGTCCGCAGCAGGTG	GCTGGCAGGCTCTGGGGAAG
АСТВ	GGGTCAGAAGGATTCCTATG	GGTCTCAAACATGATCTGGG
IRE1A	ACTTTGTCATCGGCCTTTGCAG	AGTGAGGCCGCATAGTCAAAGT
PERK	TGGTGTCATCCAGCCTTAGCAA	CATGCTTTCACGGTCTTGGTCC
DDRGK1	AAGGAGGAGGAGGAGGAGGAAGG	CTCTGTCAGGAAGCTCTGGGAC
UFL1	TCGGTTGGCAGAAGAGGTCAAT	AAGTCGCTGAGTTAGTGCCTGT
FAM134B	CCAGATGAAAGACCCAGGCTCA	TGCACACACTACAGACCAGGAG
CDK5RAP3	TGCTGGAGGATCTGATTGGCAA	ACTCGGTCCACATACCTTGGTG
SOX9	GGCAAGCTCTGGAGACTTCTGA	GGCTGGTACTTGTAATCCGGGT
ASC1	CCCACAGAGGACGACTTTGGAT	CCCAGAAGACAACCTGACGGAT
BiP	TCTGTGCAGCAGGACATCAAGT	GTCTTTGTTTGCCCACCTCCAA
CANX	CACTGCTCCTCCTTCATCTCCC	TCCACCCTGACAGAGTTCCTCT
CLIMP63	CAGGACTTCTCCCGGCAGAG	TCCAAATGTGGCTTGCAAAGACT
REEP5	GTTCCTGCACGAGAAGAACTGC	AGAGGCTCCATAACCGAACACC

 Table S6 - qRT-PCR primers used in this study. Related STAR methods for the quantitative measurement of cDNA.